AREAS OF TRIMERIZATION OF FVRS

专利摘要:
Complexes comprising polypeptides of the FVRS ectodomain and methods of preparing such complexes are disclosed. FVRS ectodomain polypeptides can be in the pre-fusion form.
公开号:BE1022778B1
申请号:E2015/5321
申请日:2015-05-22
公开日:2016-09-02
发明作者:Peter Mason；Andrea Carfi；Sumana Chandramouli；Ethan Settembre；Kurt Swanson
申请人:Glaxosmithkline Biologicals S.A.；Peter Mason；
IPC主号:

专利说明:

FIELDS OF TRIMERIZATION OF FVRS SEQUENCE LISTING
The present application includes a sequence listing that has been submitted electronically in ASCII format and is thus incorporated herein by reference in its entirety. Said ASCII copy created on May 14, 2015 is called VN56288_SL.txt and has a size of 441 843 bytes.
BACKGROUND OF THE INVENTION
Respiratory syncytial virus (RSV) is a non-fragmented, single-stranded RNA envelope of negative polarity of the family Paramyxoviridae, of the genus Pneumovirus. It is the most common cause of bronchiolitis and pneumonia in children under one year of age. RSV causes repeated infections, including severe lower respiratory tract infections, that can occur at any age, especially in the elderly or people with depressed cardiac, pulmonary or immune systems.
To infect a host cell, paramyxoviruses such as RSV, similar to other enveloped viruses such as the influenza virus and HIV, require fusion of the viral membrane with the membrane of a host cell. For RSV, the conserved fusion protein (FVRS) fuses the viral and cellular membranes by coupling the irreversible folding of the protein with the juxtaposition of the membranes. In current models based on paramyxovirus studies, the FVRS protein initially folds into a metastable "pre-fusion" conformation. During entry into the cell, the pre-fusion conformation undergoes folding and conformational changes to take on its stable "post-fusion" conformation.
The FVRS protein is translated from mRNA into a protein of about 574 amino acids, called Fo. Post-translational processing of Fo involves the deletion of an N-terminal signal peptide by a signal peptidase in the endoplasmic reticulum. Fo is then cleaved at two sites (about 109/110 and about 136/137) by cellular proteases (particularly furine) in Golgi-trans. This cleavage results in the suppression of a short intervention sequence and generates two subunits called Fx (~ 50 kDa, C-terminal, residues about 137574) and F2 (~ 20 kDa; N-terminal; residues about 1109) which remain associated with each other. Fi contains a hydrophobic fusion peptide at its N-terminus and also two amphipathic regions of heptad repeats (HRA and HRB). HRA is close to the fusion peptide and HRB is close to the transmembrane domain. Three F1-F2 heterodimers are assembled as homotrimers of F1-F2 in the virion.
A vaccine against RSV infection is not currently available, but it is highly desirable. A potential approach to producing a vaccine is a subunit vaccine based on a purified FVRS protein. Nevertheless, for this approach, it is desirable that the purified FVRS protein be in a unique form and in a conformation that is stable over time, consistent between the different vaccine lots and adequately purified.
The FVRS protein can be truncated, for example by deleting the transmembrane domain and the cytoplasmic tail to allow its expression as an ectodomain, which can be soluble. In addition, although the FVRS protein is initially translated as a monomer, the monomers are cleaved and assemble into trimers. When the FVRS protein is in the form of cleaved trimers, the hydrophobic fusion peptide is exposed. The hydrophobic fusion peptides exposed on the different trimers, for example trimers of the soluble ectodomaine, can associate with each other, resulting in the formation of rosettes. The hydrophobic fusion peptides can then associate with lipids and lipoproteins, for example from cells that are used to express the recombinant soluble FVRS protein. Because of the complexity of the processing, structure and folding of the FVRS protein, it is difficult to obtain purified and homogenous immunogenic preparations.
The structure of the pre-fusion form of FVRS has recently been updated (McLellan, JS et al., Science, 342 (6158): 592-8 (2013), incorporated herein by reference.) -Fusion of the FVRS contains epitopes that are not present on the post-fusion form. (See, e.g., Magro, M. et al., Proc Natl Acad Sci USA, 109 (8): 3089-94 (2012)). Thus, for vaccines, the stabilized pre-fusion form is generally considered to be more desirable from the antigenic point of view. Several hybrids of FVRS have been produced using the general theme of GCN stabilization. However, whenever the HRB was stabilized with GCN, disulfide bonds or genetically modified point mutations to enhance the hydrophobic core interactions of the trimeric HRB, the result was a protein that was not expressed and which was not exported from the cell effectively. T4 bacteriophage foldon sequences were also used to promote trimer formation and stabilization. Attempts to form a post-fusion FVRS that has mutations at its furin cleavage sites to prevent the release of the fusion peptide have resulted in the failure of FVRS to form trimers similar to those observed in the F protein parainfluenza virus well studied.
There is therefore a need for improved compositions of FVRS protein and methods for preparing such FVRS protein compositions.
SUMMARY OF THE INVENTION The invention provides compositions comprising a respiratory syncytial virus F protein complex (FVRS) or populations thereof, methods and compositions for preparing the complexes, and uses thereof. The invention provides a respiratory syncytial virus F protein (FVRS) complex comprising a six helix bundle, comprising: three FVRS ectodomain polypeptides, each comprising an endogenous HRA region, an endogenous HRB region, comprising further, one of an inserted HRS region of the inserted FVRS or an HRB region of the inserted FVRS, and at least one oligomerization polypeptide, wherein the three ectodomain polypeptides and the at least one oligomerization polypeptide form a six-helix bundle, provided that the six-helix bundle does not include the endogenous HRA regions and endogenous HRB regions of the FVRS polypeptides, in which the inserted HRA region or the inserted HRB region is optionally operably linked to the C-terminal end to the endogenous HRB region of the ectodomain of FVRS in the ectodomain polypeptide of FVRS.
In some embodiments, the six helix bundle comprises the inserted HRA region of each ectodomain polypeptide of the FVRS and the oligomerization polypeptide comprises a HRB region; or the six-helix bundle comprises the inserted HRB region of each ectodomain polypeptide of the FVRS and the oligomerization polypeptide comprises an HRA region. In some embodiments, the oligomerization polypeptide is not operably linked to an ectodomain polypeptide of FVRS. In some embodiments, the oligomerization polypeptide is operably linked to at least one FVRS ectodomain polypeptide.
In some embodiments, the at least one functional linkage between the ectodomain and the six-helix bundle inserted fraction and the functional linkage, when present, between the ectodomain and the oligomerization domain, include a linker polypeptide and / or a structurally restricted linker. In all embodiments, when two linkers are present, the linker composition is independently selected, for example at the length and stiffness level, although these linkers may be the same.
In some embodiments, the six helix bundle inserted fraction and the oligomerization polypeptide comprise heptad repeat regions complementary to an envelope virus fusion protein, optionally selected from the group consisting of a HRA region of the FVRS and a HRB region of the FVRS; HR1 region of HIV gp41 and HR2 region of HIV gp41; a Newcastle disease virus (NDV) HR1 region and an HR2 region of VMN, an HR1 region of human metapneumovirus and HR of human metapneumovirus; and other class I viral fusion proteins that contain 6-helix bundles in the post-fusion state. In preferred embodiments, the inserted domain and the oligomerization domain comprise a FVRS HRA and a FVRS HRB.
In some embodiments, the at least one oligomerization polypeptide comprises three oligomerization polypeptides. The present invention provides a trimeric complex of Respiratory Syncytial Virus F protein (FVRS), comprising three FVRS ectodomain polypeptides, each comprising an endogenous HRA region, an endogenous HRB region, and a truncated trimerization domain of the FVRS. bacteriophage T4 (amino acids 518-544 of SEQ ID NO: 106). In some embodiments, the complex comprises a purification tag, for example on the oligomerization polypeptide or foldon trimerization domain, which can preferably be cleaved from the complex without cleaving the ectodomain polypeptides.
In some embodiments, one or more of the FVRS ectodomain polypeptides comprise an uncleaved FVRS ectodomain polypeptide or a cloned FVRS ectodomain polypeptide. The cleavage sites may include, for example, furin cleavage sites, typically 1 or 2 furin cleavage sites, preferably optimized furine cleavage sites. In some embodiments, two furin cleavage sites are present, flanking the p27 sequence. In some embodiments, the furin cleavage site (s) contain the sequence RKRRS (SEQ ID NO: 112).
In some embodiments, the ectodomains in the FVRS complexes include the substitutions selected from the group consisting of S155C and S290C substitutions; substitutions S190F, and V207L; and the S155C, S290C, S190F, and V207L substitutions at the amino acid positions corresponding to SEQ ID NO: 1. Preferably, the four substitutions are all present. The invention further provides methods for producing a respiratory syncytial virus (FVRS) protein F complex comprising a six-helix bundle comprising: a) providing ectodomain polypeptides of the FVRS protein, comprising an endogenous HRA region and an endogenous HRB region, further comprising a six-helix bundle moiety; and at least one oligomerization polypeptide, and b) combining the FVRS ectodomain polypeptides and the at least one oligomerization polypeptide under conditions suitable for formation of a FVRS complex, whereby a complex FVRS is produced in which three of the FVRS ectodomain polypeptides and at least one of the oligomerization polypeptides form a six-helix bundle, provided that the endogenous HRA regions and the endogenous HRB regions of the polypeptides of the ectodomain of the FVRS are not part of the six-helix bundle.
In some embodiments, the six-helix bundle inserted fraction and the oligomerization polypeptide comprise heptad repeat regions complementary to an enveloped virus fusion protein selected from the group consisting of: HRA region of FVRS and HRB region of FVRS; HR1 region of HIV gp41 and HR2 region of HIV gp41; a Newcastle disease virus (NDV) HR1 region and an HR2 region of VMN, an HR1 region of human metapneumovirus and HR of human metapneumovirus; and other class I viral fusion proteins that contain 6-helix bundles in the post-fusion state.
In some embodiments, the polypeptides of the ectodomain of the FVRS protein and the oligomerization polypeptide are provided in a cell. In some embodiments, the FVRS ectodomain polypeptides and the oligomerization polypeptide are provided in conditioned cell culture media. In some embodiments, the FVRS ectodomain polypeptides and the oligomerization polypeptide are provided as expression hybrids, including expression hybrids transfected into a cell. In some embodiments, the FVRS ectodomain polypeptides and the oligomerization polypeptide are provided and, as purified components, mixed together in the absence of cells or substantially contaminating material from process cells. synthetic purification. The invention provides compositions for preparing FVRS complexes of the invention, including, for example, expression hybrids and cells containing expression hybrids. The invention further provides methods for producing trimeric FVRS complexes comprising FVRS ectodomain polypeptides, further comprising a T4 foldon trimerization domain, comprising providing a population of polypeptides of the ectodomain. the FVRS further comprising a T4 foldon trimerization domain, under conditions allowing assembly of the FVRS trimers. In some embodiments, the polypeptides of the ectodomain of the FVRS protein, further comprising a foldon trimerization domain, are provided in a cell. In some embodiments, the FVRS ectodomain polypeptides and the oligomerization polypeptide are provided in conditioned cell culture media. In some embodiments, the polypeptides of the ectodomain of the FVRS protein, further comprising a foldon trimerization domain, are provided as expression hybrids, including expression hybrids transfected into a cell. In some embodiments, the polypeptides of the ectodomain of the FVRS protein, further comprising a T4 foldon trimerization domain, are provided and, as purified components, mixed together in the absence of cells or substantially of material. contaminant from cells of synthetic purification processes. The invention provides compositions for preparing FVRS complexes of the invention, including, for example, expression hybrids and cells containing expression hybrids. The invention provides populations of FVRS complexes of the invention. In some embodiments, the FVRS complex population, at least 80% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 90% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 95% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 96% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 97% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 98% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, at least 99% of the ectodomain polypeptides are cleaved. In some embodiments, the FVRS complex population, no uncleaved FVRS polypeptide can be detected using Western blot analysis or Coomassie blue stained SDS-PAGE gel under boiling conditions. of reduction, where the bands Fl and F2 are easily visible. In the absence of complete cleavage at the two furin cleavage sites, in addition to the Fl and F2 bands, one or possibly three additional bands will be present in the full-length FVRS, Fl + p27 and / or F2 + p27 when the p27 domain was not removed from the FVRS hybrid. In some embodiments, the FVRS complex population, at least 80% of the ectodomain polypeptides are present in a trimer. In some embodiments, the FVRS complex population, at least 80% of the ectodomain polypeptides are cleaved and at least 80% of the ectodomain polypeptides are present in a trimer. The invention provides complexes of FVRS prepared by the methods of the invention. The invention provides complexes of FVRS in pharmaceutical compositions. The invention provides complexes of FVRS in immunogenic compositions. The invention provides complexes of FVRS in vaccine compositions. The invention further provides methods of administering such compositions to a subject, for example for the purpose of immunizing and / or eliciting an immune response in the subject, preferably a neutralizing immune response in the subject. Other embodiments are set forth below.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 consists of wild type FVRS (FIG IA) and an ectodomain hybrid in which the transmembrane domain and the cytoplasmic tail were removed and an optional HIS6 tag tag (SEQ ID NO: 39) was added at the C-terminus (FIG IB). For the sake of clarity, residue numbering refers to wild-type A2 strain FVRS starting at the N-terminal signal peptide and not modified in hybrids containing amino acid deletions. The signal sequence or the signal peptide (sp) is marked on the schemes. FIG. IA is a schematic of the FVRS protein showing the signal sequence or the signal peptide (SP), the p27 binding region, the fusion peptide (FP), the HRA domain (HRA), the H RB domain (HRB), the transmembrane region (TM), and the cytoplasmic tail (CT). The C-terminal bonds of the ectodomain may vary. FIG. 1B is a general diagram of the FVRS ectodomain hybrid describing the features shared with the scheme of FIG. IA and including an optional tag HlSe-tag (HIS TAG) (SEQ ID NO: 39). The furin cleavage sites are present at amino acid positions 109/110 and 136/137. FIG. IC also shows the amino acid sequence of amino acids 100-150 of FVRS (wild-type) (SEQ ID NO: 25) and several proteins (Furmt-SEQ ID NO: 3, Furdel-SEQ ID NO: 4; Furx-SEQ ID NO: 5, Furx R113Q, K123N, K124N-SEQ ID NO: 6, Furx R113Q, K123Q, K124Q-SEQ ID NO: 7;
Delp21 furx-SEQ ID NO: 8; Delp23 furx-SEQ ID NO: 9; Delp23 furdel-SEQ ID NO: 11; N-Term Furin-SEQ ID NO: 12; C-term Furin-SEQ ID NO: 13; Deletion of the Fusion Peptide 1-SEQ ID NO: 26; and Factor Xa-SEQ ID NO: 14) in which one or both furin cleavage sites and / or regions of the fusion peptide have been mutated or deleted. In FIG. IC, the symbol indicates that the amino acid in this position is deleted.
FIG. 2 is an alignment of F protein amino acid sequences from several RSV strains. The alignment was prepared using the algorithm disclosed by Corpet, Nucleic Acids Research, 1998, 16 (22): 10881-10890, using the default parameters (Blossum symbol comparison table 62, opening penalty of gap: 12, gap extension penalty: A2, F protein of the A2 strain
(deposit number AF035006) (SEQ ID NO: 27); CP52, Protein F of strain CP52 (deposit number AF013255) (SEQ ID NO: 28); B, F protein strain B (deposit number AF013254) (SEQ ID NO: 29); long, long strain F protein (accession number AY911262) strain (SEQ ID NO: 30), and strain 18537, F protein of strain 18537 (Swiss Prot deposit number P13843) (SEQ ID NO: 31). A consensus of the F protein sequences is also indicated (SEQ ID NO: 24). Each deposit number is incorporated herein by reference in the version available at the filing date of this application.
FIG. 3 is an example of a scheme showing an in vitro trimerization method, whereby the FVRS monomer solutions containing an endogenous HRA and an endogenous HRB further comprising an inserted HRA domain (the ectodomain peptides) are expressed and purified and then mixed with the HRB peptides (the oligomerization peptides), inducing the formation of a six-molecule complex which contains an inserted HRA operably linked to the ectodomain F protein and an added HRB oligomerization peptide. in the form of a VRS / trimer monomer "head" and an artificial 6-helix bundle (A, B and C). The trimers are purified and a protease may optionally be used to cleave a cleavable monomer, which may allow the globular head of the pre-fusion protein F to form (D and E).
FIG. 4 shows examples of hybrids for use of which the invention. Arm 1 hybrids include an ectodomain with endogenous HRA and HRB domains. Short or long linkers are used to operably link the HRA domain inserted to the ectodomain. Arm 2 hybrids include an ectodomain with endogenous HRA and HRB domains. Short or long linkers are used to operably link the inserted HRA domain and the oligomerization domain HRB (via the inserted HRA domain) to the ectodomain. As shown schematically, the inserted HRA domain and the HRB oligomerization domain can be linked to one another with a long or short linker. The Arm 3 hybrids are similar to the Arm 2 hybrids except that they include a truncated HRB endogenous domain in which the truncated HRB is FYDPLVFPSDEFDASISQVNEKINQS (SEQ ID NO: 41).
FIG. 5 shows examples of hybrids for use in which the invention comprises optimized furine cleavage sites. In the hybrid having the optimized double furine cleavage sites, the cleaved product sequence is indicated. The sequence of the optimized furin cleavage site between F2 and p27 prior to cleavage and the furin cleavage site, when present, between p27 and F1 before cleavage is RKRRS (SEQ ID NO: 112). FIG. 5 discloses SEQ ID NOS 137-138, 137, 139, 137-138, and 140-143, respectively in the order of appearance.
FIG. 6 is a graph summarizing the RSV neutralization titers for mice immunized with different FVRS hybrids. FIG. 7 is a bar graph summarizing the RSV neutralization titers remaining after competition with pre-fusion or post-fusion hybrids for mice immunized with different FVRS hybrids. .
DETAILED DESCRIPTION OF THE INVENTION
The inventors have developed compositions which allow an in vitro approach using oligomerizing peptides or oligomerizing insert moieties for the purpose of producing FVRS complexes in which all or a portion of the oligomerizing polypeptide or oligomerizing insert moieties form six helices with an inserted portion of the FVRS polypeptide (e.g., a HRA sequence of the inserted FVRS or a HRB sequence of the inserted FVRS). Accordingly, in certain aspects, the invention relates to soluble FVRS polypeptide complexes comprising three FVRS ectodomain polypeptides, comprising an endogenous HRA domain of FVRS and an endogenous HRB domain of FVRS; and one of a 6-helix bundle inserted domain from, for example, class 1 fusion proteins which contain 6-helix bundles, preferably a HRA, HRB, HR1, or HR2 domain, preferably an HRA domain. FVRS or an HRB area inserted from the FVRS; and three oligomerization domains typically provided in the three oligomerization domain polypeptides, including a 6-helix bundle domain from, for example, class 1 fusion proteins which contain 6-helix bundles, preferably a HRA, HRB, HR1, or HR2, typically a HRV domain-containing peptide of FVRS when the ectodomain comprises an inserted HRA domain of FVRS; or typically a HRA domain-containing peptide of the FVRS when the ectodomain comprises an inserted HRB domain of the FVRS. In some embodiments, the invention provides polypeptides comprising a six helix (6HB) beam domain, wherein the 6HB domain is formed from FVRS protein sequences, which advantageously provides a trimerization domain while reducing the risk trigger an immune response to non-protein FVRS sequences, such as a foldon sequence, which is derived from bacteriophage and, inter alia, may be considered undesirable by regulatory authorities. The 6HB-containing polypeptides provided by the invention, in some embodiments, help to maintain the pre-fusion conformation of the FVRS polypeptides provided by the invention. The invention further provides coding sequences for FVRS ectodomain polypeptides comprising all optimized (one or both) furin cleavage sites, preferably two optimized furine cleavage sites and encoded polypeptides. by the coding sequences. In a preferred embodiment, the FVRS polypeptides are initially translated with two furin cleavage sites at positions corresponding to amino acids 109/110 and 136/137 of SEQ ID NO: 1. Optimized furine cleavage allows the production of trimeric FRVS complexes in which at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or preferably all peptides of the 1 '. ectodomain detectable by staining with Coomassie blue or western blot of boiled and reduced samples resolved by SDS-PAGE are cleaved during the expression. A method for evaluating cleavage is provided in the examples below. Without being bound by theory, it is believed that inclusion of the coding sequence for the p27 portion of the FVRS ectodomain peptide enhances cleavage and subsequent folding of the polypeptide. Deletion of the coding sequence for the p27 domain, particularly without the optimization of the unique furin cleavage site, results in the production of a population of FVRS polypeptides in which uncleaved peptides can be detected. . Typically, the polypeptide population comprises at least about 5% to 10% uncleaved polypeptides. Since no effective method is known, in particular no large-scale process necessary for the production of vaccines, for the separation of trimers containing all the ectodomain polypeptides cleaved from trimers containing a mixture of polypeptides of the With cleaved and uncleaved ectodomains, it is essential that the polypeptides be cleaved at the time of trimer expression and assembly to provide acceptable homogeneous compositions for use in pharmaceutical compositions. Advantageously, it has been discovered that FVRS polypeptides comprising optimized furin cleavage sites are expressed at higher levels than polypeptides having wild-type furine cleavage sites. These embodiments are particularly advantageous since the polypeptides provided by the invention further comprise large six-helix beam domains, which may not be expressed at levels as high as the FVRS polypeptides comprising smaller domains, as trimerization domains of the foldon.
In some embodiments, the FVRS ectodomain polypeptides containing the optimized furine cleavage sites may comprise the six helix bundle moieties provided herein to assemble the trimer polypeptides. In alternative embodiments, the FVRS ectodomain polypeptides containing the optimized furine cleavage sites may comprise a foldon trimerization domain, for example a T4 foldon trimerization domain to promote the assembly of polypeptides to trimers.
As described herein, the complexes are stable and can be adequately produced on a commercial scale. The stable complexes are capable of producing immunogenic compositions in which the protein is less likely to aggregate or degrade, allowing a more predictable immune response when the composition is administered to a subject. In some embodiments, the ectodomain structure of the FVRS in the complex is in pre-fusion conformation. Epitopes of the pre-fusion conformation may be more capable of eliciting antibodies that can recognize and neutralize naturally occurring virions. The invention also relates to methods for producing such complexes, immunogenic compositions comprising the complexes and methods of using the complexes and compositions. Definitions
The "post-fusion conformation" of the FVRS protein, when present in a trimer, is characterized by the presence of a six-helix bundle, comprising 3 endogenous HRB regions and 3 endogenous HRA regions. Post-fusion conformations are also characterized by a conical shape when viewed on negatively stained electron micrographs and / or by absence of prefusion epitopes. See, for example, Magro, M. et al., Proc. Natl. Acad.
Sci. USA, 109 (8): 3089-94 (2012)). FVRS proteins having a post-fusion conformation are not bound by the D25 antibody (Kwakkenbos et al., Nature Medicine 16: 123128 (2010)), whereas the pre-fusion and post-fusion FVRSs are all two linked by Motavizumab antibody (Beeler and van Wyke Coelingh, J. Virol 63: 2941-2950 (1989), incorporated herein by reference). It is understood that the entire FVRS protein does not necessarily need to be present for parts of the protein to be present in a post-fusion conformation.
The "pre-fusion conformation" of the FVRS protein, when present in a trimer, is characterized at least in part by having endogenous HRA regions that do not interact with the endogenous HRB regions to form a six-helix beam. A six-helix bundle may be present in the pre-fusion conformation, provided that the endogenous HRA regions and the endogenous HRB regions are not part of a six-helix bundle. The pre-fusion conformations are further characterized by a rounded shape when viewed on negatively colored electron micrographs, similar to what can be seen on the structure of PIV5 pre-fusion protein F (see McLellan example, JS et al., Science, 342 (6158): 592-8 (2013), Yin HS, et al (2006) Nature 439 (7072): 38-44) and / or by epitopes of fusion that are not present on the post-merger conformations. See, for example, Magro, M. et al., Proc. Natl. Acad. Sci. USA, 109 (8): 3089-94 (2012)) The FVRS proteins having a pre-fusion conformation are bound by the D25 antibody, whereas the pre-fusion and post-fusion FVRS are both bound by Motavizumab antibody. It is understood that the entire FVRS protein does not necessarily need to be present for parts of the protein to be present in a pre-fusion conformation.
As used herein, the term "endogenous HRA region," or domain, refers to an HRA region that is present in a F protein polypeptide in substantially the same position as the HRA region in the amino acid sequence of the form. F0 of the naturally occurring F protein from which the cleaved Fl and F2 peptides are derived. In the case of FVRS proteins, such as a FVRS ectodomain polypeptide or a recombinant ectodomain FVRS polypeptide, the endogenous HRA region ranges from about 154 amino acid to about 200 amino acid. of the polypeptide. The amino acid numbering of the FVRS protein throughout the present application, unless otherwise stated, is based on the wild-type A2 sequence of FVRS (SEQ ID NO: 1) including the signal peptide, and Amino acid positions are assigned to residues that are deleted. For example, if the FVRS fusion peptide is deleted in whole or in part, the deleted amino acids will be numbered so that the amino acids of the H RA region have the same position numbers as in the wild-type sequence. In preferred embodiments, the endogenous HRA region is a full length HRA region. However, deletions and truncations of the HRA region are included within the scope of the present invention as long as these deletions and truncations do not substantially alter the ability of the FVRS to fold into an acceptable conformation (either pre-fusion or post-fusion) for the purposes intended. An endogenous HRA region may include one or more mutations as set forth herein.
As used herein, the term "inserted HRA region," or domain, refers to an HRA region that is present in a F protein polypeptide at a position different from that of the HRA region in the amino acid sequence of the HRA region. FO form of the naturally occurring F protein. For example, a FVRS polypeptide may contain an inserted HRA region, for example at the carboxyterminal (i.e., C-terminal) end of the endogenous HRA region and the HRB region, and proximal to the endogenous HRB region. In some embodiments, the inserted HRA region is a full length HRA region. However, mutations, deletions, and truncations of the HRA region are included within the scope of the present invention as long as these deletions and truncations do not substantially alter the ability of the HRA domain to form an alpha helix that can subsequently assemble into a six-helix beam. The sequence of the inserted HRA region is chosen independently of the sequence of the endogenous HRA region.
The truncated HRA domains may be truncated at either the C-terminus or N-terminus or both C-terminally and N-terminally of the HRA domain. In some embodiments, the truncation comprises a deletion of about 1-20, 1-15, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 13, 1-2, or 1 amino acids at one or both ends of the HRA domain. A truncated HRA preferably has an identity of at least 70%, 75%, 80%, 85%, 90%, or 95% relative to the entire length of the domain and forms an alpha-helical structure allowing the formation of a six-helix beam.
As used herein, the term "endogenous HRB region," or domain, refers to an HRB region that is present in a protein F polypeptide in substantially the same position as the HRB region in the amino acid sequence of the form. F0 of the naturally occurring F protein. In the case of FVRS proteins, such as a FVRS ectodomain polypeptide or a recombinant ectodomain FVRS polypeptide, the endogenous HRB region ranges from about 474 amino acid to about 525 amino acid. relative to SEQ ID NOs: 1 or 2. The amino acid numbering is based on the wild-type A2 sequence of FVRS (SEQ ID NO: 1) including the signal peptide, and amino acid positions are assigned to the residues that are deleted. For example, if the FVRS fusion peptide is deleted in whole or in part, the deleted amino acids will be numbered so that the amino acids of the HRB region have the same position numbers as in the wild-type sequence. In some embodiments, the endogenous HRB region is a full-length HRB region. However, deletions and truncations of the HRB region are included within the scope of the present invention as long as these deletions and truncations do not substantially alter the ability of the FVRS to fold into an acceptable conformation (either pre-fusion or post-fusion) for the purposes intended. An endogenous HRB region may include one or more mutations as set forth herein.
As used herein, the term "inserted HRB region," or domain, refers to an HRB region that is present in a protein F polypeptide at a position different from that of the HRB region in the amino acid sequence of the FO form of the naturally occurring F protein. For example, a FVRS polypeptide may contain an inserted HRB region, for example at the carboxy terminal end of the endogenous HRA region and the endogenous HRB region, and proximal to the endogenous HRB region. In some embodiments, the inserted HRB region is an entire length HRB region. However, the mutations, deletions, and truncations of the HRB region are included within the scope of the present invention as long as these deletions and truncations do not substantially alter the ability of the HRB domain to form an alpha helix which can subsequently assemble into a six-helix beam. The sequence of the inserted HRB region is chosen independently of the sequence of the endogenous HRB region.
The truncated HRB domains may be truncated at either the C-terminus or N-terminus or both C-terminally and N-terminally of the HRB domain. In some embodiments, the truncation comprises a deletion of about 1-20, 1-15, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 13, 1-2, or 1 amino acid at one or both ends of the HRB domain. A truncated HRB preferably has an identity of at least 70%, 75%, 80%, 85%, 90%, or 95% relative to the entire length of the domain and forms an alpha-helical structure allowing the formation of a six-helix bundle and is illustrated by SEQ ID NO: 41.
As used herein, the term "FVRS ectodomain polypeptide" refers to a FVRS polypeptide that essentially contains the extracellular portion of the mature FVRS protein, with or without the signal peptide (e.g., about amino acid). 1 to about 524 amino acid, or about 224 amino acid to about 524 amino acid) but lacking the transmembrane domain and cytoplasmic tail (as hereinafter described) of the FVRS protein existing in the natural state. The ectodomain polypeptide of FVRS comprises an endogenous HRA domain and an endogenous HRB domain. In some embodiments, a FVRS ectodomain polypeptide comprises a truncated endogenous HRB domain. The FVRS ectodomain polypeptides of the invention further comprise an inserted 6-helix bundle domain, e.g., a 6-helix bundle domain derived from a class 1 fusion protein, including but not limited to, an HR1 region of HIV gp41, HR2 region of HIV gp41, HR1 / HR2 regions of Newcastle disease virus (NDV), HR1 / HR2 regions of human metapneumovirus. Most typically, a 6-helix bundle domain from a class 1 fusion viral protein is an inserted HRA domain of the FRVS or an inserted HRB domain of the FVRS.
As used herein, the term "cloned FVRS ectodomain polypeptide" refers to an FVRS ectodomain polypeptide that has been cleaved at one or more positions corresponding to amino acid positions ranging from about / 102 to about 160/161 of SEQ ID NO: 1 to produce two subunits, where one of the subunits comprises Fi and the other subunit comprises F2. In some embodiments, all or part of the sequence between amino acids 101 to 161, for example all or part of the sequence between amino acids 101 and 132, for example, all or part of of the sequence between amino acids 109 and 133 is removed from the FVRS ectodomain polypeptide such that a single cleavage results in a cleaved 1'ododomaine polypeptide that does not include most or all of the sequence p27. As used herein, cleavage of a complex to remove a purification tag is not understood to be a cloned FVRS ectodomain polypeptide. The amount of polypeptide cleaved in a sample can be determined, for example, by Western blot or SEC and can be expressed as a percentage by weight.
As used herein, the term "uncleaved FVRS ectodomain polypeptide" refers to an FVRS ectodomain polypeptide that is not cleaved at one or more positions corresponding to amino acid positions ranging from From about 101/102 to about 160/161 of SEQ ID NO: 1. An uncleaved FVRS ectodomain polypeptide may for example be a monomer or a trimer. In some embodiments, it is a single-stranded molecule, i.e., in which the Fl and F2 domains lack an intervening furin cleavage site.
As used herein, a "purified" protein, polypeptide, or complex is a protein, polypeptide, or complex that has been produced by a recombinant or synthetic method or product (e) by its natural host, and which has been isolated from the other components of the recombinant or synthetic production system or from the natural host so that the amount of protein relative to the other macromolecular components present in a composition is substantially greater than that present in a crude preparation or the amount of desired complex present relative to the amount of components not present in the desired complex, i.e., monomers, inadequately assembled complexes. In general, a purified protein will comprise at least about 50% protein in the preparation and more preferably at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% of the protein. protein in the preparation by weight.
As used herein, the term "substantially lipid-free" or "substantially free of contaminating lipids" refers to compositions, proteins and polypeptides that are at least 95% (e.g., at least 96%, at least 97%). at least 98%, at least 99%) free of contaminating lipids, for example cellular proteins from cells in which the polypeptides have been expressed, on a weight basis when the purity of the protein and / or polypeptide (by (eg, FVRS polypeptide) is observed on an SDS PAGE gel and the total protein content is measured using either UV280 absorption or BCA analysis, and the lipid and lipoprotein content is determined using the Phospholipase C (Wako, code No. 433-36201). It is understood that the lipid compositions for the formulation of vaccines, for example MF59 or other lipid-containing adjuvants are not contaminating lipids. As used herein, compositions "substantially free of contaminating lipids" can include added lipids (e.g., MF59 or other lipids for use in pharmaceutical compositions) not derived from cells in which proteins have been expressed. .
As used herein, the term "modified furine cleavage site" refers to the amino acid sequence at positions approximately 106-109 or at positions approximately 133-136 in naturally occurring FVRS protein (SEQ ID NO. NO: 1) recognized and cleaved by furin or furin proteases but which contains, in an uncleaved FVRS ectodomain polypeptide, one or more amino acid replacements, one or more acid deletions, or a combination of one or more amino acid substitutions and one or more amino acid deletions, such that a FVRS ectodomain polypeptide that contains a furin cleavage site The modified protein is secreted from a cell that produces it in uncleaved form at the modified furin cleavage site at one or both furin cleavage sites present in the FVRS. As used herein, a modified furine cleavage site is an inactivated furine cleavage site.
As used herein, an "optimized furine cleavage site" is a peptide cleavage site that includes selection of the optimal furin consensus sequence (eg RARR (SEQ ID NO: 109) and RKRR (SEQ ID NO: 110)) for the specific furin cleavage site in the context of the protein where the site is present. Optionally, an optimized furine cleavage site further comprises one or more mutations (i.e., substitution, insertion, or deletion) relative to the native sequence of the RSV contiguous at the furin cleavage site so that to promote furl cleavage, for example the insertion of a serine and, optionally, a glycine at the immediately C-terminal end of the final R into the furin cleavage site, or the substitution of the acids phenylalanine native amines by a serine and, optionally, the substitution of native leucine by a glycine at the C-terminus immediately at the furin cleavage site. In a preferred embodiment, an optimized furine cleavage site is cleaved more efficiently, for example more completely than a native furine cleavage site at a comparable position in the FVRS. In the present invention, an optimized cleavage site may include, for example, the RKRR sequence (SEQ ID NO: 110) immediately followed by a serine, where the S is preferably an F137S mutation in the FVRS protein. In some embodiments, an optimized furine cleavage site comprises the RKRRS sequence (SEQ ID NO: 112).
As used herein, the term "oligomerization polypeptide" refers to a polypeptide or polypeptide conjugate, which may be a molecule separate from the FVRS polypeptides described herein and which preferably contains an oligomerization domain, but which may contain two or three oligomerization domains, and optionally a functional region. The oligomerization region contains an amino acid sequence that can form a six-helix bundle with the inserted domain of the Fods ectodomain polypeptide. For example, the oligomerization polypeptide may comprise a 6-helix bundle domain from a class 1 viral fusion protein, for example an HRA domain, an HRB domain, an HR1 domain, or an HR2 domain. In some embodiments, the oligomerization polypeptide comprises an amino acid sequence HRB of FVRS, which can form a six-helix bundle with the inserted HRA region of a FVRS polypeptide. Alternatively, when the oligomerization polypeptide comprises an HRA amino acid sequence of FVRS, it can form a six-helix bundle with the inserted HRB region of a FVRS polypeptide. In some embodiments, the oligomerization polypeptide is operably linked to the inserted HRA or HRB domain inserted. In some embodiments, the oligomerization polypeptide is not operably linked to the inserted HRA domain or the inserted HRB domain. When the oligomerization polypeptide contains an oligomerization region and a functional region, the two regions are operably linked so that the oligomerization region can form a six-helix bundle with the FVRS ectodomain polypeptide and the functional region retains the desired functional activity.
As used herein, the term "6-helix bundle C-terminal moiety" or "6-helix bundle C-terminal domain" refers to a portion of a recombinant FVRS ectodomain polypeptide which can form a six-helix bundle and is 1) located at the C-terminus of the endogenous HRB region of the naturally occurring FVRS protein, and 2) is not located at that location in the existing FVRS protein at the natural state. In one example, the C-terminal 6-helix bundle is a HRA region of the FVRS that is inserted at the C-terminus of the endogenous HRB region of the FVRS, with or without the use of a link sequence. A 6-helix bundle C-terminal fraction can form a six-helix bundle with one or more oligomerization polypeptides.
As used herein, a "foldon" or "T4 bacteriophage foldon" sequence comprises a sufficient portion of the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 113) to promote the trimerization of the polypeptides of the ectodomain of the FVRS, particularly FVRS ectodomain polypeptides comprising optimized furine cleavage sites.
As used herein, the term "linker" is understood to be a chemical moiety that connects two molecules, for example peptide molecules. In some embodiments, the linker is a non-covalent linker, for example avidin and biotin; an antibody and an antigen. In some embodiments, the linker is a covalent linker, for example a peptide linker, a chemical crosslinking agent. In some embodiments, the peptide linkers may include the insertion of additional amino acids between the peptides to be bound. In some embodiments, the linker may be structurally restricted. In some embodiments, the structurally restricted linkers include a Pro-Gly sequence for the purpose of inducing flexion, for example GPGA sequences (SEQ ID NO: 111). In some embodiments, the structurally restricted linkers may include alpha-helical peptides. In some embodiments, the linker peptides comprise flexible (i.e., structurally unrestricted) peptides. In some embodiments, the linkers are based on RSV sequences. For example, in some embodiments, the RSV-based binding sequences include GVGSA (SEQ ID NO: 114) or ELSNIKENKSNGTDAK (SEQ ID NO: 115), including combinations and concatamers of one or the same. other of these sequences, including 1, 2, 3, 4, 5 copies of these linkers or more. In some embodiments, the linkers are not based on RSV sequences. The linkers can be of any length. Preferred linkers have a length of about 3-30, 3-21, 3-15, 3-10, 4-8, or 5-7 amino acids.
When multiple linkers are present, the nature and length of each linker are independently selected. In some embodiments, the linkers comprise at least one consensus glycosylation sequence, as predicted by the NetNGlyc 1.0 server (in the version available at the filing date of this application). In some embodiments, the linkers comprise at least two glycosylation consensus sequences.
Linkers are used to "link functionally" or simply "bind" the molecules together. It is understood that the presence of a linker does not substantially inhibit the desired activity of the molecules it connects, and optionally promotes it. For example, a peptide linker between an inserted HRA region and an oligomerization domain comprising a HRB region preferentially favors the pairing of the inserted HRA region and the HRB region in the HRB region oligomerization domain to allow the formation of the HRA region. a six-helix bundle and / or inhibits the pairing of the inserted HRA region or the HRA region in an oligomerization domain with the endogenous HRB region; and / or inhibits the pairing of the inserted HRB region or the HRB region in an oligomerization domain with the endogenous HRA region. A T4 foldon sequence may be operably linked to an ectodomain polypeptide.
The characteristics of the ectodomains of the FVRS protein suitable for use in the present invention are described herein with reference to particular amino acids that are identified by the position of the amino acid in the sequence of the FVRS protein from the strain. A2 (SEQ ID NO: 1), unless otherwise clearly stated. The ectodomains of the FVRS protein may have the amino acid sequence of the F protein from strain A2 or any other desired strain. When the ectodomain of F protein from a strain other than strain A2 is used, the amino acids of protein F should be numbered with reference to the numbering of F protein from strain A2, with insertion of gaps if necessary. This can be achieved by aligning the sequence of any desired FVRS protein with F protein of strain A2, as shown here for F proteins from strain A2, strain CP52, strain B, strain long, and strain 18537. See FIG. 2. The sequence alignments are preferably produced using the algorithm indicated by Corpet, Nucleic Acids Research, 1998, 16 (22): 10881-10890 (incorporated herein by reference), using the default parameters (comparison chart symbols Blossum 62, opening gap penalty: 12, gap extension penalty: 2).
FVRS Glycoprotein
RSV F glycoprotein directs viral penetration by fusion between the virion envelope and the plasma membrane of the host cell. It is a full-length, type I pass membrane protein with four general domains: N-terminal RE translocation signal sequence (SS), ectodomain (ED), transmembrane domain (TM), and cytoplasmic tail (CT). CT contains a single palmitoyl cysteine residue. The F protein sequence is highly conserved among RSV isolates, but is in constant evolution (Kim et al (2007) J Med Virol 79: 820828). Unlike most paramyxoviruses, F protein in RSV can induce the entry and formation of a syncytium independently of other viral proteins (HN is usually required in addition to F in other paramyxoviruses). FHRRI ARMn is translated into a 574 amino acid precursor protein called F0, which contains an N-terminal signal peptide sequence which is replaced by a signal peptidase in the endoplasmic reticulum. F0 is cleaved at two sites (aa 109/110 and 136/137) by cellular proteases (particularly furine) in Golgi-trans, removing a short glycosylated intervening sequence and generating two subunits called Fi (~ 50 kDa, C-terminal, residues 137-574) and F2 (~ 20 kDa, N-terminal, residues 1-109) (See, for example, FIG 1). Fi contains a hydrophobic fusion peptide at its N-terminus and also two regions of hydrophobic heptad repeats (HRA and HRB). HRA is close to the fusion peptide and HRB is close to the transmembrane domain (see, for example, FIG. The heterodimers Fi-F2 are assembled as homotrimers in the virion.
RSV exists as a single serotype but has two antigenic subgroups: A and B. The F glycoproteins of both groups are about 90% identical in their amino acid sequence. Subgroup A, subgroup B, or a combination or a hybrid of the two may be used in the invention. An exemplary sequence for subgroup A is SEQ ID NO: 1 (strain A2; GenBank GI: 138251; Swiss Prot P03420, incorporated by reference into the version available at the filing date of this application; or several of the substitutions P102A, I379V, and M447V, including all of P102A, I379V, and M447V), and for subgroup B is SEQ ID NO: 2 (strain 18537; GI: 138250; Swiss Prot P13843; incorporated by reference into the version available at the filing date of this application). SEQ ID NO: 1 and SEQ ID NO: 2 are both sequences of 57 4 amino acids. The signal peptide in strain A2 is a.a. 1-21, but in strain 18537, it's 1-22. In both sequences, the TM domain is at about 530-550, but has been alternatively reported as 525-548. The invention can use any amino acid sequence of the desired FVRS, such as the amino acid sequence of SEQ ID NO: 1 or 2, or a sequence having an identity with SEQ ID NO: 1 or 2. Typically, it will have an identity of at least 75% with SEQ ID NO: 1 or 2 for example an identity of at least 80%, at least 85%, at least 90%, at least 95% at least 97%, at least 98%, at least 99%, with SEQ ID NO: 1 or 2. The sequence can occur naturally in RSV.
Preferably, an ectodomain of the F protein, in whole or in part, which may contain: (i) a polypeptide comprising the amino acids of about 22- 525 of SEQ ID NO: 1; (ii) a polypeptide comprising the amino acids of about 23- 525 of SEQ ID NO: 2; (iii) a polypeptide comprising an amino acid sequence having an identity of at least 75% (eg, at least 80%, at least 85%, at least 90%, minus 95%, at least 97%, at least 98%, at least 99%) with (i) or (ii), preferably relative to the entire length of the polypeptide; or (iv) a polypeptide comprising a fragment of (i), (ii) or (iii), wherein the fragment comprises at least one epitope of the F protein. The fragment will usually have a length of at least 100 amino acids for example, a length of at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450 amino acids. The ectodomain may be a Fo form with or without a signal peptide, or may comprise two separate peptide chains (for example a subunit Fi and a subunit F2) which are associated with each other, for example, the subunits can be linked by a disulfide bridge. Therefore, all or part (eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, or 60) amino acids from about 101 to about 161, such as amino acids 110136 (c that is, the p27 domain, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , 21, 22, 23, 24, 25, or 26 amino acids thereof), may be absent from the ectodomain. Thus, all or part of the ectodomain may comprise: (v) a first peptide chain and a second peptide chain that is associated with the first polypeptide chain, wherein the first peptide chain comprises an amino acid sequence having a at least 75% identity (eg at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least minus 98%, at least 99%, or even 100%) with the amino acids about 22 to about 101 of SEQ ID NO: 1 or the amino acids about 23 to about 101 of SEQ ID NO: 2, and the second peptide chain comprises an amino acid sequence having an identity of at least 75% (e.g. at least 80%, at least 85%, at least 90%, minus 95%, at least 97%, at least 98%, at least 99%, or even 100%) with amino acids from about 162 to about 525 of SEQ ID NO: 1, or with about 13 amino acids 7 to about 525 of SEQ ID NO: 1; or with the amino acids about 162 to 525 of SEQ ID NO: 2, or with the amino acids about 137 to about 525 of SEQ ID NO: 2; (vi) a first peptide chain and a second peptide chain that is associated with the first polypeptide chain, wherein the first peptide chain comprises an amino acid sequence containing an amino acid fragment of about 22 to about 101 of SEQ ID NO: 1 or about 23 to about 109 amino acids of SEQ ID NO: 2, and the second peptide chain comprises a fragment of about 162 to about 525 amino acids, or about 137 to about 525 amino acids of SEQ ID NO: 1 or amino acids from about 161 to about 525, or amino acids from about 137 to about 525 of SEQ ID NO: 2. A fragment or both fragments will comprise at least one epitope of F protein. The fragment in the first chain the peptide will usually have a length of at least 20 amino acids, for example a length of at least 30, at least 40, at least 50, at least 60, at least 70, minus 80 amino acids. The fragment in the second peptide chain will usually have a length of at least 100 amino acids, for example at least 150, at least 200, at least 250, at least 300, at least 350, of at least 400, of at least 450 amino acids; or (vii) a molecule obtainable by furine digestion of (i), (ii), (iii) or (iv).
Thus, an amino acid sequence used with the invention can be found naturally within the FVRS protein (for example a soluble FVRS protein lacking the TM and CT domains, amino acids approximately 522-574 SEQ ID NOs : 1 or 2), and / or it may have one or more mutations (for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 , 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30) of a single amino acid (insertions, deletions or substitutions) with respect to a natural sequence of RSV . For example, it is known to mutate F proteins to eliminate their furin cleavage sequences, thereby avoiding intracellular transformation. In some embodiments, the FVRS protein lacks TM and CT domains (about 522-574 amino acids of SEQ ID NOs: 1 or 2) and contains one or more mutations (e.g., 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 ) of a single amino acid (insertions, deletions or substitutions) compared to a natural sequence of RSV.
The FVRS polypeptides or proteins may contain one or more mutations that inhibit cleavage at one or both furin cleavage sites (i.e., amino acids 109 and 136 of SEQ ID Nos: 1 and 2). The
Fodecectodomain polypeptides that contain these mutations are not cleaved in vivo by the cells that produce the polypeptides and are produced as monomers. Examples of mutations of furin cleavage sites for interrupting furin cleavage include substitution of amino acid residues 106-109 of SEQ ID NO: 1 or 2 with RARK (SEQ ID NO: 32). , RARQ (SEQ ID NO: 33), QAQN (SEQ ID NO: 34), or IEGR (SEQ ID NO: 35). Alternatively, or in addition, the amino acid residues 133-136 of SEQ ID NO: 1 or 2 may
be substituted with RKKK (SEQ ID NO: 36), AAAR, QNQN (SEQ ID NO: 37), QQQR (SEQ ID NO: 38) or IEGR (SEQ ID NO: 35) (Δ indicates that the amino acid residue has been deleted.) These mutations can be combined, if desired, with other mutations described herein or known to the state of the art, such as mutations in the p27 region (amino acids 110-136 of SEQ IDs). NOs: 1 or 2), comprising the deletion of the p27 region in whole or in part.
In some embodiments, the amino acid sequence of an ectodomain of the uncleaved FVRS protein is modified to inhibit cleavage at native furin cleavage sites corresponding to positions 109/110 and 136/137 of the present invention. SEQ ID NO: 1, but contains a naturally occurring or naturally occurring protease cleavage site which, once cleaved, produces a subunit Fi and a subunit F2 (eg, the sequence p27 is deleted if although a single cleavage is necessary to produce the Fl and F2 polypeptides). For example, the ectodomain polypeptide of the uncleaved FVRS protein may have an amino acid sequence that is modified to avoid cleavage at the furin cleavage sites at about 109/110 and about / 137 (optionally with the deleted intervention sequence), but contain one or more protease cleavage sites inserted or naturally occurring from about position 101 to about position 161. The protease cleavage sites may comprise , but not limited to, the protease cleavage sites of TEV (tobacco etch virus), rhinovirus 3c protease cleavage sites, thrombin cleavage sites, cleavage with trypsin, and furin cleavage sites. In some embodiments, the domain of the PF is removed at least in part and a furin cleavage domain is inserted. In some embodiments, the ectodomain of the FVRS protein does not contain an inserted protease cleavage site. In some embodiments, the ectodomain of the FVRS protein does not contain a furin cleavage site.
In some embodiments, the ectodomain of the FVRS protein contains a furin cleavage site. In some embodiments, the furin cleavage site is an optimized furine cleavage site. In a preferred embodiment, an optimized furine cleavage site comprises the RKRRS sequence (SEQ ID NO: 112). In some embodiments, the furin cleavage site is present in an FVRS ectodomain polypeptide of the invention wherein all or a portion of the p27 sequence is deleted. In some embodiments, the ectodomain of the FVRS protein contains a furin cleavage site. In some embodiments, the ectodomain of the FVRS protein contains two furin cleavage sites. The one or two furin cleavage sites are preferably located at the positions corresponding to the positions of the cleavage site of the native protein, i.e., at positions 109/110 and 136/137 of SEQ ID NO: 1. The FVRS ectodomain polypeptides having optimized furine cleavage sites preferably comprise at least one mutation at a position corresponding to F137, for example, a F137S mutation. In some embodiments, a FVRS ectodomain polypeptide comprises mutations corresponding to A107K, E110S, and F137S.
A variety of particular amino acid sequences that will allow uncleaved FVRS ectodomain polypeptides to be produced and expressed by host cells, including amino acid sequences that are not cleaved at the Furin cleavage sites at or about the positions corresponding to positions 109/110 and 136/137 of SEQ ID NO: 1, can be easily designed and provided by those skilled in the art. In general, one or more amino acids that are part of, or are located near, furin cleavage sites at approximately position 109/110 and at approximately position 136/137 are substituted or deleted independently. Certain amino acid substitutions and deletions that are suitable to avoid cleavage of the ectodomain polypeptides of the FVRS protein are known. For example, the substitutions R108N, R109N, R108N / R109N, which inhibit cleavage at the 109/110 level, and the K131Q substitution or deletion of amino acids at positions 131-134, which inhibit cleavage at the 136/137 level, have have been described by Gonzalez-Reyes et al., Proc. Natl. Acad. Sci. USA, 98: 9859-9864 (2001). An uncleaved FVRS ectodomain polypeptide which contains the amino acid substitutions R108N / R109N / K131Q / R133Q / R135Q / R136Q has been described. Ruiz-Arguello et al., J. Gen. Virol. 85: 3677687 (2004). As described herein, the additional amino acid sequences of the FVRS protein that will allow the FVRS ectodomain polypeptide to be secreted by a host cell in uncleaved form contain modified furin cleavage sites, for example amino acid sequences modified at positions about 106-109 and positions about 133-136. The modified furine cleavage sites contain at least one amino acid substitution or deletion at positions about 106-109, and at least one amino acid substitution or deletion at positions about 133-136 to avoid cleavage at the cleavage site by the native furine.
Similarly, a variety of particular amino acid sequences of the uncleaved FVRS ectodomain polypeptides that contain a protease cleavage site (eg, inserted or naturally occurring) which, once cleaved , produce a first subunit that includes Fi and a second subunit that includes F2 can be easily designed and provided. For example, the amino acid sequence of the FVRS protein from about position 101 to about position 161 contains trypsin cleavage sites, and one or more trypsin cleavage sites can be cleaved, for example, in vitro. , by trypsin to give subunits Fi and F2. If desired, one or more protease recognition sites may be inserted into the un-cleaved FVRS ectodomain polypeptide, e.g., between about position 101 and position about 161. The recognition sites by the inserted protease can be cleaved using the appropriate protease to generate F1 and F2 subunits.
In particular embodiments, the sequence of amino acid residues 100-150 of the FVRS polypeptide or protein, such as SEQ ID NO: 1, SEQ ID NO: 2, or their soluble ectodomains, is Furmt, (SEQ ID NO: 3); Furdel (SEQ ID NO: 4); Furx (SEQ ID NO: 5); Furx R113Q, K123N, K124N (SEQ ID NO: 6); Furx R113Q, K123Q, K124Q (SEQ ID NO: 7); Delp21 Furx (SEQ ID NO: 8); Delp23 Furx (SEQ ID NO: 9); Delp21 furdel (SEQ ID NO: 10); Delp23 furdel (SEQ ID NO: 11); Nterm Furin (SEQ ID NO: 12); Cterm Furin (SEQ ID NO: 13); Factor Xa (SEQ ID NO: 14) as shown in Figure IC; or SEQ ID NO: 15 (of WO 2010/077717, incorporated herein by reference).
In some embodiments, the FVRS polypeptides or proteins may contain one or more furin cleavage sites optionally comprising mutations that promote cleavage at one or both furin cleavage sites (i.e. ie amino acids 109/110 and 136/137 of SEQ ID NOs: 1 and 2) or positions corresponding to amino acids 109/110 and 136/137 of SEQ ID NOs: 1 and 2. In some embodiments, the p27 region is deleted or substantially deleted (e.g. 10 consecutive amino acids or less from the conserved p27 domain) while a single furin cleavage site is retained. In some embodiments, the p27 region is conserved, a single furine cleavage site being conserved within or adjacent to the p27 region. In some embodiments, the p27 region is conserved, a single furine cleavage site being conserved in the vicinity of the p27 region. In some embodiments, a single furine cleavage site is conserved in the vicinity of the p27 region. In some embodiments, a furine cleavage site is optimized in the FVRS polypeptide. In some embodiments, about 106 to about 132 amino acids are deleted while retaining the second amino acid furine cleavage site 133-136. In addition, the sequence is modified to insert a serine in a position immediately adjacent to amino acid 136 either by insertion of a serine or by substitution F137S to optimize the cleavage site.
FVRS Complexes
The complexes contain an FVRS ectodomain trimer and are characterized by a six-helix bundle, provided that endogenous HRA and endogenous HRB are not part of the six-helix bundle.
In one aspect, the complexes may contain an FVRS ectodomain trimer in the form of a complex that contains three FVRS ectodomain polypeptides and at least one oligomerization polypeptide. The oligomerization polypeptide contains an oligomerization region or a moiety that can bind to inserted portions of the FVRS ectodomain polypeptides for the purpose of forming a six-helix bundle. Thus, the complex contains a six-helix bundle that is formed by an inserted portion of the FVRS ectodomain polypeptides and all or a portion of the oligomerization polypeptides. In some embodiments, the oligomerization polypeptide is operably linked to a FVRS ectodomain polypeptide typically at the C-terminal end of the inserted six-helix bundle inserted at the C-terminus. terminal of the endogenous HRB domain of the FVRS. In some embodiments, an oligomerization polypeptide is operably linked to each FVRS ectodomain polypeptide. In some embodiments, an oligomerization polypeptide comprises a plurality of oligomerization domains. In some embodiments, the oligomerization polypeptide further comprises a functional domain (e.g., a purification tag, an antigen, particularly a clinically relevant antigen). The ectodomain of the FVRS also contains parts that are capable of forming a six-helix bundle. For example, when present, an inserted HRB region of a FVRS ectodomain polypeptide can form a six-helix bundle with an oligomerization polypeptide, either expressed in the same protein as the inserted domain forming a six-helix bundle, for example a HRB region, is expressed as a separate peptide, which contains the amino acid sequence of a complementary fraction forming a six-helix bundle, for example the HRA region of the FVRS.
If desired, one or more of the FVRS domains present in the complexes may be a recombinant FVRS ectodomain polypeptide which comprises an inserted C-terminal moiety forming a 6-helix bundle (e.g. inserted HRA region of FVRS, an oligomerization domain comprising an HRB region of FVRS optionally operably linked). These recombinant ectodomain polypeptides of FVRS can be prepared using standard methods in the state of the art. The 6-helix bundle C-terminal fraction may be derived from the FVRS, but is present at a C-terminal location that is different from (or in addition to) the location where the fraction appears in the existing FVRS at the same time. natural state. In one example, the C-terminal fraction forming a 6-helix bundle is the HRA region of the FVRS. This recombinant ectodomain polypeptide of FVRS can form a six-helix bundle with an added oligomerization polypeptide that contains the amino acid sequence of the HRB region of FVRS. Alternatively, the C-terminal 6-helix bundle may be an exogenous moiety that is obtained from a protein other than FVRS, such as the HR1 region of HIV gp41. Several polypeptides forming a six-helix bundle are well known in the art, such as the heptad repeat regions (eg HRA and HRB) of type I fusion proteins of enveloped viruses, such as FVRS , VIP and the like. See, for example, Weissenhorm et al., FEBS Letters 581: 2150-2155 (2007), Table 1, which is incorporated herein by reference.
The oligomerization polypeptide comprises an oligomerization region which is capable of binding to a 6-helix bundle inserted domain amino sequence, which is bound to the ectodomain of a FVRS polypeptide, e.g. a 6-helix bundle of the class 1 viral fusion protein, the HIV gp41 HR1A region, an HIV gp41 HR2B region, the HR1 / HR2 regions of the Newcastle Disease Virus (NDV), HRA, HRB, or other inserted C-terminal fraction forming a 6-helix bundle, and thereby promote the formation of a six-helix bundle complex. Several polypeptide sequences suitable for use as oligomerization regions are well known in the state of the art such as heptad repeat regions (e.g., HRA and HRB) of envelope fusion proteins, like FVRS, VIP and the like.
For example, when the ectodomain polypeptide of FVRS further comprises an inserted HRB region, the oligomerization region may contain the amino acid sequences of a HRA region of FVRS. Similarly, when the recombinant ectodomain polypeptide of FVRS further comprises a 6 helical bundle C-terminal fraction which is the HRA region of FVRS or the HR1 region of HIV gp41, e.g. Oligomerization region may be the HRB region of the FVRS or the HR2 region of HIV gp41, respectively.
If desired, the oligomerization polypeptide or foldon region may further comprise a functional region that is operably linked to the oligomerization region. Processes suitable for producing functional bonds between a polypeptide (i.e., the oligomerization region) and a desired functional region, such as another polypeptide, a lipid, a synthetic polymer, are well known in the art. state of the art. For example, the oligomerization polypeptide may be a polypeptide in which an amino acid sequence comprising the oligomerization region and an amino acid sequence comprising the functional region are components of a contiguous polypeptide chain, with or without intervention link sequence. In one embodiment, the oligomerization polypeptide may be expressed and purified as a fusion of the oligomerization peptide and the additional functional region. For example, the oligomerization polypeptide may comprise the HRB region of the FVRS and may be fused to the VRS central G domain, with or without an intervening linkage sequence. In addition, two polypeptides or a polypeptide and another molecule (for example a lipid, a synthetic polymer, or a combination thereof) can be chemically conjugated directly or via a linker using a variety of approaches. known. See, for example, Hermanson, G. T., Bioconjugate Techniques, 2nd Edition, Academie Press, Inc. 2008, incorporated herein by reference.
Suitable functional regions include all or part of an immunogenic carrier protein, an antigen (eg, a clinically relevant antigen, for example an immunogen to stimulate a response to a pathogen), a polypeptide-forming particle ( for example a viral particle or a non-infectious virus type particle), a lipid, and polypeptides that may associate the oligomerization polypeptide with a liposome or particle (eg, hydrophobic peptides, such as a transmembrane region, or a polypeptide which forms a super helix). When the functional region contains a portion of an immunogenic carrier protein, an antigen, a peptide-forming particle, a lipid, and a polypeptide that can associate the oligomerization polypeptide with a liposome or a particle, the part that is present is sufficient for the desired function. For example, when the. Oligomerization polypeptide contains a portion of an immunogenic carrier protein, the moiety is sufficient to enhance the immunogenicity of the FVRS complex. Similarly, when the oligomerization polypeptide contains a portion of an antigen, the portion is sufficient to induce an immune response.
Suitable immunogenic vehicle proteins are well known in the art and include, for example, albumin, keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, CRM197, rEPA (ExoProteinA no Pseudomonas aeruginosa toxin), Haemophilus influenzae non-typable D protein (NTHiD), N19 poly-epitope, and the like.
Suitable antigens are well known in the art and include any antigen from a pathogen (eg, a viral, bacterial, or fungal pathogen). Examples of antigen include, for example, RSV proteins such as FVRS and GVRS, HIV proteins such as HIV gp41, influenza proteins such as haemagglutinin, and paramyxovirus proteins such as hPIV5 fusion protein, hPIV3. , or Newcastle disease virus.
Suitable particle-forming peptides are well known in the state of the art and include, for example, viral polypeptides which form viral particles such as capsid proteins from nodavirus, norovirus, human papillomavirus (L1 and L2), parvovirus B19 (VP1 and VP2), hepatitis B virus (core protein), as well as the monomers of self-assembling peptide nanoparticles, for example those described in the specification of United States Patent Application No. 2011 / 0020378. In one embodiment, the oligomerizing polypeptide comprises an oligomerization region that is operably linked to a monomer of a self-assembling peptide nanoparticle as disclosed in US Patent Application Ser. 2011/0020378 (incorporated herein by reference).
Suitable lipids are well known in the art and include, for example, fatty acids, sterols, mono-, di- and triglycerides, and phospholipids. These lipids can anchor the FVRS complexes that contain them to liposomes, membranes, oil-in-water emulsion droplets, and other structures. Examples of lipids that can be used as a functional region of an oligomerization polypeptide include myristoyl, palmitoyl, glycophosphatidylinositol, pegylated lipids, neutral lipid, and nanodisks. Advantageously, myristoyl, palmitoyl and glycophosphatidylinositol may be incorporated into the in vivo oligomerization polypeptide by expression of a hybrid that encodes the oligomerization polypeptide in a suitable host cell.
A variety of suitable polypeptides that can associate the oligomerization polypeptide with a liposome or particle can be included in the oligomerization polypeptide and are well known in the art (see for example WO2010 / 009277 and US Pat. WO2010 / 009065, both incorporated herein by reference). For example, hydrophobic polypeptides, for example a transmembrane region or a fusion peptide, which associate with or insert into liposomes or lipid nanoparticles can be used. Polypeptides that form a super-helix can be used to link the oligomerization polypeptide to other structures that contain a super-helix-forming peptide, for example a synthetic nanoparticle or a liposome; viral polypeptides, or viral particles. In one embodiment, the oligomerizing polypeptide comprises an oligomerization region that is operably linked to a superhelix-forming peptide that can bind the complex to a self-assembling peptide nanoparticle, as described in the specification of the application. U.S. Patent No. 2011/0020378.
In some embodiments, the oligomerization peptide may further include an affinity tag to facilitate purification (e.g., 6X His (SEQ ID NO: 39), HAI, GST, Strep (SEQ ID NO: 108), Myc, etc., including their combinations). In some embodiments, more than one copy of the tag is present (eg, 2 copies, 3 copies, 4 copies). In some embodiments, the tags are present in tandem. In some embodiments, the tags are present in tandem with little or no intervening sequences. In some embodiments, the affinity purification tag (s) may be removed by protease cleavage. In a preferred embodiment, removal of the tag by protease cleavage does not cause substantial cleavage of the FVRS protein, the inserted HRA or HRB domain, or the six-helix bundle portion of the polypeptide. oligomerization.
In some embodiments, the invention is a FVRS complex that contains three FVRS ectodomain polypeptides and three oligomerization polypeptides. The complex is characterized by a six-helix bundle formed, for example, by an inserted HRB region of each of the three ectodomain polypeptides of FVRS and all or a portion (i.e. oligomerization region) of each of the three oligomerization polypeptides containing HRA.
In particular embodiments, the FVRS ectodomain polypeptides are recombinant and each comprises a C-terminal 6-helix bundle. The complex of these embodiments is characterized by a six-helix bundle formed by the C-terminal 6-helix bundle of each of the three ectodomain polypeptides of FVRS and all or a portion ( i.e., the oligomerization region) of each of the three oligomerization polypeptides.
In other aspects, the complex does not include an oligomerization polypeptide unrelated to at least one of the ectodomain polypeptides. The complexes of this aspect contain three FVRS ectodomain polypeptides further comprising two paired domains of a C-terminal moiety forming a 6-helix bundle, for example both an inserted HRA domain and an HRB domain as a domain. oligomerization. The complex is characterized by a six-helix bundle which is formed by the C-terminal 6-helix bundle bound to the endogenous portions of the FVRS ectodomain polypeptides. For example, such a complex may comprise one, two or three recombinant ectodomain FVRS polypeptides which contain a first C-terminal 6-helix bundle fraction, such as an inserted HRA amino acid sequence of FVRS, and the oligomerization domain which provides a second C-terminal 6-helix bundle, such as a FVRS amino acid sequence HRB. The first 6-helix bundle C-terminal fraction (for example an inserted HRA sequence) can form a six-helix bundle with the oligomerization domain which provides a second 6-helix bundle fraction (e.g. HRB sequence ). Without wishing to be bound by any particular theory, it is thought that the first C-terminal 6-helix-shaped fraction can fold over the second six-helix bundle and form the six-helix bundle in combination with the bundles. six paired helices from the other two polypeptides of the RSV ectodomain. Therefore, in this aspect, linker sequences may be included to limit the interaction between the C-terminal 6-helix bundle and the endogenous portions of the polypeptide and to promote interaction between the C-terminal insert domain forming the bundle to 6-helices in the RSV ectodomain polypeptide and the 6-helix beam forming domain in the oligomerization polypeptide to form the six-helix bundle that does not include the endogenous HRA or HRB sequences. Further, it is understood that the 6 helix bundle moieties are conveniently arranged in the FVRS ectodomain polypeptides to allow the pairing of the first and second helix bundle and in addition, allow the trimerization of ectodomains of FVRS by paired fractions forming a 6-helix bundle.
The methods for detecting the formation of trimers are well known in the state of the art and provided herein (for example Western blot analysis using non-boiled and unreduced samples, size exclusion chromatography including chromatography). steric exclusion combined with antibody binding). Although these methods do not allow direct observation of the six-helix bundle, the formation of a trimer without significant formation of dimers or higher-order structures, as may be determined by Western blot analysis, may be understood as indicative of the formation of a six-helix bundle. In size exclusion chromatography, the formation of a mobility complex suitable for a trimeric peak in the proper position without significant shoulder, indicative peaks of non-trimeric forms or a significant flow indicative of higher order structures. Suitable controls for determining the mobility of the trimers (e.g., DS-CAV1 with a foldon trimerization domain as proposed by McClellan et al., 2013) and monomers (e.g. delta p23 furdel) can be readily identified by the skilled person. In a preferred embodiment, at least 60% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. In a preferred embodiment, at least 70% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. In a preferred embodiment, at least 75% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer.
In a preferred embodiment, at least 80% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. In a preferred embodiment, at least 85% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. In a preferred embodiment, at least 90% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. In a preferred embodiment, at least 95% of the FVRS ectodomain polypeptides (by weight) in a sample are present in a trimer. Methods, such as western blot, can be used to determine the amount of protein present in the monomeric and trimeric forms. It is understood that western blots can have variations of about 3%, typically up to 5% or more. Those skilled in the art are aware of the use of adequate control and standard samples to give quantitative results or results of western blots that would allow the determination of the relative portion of the protein present in a monomeric, trimeric or other form. Similarly, chromatographic methods can be performed with appropriate controls to determine at least the relative amounts of protein in monomeric, trimeric or other forms. Similarly, these methods can be used to determine the amount of cleaved protein in a mixture and to determine other characteristics of a population of FVRS proteins of the invention. It is understood that after the formation of the trimers, purification steps such as those provided herein and known in the state of the art can be used to obtain the required level of assembled trimers.
One or more of the FVRS ectodomain polypeptides in the complex may be an uncleaved FVRS ectodomain polypeptide, and the remainder may be a cloned FVRS ectodomain polypeptide. In some embodiments, each of the FVRS ectodomain polypeptides in the complex contains one or more modified furine cleavage sites. In some embodiments, the FVRS ectodomain polypeptide comprises at least one furin cleavage site. In some embodiments, the furin cleavage site is an optimized furine cleavage site.
In particular embodiments, the amino acid sequence of the FVRS ectodomain polypeptides comprises a sequence selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt) , SEQ ID NO: 4 (Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO : 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), SEQ ID NO: 12 (N-term Furin), SEQ ID NO: 13 (C-term Furin), SEQ ID NO: 14 (Xa Factor), SEQ ID NO: 15, SEQ ID NO: 26 (Deletion of the Fusion Peptide 1), and any one of the preceding in which the signal peptide and / or HIS-tag is absent .
In more particular embodiments, the amino acid sequence of the FVRS ectodomain polypeptides comprises, consists essentially, or consists of a sequence in which the amino acids corresponding to amino acids 100-150 of the SEQ ID NO: 1 or SEQ ID NO: 2 are selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 (Furdel), SEQ ID NO : Furx, SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), and any one of the preceding in which the signal peptide and / or HIS-tag is absent.
In even more particular embodiments, the amino acid sequence of the FVRS ectodomain polypeptides corresponding to residues 100-150 of the wild-type FVRS polypeptide, such as SEQ ID NO: 1 or SEQ ID NO : 2, is selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 (Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), and any one of the preceding wherein the signal peptide and / or HIS-tag is absent.
In some embodiments, the FVRS ectodomain polypeptide comprises one or at least one furin cleavage site, which is optionally an optimized furine cleavage site. In a preferred embodiment, the furin cleavage site results in cleavage of the FVRS protein at a position such that the resulting peptides are similar at the wild type F1 and F2 domain sequence. In a preferred embodiment, cleavage results in the production of peptides that are at least 80% identical to the native FVRS peptide sequence over the entire length of the F1 and F2 domains. In some embodiments, the identity of each of the two domains F1 and F2 is independently selected from at least 85%, at least 90%, at least 95%, at least 98% identity. at least 99% or an identity with wild-type FVRS sequence sequences. In some embodiments, the alterations in the FVRS1 and FVRS2 sequences are different from the wild-type sequence within the furin cleavage site. In some embodiments, the modifications in the FVRS1 and FVRS2 sequences are different from the wild type sequence within and / or in the vicinity of the furin cleavage site (e.g., within 3 amino acids, within 2 amino acids or directly in the vicinity of the furin cleavage site). In some embodiments, the ectodomains of the FVRS of the invention contain mutations to promote or stabilize the ectodomain in pre-fusion conformation. For example, ectodomains may include mutations to promote the formation of disulfide bonds, for example S155C and S290C mutations. Alternatively, or preferably, in conjunction, the ectodomains contain one or preferably two mutations at amino acids 190 and 207, preferably S190F and V207L, to further promote stabilization of the ectodomain polypeptide in conformation. fusion.
In some embodiments, a single furin cleavage site, either having the native sequence or having an optimized sequence, is present at a position of a furin cleavage site in the ectodomain of the FVRS. In some embodiments, the p27 domain sequence is absent from the ectodomain of FVRS so that cleavage results in the formation of an F1 domain and F2 domain similar in length to the wild type sequences. In some embodiments, the p2 domain sequence is conserved in the FVRS domain so that cleavage at a single furin cleavage site on the amino acid of about 109 results in the formation of a Fl domain comparable to the wild-type F1 domain and a F2 domain with the N-terminal-linked p27 sequence. Alternatively, in some embodiments, cleavage at a single furin cleavage site about amino acid 136 results in the formation of an F1 domain with the p27 sequence linked to the C-terminus of the Fl domain and a F2 domain comparable to the wild-type F2 domain. Protease cleavage sites will be used for proteases that are not expressed by cells used for the expression of FVRS ectodomains in processes where cleavage of trimers has been performed outside of cells (on trimers assembled inside or outside the cells). The use of furin cleavage sites allows the cleavage of FVRS ectodomain polypeptides in cells during the expression and assembly of the FVRS trimers of the invention.
In some embodiments, the furin cleavage site or the optimized furine cleavage site in the previous embodiments is replaced by a cleavage site for an alternative protease. For example, a furin cleavage site may be replaced by a protease cleavage site such as, but not limited to, trypsin, TEV protease, rhinovirus 3c protease, and thrombin. In a preferred embodiment, the protease used in place of furin does not result in cleavage of the FVRS ectodomain polypeptide at sites other than the positions corresponding to the cleavage site (s). native furin (s) and does not result in cleavage of the oligomerization peptide.
In particular embodiments, the amino acid sequence of the oligomerization polypeptide is selected from the group consisting of: SEQ ID NO: 16 (RSV HRA, HRA oligomerization peptide), SEQ ID NO : 17 (short HRA, an oligomerization peptide that is slightly shorter than RSV HRA, SEQ ID NO: 16), or any one of the above in which the GST sequence, the cleavage sequence, and / or the sequence link is absent. In SEQ ID NO: 16, amino acids 1-237 are glutathione S-transferase (GST), amino acids 238-245 are a cleavage sequence, amino acids 246-252 are a linker and amino acids 253 -300 are the HRA. In SEQ ID NO: 17, amino acids 1-237 are glutathione S-transferase (GST), amino acids 238-245 are a cleavage sequence, amino acids 246-252 are a linker and amino acids 253 -290 are the HRA. It is understood that the HRB sequences can replace the HRA sequences for the production of HRB oligomerization domains. In addition, it is understood that variants of purification labels (for example strep, 6 X HIS (SEQ ID NO: 39)) can be used in place of the exemplary GST label.
In particular embodiments, the FVRs complex contains an ectodomain polypeptide of FVRS and an oligomerization polypeptide that comprises a functional region, such as an antigen. For example, the oligomerization polypeptide may comprise the amino acid sequence SEQ ID NO: 18 (Short HRA VRS Gb CC, in which an HRA oligomerization sequence is fused to the VRS central G domain from strain b). , SEQ ID NO: 19 (short VRS Ga CC HRA, in which an HRA oligomerization sequence is fused to the central VRS G domain from strain a), SEQ ID NO: 20 (VRS Gb CC HRB, wherein an oligomerization sequence HRB is fused to the VRS central G domain from strain b), SEQ ID NO: 21 (VRS Ga CC HRB, in which an oligomerization sequence HRB is fused to the VRS central domain G from strain a), or any one of the preceding wherein the glutathione S-transferase (GST) sequence, the cleavage sequence and / or the amino-terminal linker sequence is absent, and / or the GST sequence is replaced by a variant of purification label (e.g. strep, 6X HIS (SEQ ID NO: 39)). In SEQ ID NOS 18 and 19, amino acids 1-237 are a GST sequence, amino acids 238-245 are a protease cleavage site, amino acids 246-252 are a binding sequence, amino acids 253-292 are a Gb or Ga sequence, respectively, amino acids 293-299 are a second linker, and amino acids 300-337 are an HRA sequence. In SEQ ID NOs: 20 and 21, amino acids 1-233 are a GST sequence, amino acids 234-241 are a protease cleavage site, amino acids 242-248 are a binding sequence, the acids are Amino acids 249288 are a Ga or Gb sequence, respectively, amino acids 289-295 are a second linker, and amino acids 96-329 are a HRB sequence.
In some embodiments, the FVRS ectodomain polypeptide is linked to a T4 foldon sequence to promote the trimerization of ectodomains. In a preferred embodiment, the ectodomains comprise 1, preferably 2 furin cleavage sites where the cleavage sites are optimized furine cleavage sites.
In other particular embodiments, the FVRS complex comprises a hybrid of the FVRS ectodomain selected from the group consisting of SEQ ID NO: 22 (FVRS del P23 furdel Truncated HRA HIS), or SEQ ID NO : 23 (FVRS delP23 furdel C509C510 C481C489 HRA HIS); or any of the foregoing wherein the HIS tag and / or the linker are absent. In SEQ ID NOs: 22-23, amino acids 1-495 are a sequence of the ectodomaine of FVRS, amino acids 496-533 are a C-terminal HRA sequence inserted, amino acids 534-540 are a binding sequence, and amino acids 541-546 are a HIS-tag sequence. SEQ ID NO: 23 also includes cysteines introduced at positions 481, 489, 509 and 510.
In preferred embodiments, the FVRS ectodomain polypeptides in the complex are in pre-fusion conformation. While not wishing to be bound by any particular theory, it is believed that the pre-fusion form of the FVRS trimer is stabilized in the complexes described herein because the 6-helix bundle domains inserted and the oligomerization domains induce the complex formation and prevent the endogenous HRA regions and endogenous HRB regions of the FVRS protein from interacting with each other. The interaction of the endogenous HRA region and the endogenous HRB region of the FVRS protein leads to folding into the postfusion form.
In other preferred embodiments, the complex is characterized by a rounded shape (pre-fusion) when viewed on negatively colored electron micrographs.
In other embodiments, the complex is characterized by the ability to bind the D25 antibody that has been characterized as binding to the pre-fusion structure of FVRS.
In other preferred embodiments, the complex comprises pre-fusion epitopes that are not present on the post-fusion forms of FVRS.
Optionally, additional cysteine residues may be inserted into the HRB region to form disulfide bridges and further stabilize the ectodomains of the FVRS described herein.
In some embodiments, the FVRS ectodomain polypeptide comprises an S155C mutation and an S290C mutation.
In some embodiments, the FVRS ectodomain polypeptide comprises a mutation on amino acid 190 or amino acid 207. In some embodiments, the ectodomains of FVRS comprise an S190F mutation and / or a mutation V207F.
In some embodiments, the FVRS ectodomain polypeptide comprises an S155C mutation, an S290C mutation, an S190F mutation, and a V207F mutation.
In some embodiments, the FVRS ectodomain polypeptide further comprises an internal deletion of all or part of the p27 sequence, optionally with a corresponding deletion of one or more fur sites. In some embodiments, the FVRS ectodomain comprises an internal deletion of about 103 amino acid to about 136 amino acid, or about 103 to 161 amino acids.
In one embodiment, the FVRS ectodomain polypeptide comprises FVRS sequences of DS-CAV1 (McClellan et al., 2013).
In some embodiments, the FVRS complex may be further stabilized in the form of pre-fusion using interchain disulfides, including those disclosed in WO 2012/158613, incorporated herein by reference in its entirety, in its entirety. using peptides conjugated to oligomerizing agents including, but not limited to, viral-like particles (VLPs), albumin or GVRS, or using other mutations that further stabilize the monomer so that it retains its pre-fusion conformation during formulation and immunization.
In some embodiments, the FVRS complex may be further stabilized in its pre-fusion form using disulfide bridges or cavity-filling mutations such as those disclosed in McLellan, JS et al., Science, 342 (6158). ): 592-8 (2013) (incorporated herein by reference).
In some embodiments, a FVRS polypeptide, such as a 1 / ectodomain polypeptide, may comprise amino acid changes, with respect to SEQ ID NO: 1, P102A, I379V, M447V, or a combination of these, for example all of P102A, I379V, and M447V.
In particular embodiments, a FVRS polypeptide for use in the invention comprises fragments of the embodiments described herein - e.g. including any of the foregoing mutations and combinations thereof. In some embodiments, the fragment comprises a deletion of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acids or more, such as about 15, 20, 25, 30 , 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 amino acids or more. In some embodiments, the fragment comprises a deletion of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10%, or more, of the sequence of the reference FVRS, e.g. of 15, 20, 25, 30, 35, 40%, or more. In some embodiments, a deletion is that of a contiguous portion of the FVRS polypeptide. In particular embodiments, a fragment of a FVRS polypeptide provided by the invention substantially retains the tertiary, quaternary, or tertiary and quaternary structure of the reference sequence evaluated, for example, by binding to specific antibodies. to the conformation. In particular embodiments, the invention provides fragments comprising an amino acid sequence of a reference sequence having an identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, 100% with any of the sequences including the FVRS ectodomain provided herein, such as any of SEQ ID NOS .: 47-87, 89 -105, or 117-136, including truncations thereof, e.g., absence of signal sequences, purification labels, or signal sequences and purification labels.
Methods for preparing the complexes The invention also relates to methods for producing the FVRS complexes described herein. In one aspect, the invention relates to methods for producing a FVRS complex that comprises three FVRS ectodomain polypeptides, each containing an inserted HRA domain or an inserted HRB domain, three oligomerization domains present in the FVRS complex. one or more polypeptides, and is characterized by a six-helix bundle. The method comprises a) providing ectodomain FVRS polypeptides, each further comprising an inserted HRA domain or an inserted HRB domain and at least one oligomerization polypeptide, and b) combining the ectodomain polypeptides. the FVRS further comprising an inserted HRA domain or an inserted HRB domain and the oligomerization polypeptide (s) under conditions suitable for formation of a FVRS complex, whereby a FVRS complex is produced, which comprises three ectodomain polypeptides of the FVRS, each containing an inserted HRA domain or an inserted HRB domain, three oligomerization domains present in one or more polypeptides, and is characterized by a six-helix bundle. As described herein, the six-helix bundle is formed by the portion of the inserted HRA domain or HRB domain inserted from each of the FVRS ectodomain polypeptides and all or a portion of the oligomerization polypeptides, the six-helix bundle. does not include the endogenous HRA domain of FVRS or the endogenous HRB domain of FVRS.
If desired, one or more of the FVRS ectodomain polypeptides may be a recombinant FVRS ectodomain polypeptide which comprises an inserted C-terminal moiety forming a 6-helix bundle, e.g., a repetition region heptads from a class 1 fusion viral protein that contains 6-helix bundles such as the HRA region of FVRS or the HR1 region of HIV gp41, for example. In this practice of the method, the oligomerization polypeptide comprises an oligomerization region that can bind to an inserted portion of the FVRS ectodomain polypeptide, further comprising a 6-helix bundle moiety, e.g. FVRS HRB region or HR1 region of HIV gp41, or a complementary 6-helix bundle fraction from a class 1 fusion viral protein that contains 6-helix bundles, thereby promoting complex formation .
In some embodiments, the FVRS ectodomain polypeptides further comprise a T4 foldon trimerization domain of the six-helix bundle formed by the non-endogenous HRA and HRB domains.
Optionally, the method may further comprise the step of c) cleaving the ectodomain polypeptides of the FVRS protein (within a portion of the protein corresponding to the native FVRS ectodomain sequence ) in the complex produced with a suitable protease, whereby a FVRS complex is produced, which comprises three cloned ectodomain polypeptides of FVRS, each further containing an inserted C-terminal fraction forming a 6-helix bundle, and the oligomerization polypeptide (s), which may be bound or unrelated to the ectodomain polypeptides of FVRS, and is characterized by a six-helix bundle.
It is understood that when the complexes are expressed and assembled in the cells, the order of the steps is not directly controlled and is carried out by normal cellular processes. Therefore, the order of the steps is not binding.
In some embodiments, when the ectodomain polypeptide of FVRS and / or the oligomerization peptide comprises a purification tag. In some embodiments, typically after assembly and at least partial purification of the trimer, the purification tag may be removed from the FVRS complex by protease cleavage after assembly of the complex.
Assembly of the complex from purified components
The complexes of the invention can be formed from purified components. The complex was formed by combining three FVRS ectodomain polypeptides each further comprising an inserted C-terminal fraction forming a 6-helix bundle; and at least one, preferably three, oligomerization polypeptides, which may be bound or unrelated to the ectodomain polypeptides of FVRS. When bound to the ectodomain polypeptides, the oligomerization domains are present in a 1: 1 ratio with the ectodomain polypeptides. However, when they are not bound to the ectodomain polypeptides, the excess oligomerization domains, typically with each domain present in a separate polypeptide, can be used, and in practice a molar excess of 2 times, 3-fold molar excess, 4-fold molar excess, 5-fold molar excess, 6-fold molar excess, 7-fold molar excess, 8-fold molar excess, 9-fold molar excess, excess molar 10 times or more, oligomerization domains. The FVRS ectodomain polypeptides, each comprising an inserted C-terminal 6-helix bundle, and three oligomerization domains, typically in the three polypeptides, are combined under conditions appropriate to the formation of the the FVRS. In some embodiments, the FVRS ectodomain polypeptides and oligomerization polypeptides are combined in a buffered aqueous solution (e.g., at a pH of about 5 to about 9). If desired, mild denaturing conditions may be used, such as including urea, small amounts of organic solvents, or heat to gently denature the FVRS ectodomain polypeptides and remove the denaturing conditions (eg example by dialysis or dilution) to promote the folding or assembly of complexes.
Any adequate preparation of the FVRS ectodomain polypeptides and oligomerization polypeptides can be used in the method. . The use of uncleaved FVRS ectodomain polypeptides in the process provides advantages. As described herein, it has been found that in vivo cleavage of native FVRS ectodomain FVRS polypeptides results in the production of post-fusion ectodomains which are hydrophobic and frequently aggregated, making it difficult to purification. In vivo cleavage of FVRS polypeptides with modified characteristics designed to stabilize the pre-fusion form often results in poor yields or untransformed / misfolded FVRS proteins. However, FVRS ectodomain polypeptides that are not cleaved in vivo are produced in good yields as monomers and when the fusion peptide is modified in these ectodomain polypeptides, the protein may be soluble. and not aggregated (see for example WO2011008974, incorporated herein by reference). Uncleaved monomers can be adequately purified and used in the process to produce FVRS complexes. Thus, the purified FVRS ectodomain polypeptide monomers provided herein include an inserted C-terminal 6-helix bundle for use in assembly methods of the complex provided herein. The FVRS ectodomain polypeptides that are provided and used in the method are preferably uncleaved FVRS ectodomain polypeptides further containing an inserted C-terminal 6-helix bundle, and in some instances Embodiments, the uncleaved FVRS ectodomain polypeptides contain modified (i.e., inactivated) furine cleavage sites. In some embodiments, the ectodomains include furine cleavage sites. In some embodiments, the furin cleavage site is an optimized furine cleavage site. In some embodiments, the amino acid sequence of the FVRS ectodomain polypeptides that are provided and used in the method comprises, consists essentially or consists of a sequence, wherein the amino acids corresponding to the Amines 100-150 of SEQ ID NO: 1 or SEQ ID NO: 2 are selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 ( Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), SEQ ID NO: 12 (N-term Furin), SEQ ID NO: 13 (C-term Furin), SEQ ID NO: 14 (Factor Xa), SEQ ID NO: 15, SEQ ID NO: 26 (Deletion of the Fusion Peptide 1), and any one of the preceding ones in which the signal peptide and / or the HIS tag and / or the fusion peptide is modified or absent.
In some embodiments, the amino acid sequence of the FVRS ectodomain polypeptides that are provided and used in the method comprises, consists essentially or consists of a sequence, wherein the amino acids corresponding to the Amines 100-150 of SEQ ID NO: 1 or SEQ ID NO: 2 are selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 ( Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), and any one of the preceding in which the signal peptide and / or the HIS tag and / or the fusion peptide is altered or absent.
In some embodiments, the amino acid sequence of the FVRS ectodomain polypeptides (which are provided and used in the method) corresponding to residues 100-150 of the wild-type FVRS polypeptide, such as SEQ ID NO: 1 or SEQ ID NO: 2, is selected from the group consisting of: SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 (Furdel), SEQ ID NO : Furx, SEQ ID NO: 6 (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), and any one of the preceding in which the signal peptide and / or the HIS tag and / or the fusion peptide is altered or absent.
In some embodiments, the FVRS ectodomain polypeptides further include the S155C and S290C substitutions at the positions corresponding to SEQ ID NO: 1. In some embodiments, the FVRS ectodomain polypeptides comprise at least one F substitution on amino acid 190 and / or an L substitution on amino acid 207. In some embodiments, the amino acid sequence of the FVRS ectodomain polypeptides comprises S155C substitutions, S290C, S190F, and V207L. In some embodiments, the FVRS ectodomain polypeptide has a deletion of most or all of the p27 domain. In some embodiments, the FVRS ectodomain polypeptide has a deletion of about 101 amino acid to about 161. In some embodiments, the FVRS ectodomain polypeptide has a deletion of amino acids about 106 to about 130, or amino acids about 103-130, or amino acids about 103-136.
Assembly of complexes in cells
Fodecectodomain polypeptides (e.g., uncleaved FVRS ectodomain polypeptides) are typically prepared by expression in a recombinant host system through the expression of recombinant hybrids that encode ectodomains within the recombinant host system. adequate recombinant host cells, although any suitable methods may be used. Preferred recombinant host cells are cultured mammalian cells that can be easily transfected and / or in which stable lines can be generated for the expression of the peptides of the invention. The specific transfection method is chosen on the basis of general considerations well known in the state of the art, for example the type of cells to be transfected and the volume in which the transfection is performed. Preferred cell lines to use include 293 cells, CHO cells and HEK cells. Other suitable recombinant host cells include, for example, insect cells (e.g., Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni), mammalian cells (eg, humans, primates). non-humans, horses, cows, sheep, dogs, cats, and rodents (eg hamster), avian cells (eg chicken, duck and goose), bacteria (eg examples of E. coli, Bacillus subtilis, and Streptococcus spp.), yeast cells (for example Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenual polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica), Tetrahymena cells (e.g. Tetrahymena thermophila) or combinations thereof. Several insect cells and appropriate mammalian cells are well known in the art. Suitable insect cells include, for example, Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and High Five cells (a clone isolate derived from the parental BTI-TN-5B1-4 cell line). Trichoplusia ni (Invitrogen®)). Suitable mammalian cells include, for example, Chinese hamster ovary (CHO) cells, human embryonic kidney cells (HEK293 cells typically transformed with sheared DNA of type 5 adenovirus), NIH-3T3 cells, cells 293-T, Vero cells, HeLa cells, PERC.6 cells (ECACC deposit number 96022940), Hep G2 cells, MRC-5 (ATCC® CCL-171), WI-38 (ATCC® CCL-75 ), Rhesus fetal lung cells (ATCC® CL-160), Madin-Darby bovine kidney cells ("MDBK"), Madin-Darby canine kidney cells ("MDCK") (eg MDCK (NBL2), ATCC® CCL34 or MDCK 33016, DSM ACC 2219), baby hamster kidney (BHK) cells, such as BHK21-F, HKCC and the like. Suitable avian cells include, for example, chicken embryonic stem cells (e.g. EBx® cells), chicken embryo fibroblasts, chicken embryonic germ cells, duck cells (e.g. AGE1.CR and AGE1 cell lines). .CR.pIX (ProBioGen®) which are described, for example, in Vaccine 27: 4975-4982 (2009) and WO2005 / 042728), EB66 cells and the like.
Suitable insect cell expression systems, such as baculovirus systems, are known to those skilled in the art and are described, for example, in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Materials and methods for baculovirus / insect cell expression systems are commercially available in kit form among others from Invitrogen®, San Diego CA. The avian cell expression systems are also known to those skilled in the art and described for example in US Pat. Nos. 5,340,740, 5,656,479, 5,830,510, 6,114,168 and 6,500,668, the European patent. EP 0787180B; European Patent Application No. EP03291813.8; WO 03/043415; and WO 03/076601. Similarly, bacterial and mammalian cell expression systems are also known from the state of the art and described, for example, in Yeast Genetic Engineering (Barr et al., Eds., 1989) Butterworths, London.
Recombinant hybrids encoding ectodomains of the FVRS protein can be prepared in appropriate vectors using standard methods. A number of suitable vectors for the expression of recombinant proteins in insect or mammalian cells are well known and common in the state of the art. The appropriate vectors may contain a number of components, including, but not limited to, one or more of the following: an origin of replication; a selection marker gene; one or more expression control elements, such as a transcriptional control element (e.g. a promoter, an activator, a terminator), and / or one or more translation signals; and a signal sequence or leader sequence for targeting the secretory pathway in a selected host cell (e.g. of mammalian origin or from a mammalian or non-mammalian heterologous species). For example, for expression in insect cells, a suitable baculovirus expression vector such as pFastBac® (Invitrogen®) is used to produce recombinant baculovirus particles. The baculovirus particles are amplified and used to infect insect cells to express the recombinant protein. For expression in mammalian cells, a vector is used which will direct the expression of the hybrid in the desired mammalian host cell (e.g., Chinese hamster ovary cells).
The selection of expression hybrids and promoters for use in the manufacture of the complexes of the invention depends, for example, on the fact that the complex must be assembled from two different components, for example an ectodomain polypeptide. including one of the inserted HRA or HRB domains and a separate oligomerization polypeptide; or because the complex is to be assembled from a group of ectodomain polypeptides which include, for example, both an inserted HRA domain and a bound oligomerization domain comprising a HRB domain. Expression hybrids are known from the state of the art. Expression hybrids typically include, for example, promoter sequences for directing the expression of the coding sequence, the origins of replication to allow replication of the plasmid (either in bacteria or in mammalian cells), and optionally sequences for promoting integration of the expression hybrid stably into a cell for expression. Expression vectors comprising sequences for integration into the host genome will typically include sequences for selection, e.g., antibiotic resistance genes.
Transfection of coding sequences for the expression of ectodomain polypeptides linked to oligomerization domains
In some embodiments, the invention includes expression of the ectodomain polypeptides including an endogenous HRA domain of the FVRS, an endogenous HRB domain of the FVRS, and an inserted HRA domain or an inserted HRB domain, wherein the polypeptide of ectodomain is further operably linked to an oligomerization domain, i.e., an HRB domain when an inserted HRA domain is present in the ectodomain peptide, or a HRA domain when an Inserted HRB domain is present in the ectodomain peptide. In a preferred embodiment, when the oligomerization domain is operably linked to the ectodomain polypeptide, it is linked by co-translation of the ectodomain polypeptide and the oligomerization domain. Expression hybrids containing these coding sequences can be generated for expression in the type of cells of interest using methods and expression vectors known from the state of the art.
Similarly, when a T4 foldon sequence is operably linked to the ectodomain polypeptide, coding sequences encoding the hybrids can be generated using routine methods and transfected into a cell line suitable for expression.
Co-transfection of Coding Sequences for Iododomain Polypeptides and Oligomerization Polypeptides
Strategies for the expression of two distinct polypeptides in a single cell are known from the state of the art. For example, expression vectors encoding two distinct polypeptides may be co-transfected into cells. Co-transfection of expression vectors allows manipulation of the ratio of expression hybrids in a cell. As used herein, it is assumed that the ratio of the expression hybrids transfected into the cell reflects the ratio of the hybrids absorbed by the cell. For the sake of simplicity, an expression hybrid for the expression of an ectodomain polypeptide is considered to have the same molecular weight as an expression vector for the expression of an oligomerization domain. . Therefore, transfection of 1 μg of an expression vector containing a sequence for the expression of an ectodomain polypeptide with 1 μg of an expression vector containing a sequence for expression of a The single oligomerization domain will be understood to be a ratio of 1: 1 of the ectodomain to the oligomerization domain. Transfection of 1 μg of an expression vector containing a sequence for the expression of an ectodomain polypeptide with 4 μg of an expression vector containing a sequence for the expression of a unique domain of The oligomerization will be understood to be a ratio of 1: 4 of the ectodomain to the oligomerization domain. Other ratios for transfection of the coding sequences encoding the ectodomain polypeptide to the oligomerization polypeptide coding sequences include, but are not limited to, the 2: 1 to 1: 8 ratios. In preferred embodiments, the coding sequences for the oligomerization peptide are present in at least the same amount as the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization polypeptide are present in at least two times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization polypeptide are present in at least three times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization polypeptide are present in at least four times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization polypeptide are present in at least five times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization peptide are present in at least six times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization polypeptide are present in at least seven times the amount of the coding sequence for the ectodomain polypeptides. In some embodiments, the coding sequences for the oligomerization peptide are present in at least eight times the amount of the coding sequence for the ectodomain polypeptides.
In such a strategy where the ratio of the expression vectors containing the coding sequences for the different peptides is different from 1: 1, the expression vectors will typically comprise the same regulatory sequences for expression. The levels of expression can thus be modulated by the selection of promoter sequences or other transcriptional translational regulatory sequences. Stronger promoter, enhancer, and / or replication sequences to increase the relative number of transcripts from an expression hybrid relative to another expression hybrid initially introduced into the cell at the same level. These considerations are well understood by those skilled in the art.
Coding sequences for two distinct polypeptides may be included in a single expression hybrid, for example, a hybrid comprising an IRES sequence. The bicistronic expression vectors for the expression of two coding sequences are available, for example, from Clontech®. The use of these bicistronic vectors can facilitate the production of stable cell lines for expression of the complexes of the invention.
Without being bound by theory, it is believed that the presence of excess oligomerization domains (when not operably linked to the ectodomain polypeptides) will promote the formation of complexes containing ectodomain polypeptides. and oligomerization domains rather than complexes containing ectodomains only. Lead Sequences The assembly of FVRS complexes within cells occurs in the endoplasmic reticulum (ER) so that the complexes can be secreted from the cells. Therefore, the coding sequences for the ectodomain polypeptide and the separated oligomerization domain, when present, need to include an N-terminal "leader" sequence (also known as a signal sequence), preferably a cleavable N-terminal "leader" sequence, to promote peptide transduction into the ER. Known "leader" sequences include, but are not limited to, the "leader" sequence of native FVRS, the "leader" IgK sequence, the "leader" sequence of albumin serum protein (SAP), and the "leader" sequence. CD33. An appropriate "leader" sequence may be selected based on routine considerations in the state of the art such as the type of cell in which the proteins are to be expressed.
In a preferred embodiment, the native cleavable "leader" sequence of the ectodomain polypeptide of FVRS is used. However, it is understood that other "leader" sequences, preferably cleavable "leader" sequences, may be used.
When the oligomerization peptide is provided as a peptide separated from the ectodomain peptide, it then comprises an N-terminal "leader" sequence, preferably a cleavable N-terminal "leader" sequence, to promote transduction in the RE. The "leader" sequences for promoting transduction of the oligomerization peptide include, but are not limited to, the "leader" sequence of native FVRS, the "leader" IgK sequence (SEQ ID NO: 107), the "leader" sequence. Of the serum albumin protein (SAP), and the leader sequence CD33. Commercial expression vectors that contain "leader" sequences can be purchased to direct proteins to RE and secretion from the cell (eg Invitrogen® pDisplay ™ and pSecTag2 A, B, & C). Link Sequences
The ectodomain hybrids of the invention typically comprise at least one linker, preferably a peptide linker, between the endogenous HRB sequence of the FVRS and the inserted HRA or HRB sequence, the linker preferably being attached to the C-terminus. -terminal of the endogenous HRB sequence of the FVRS and between the endogenous HRB sequence of the FVRS and the inserted six-helix bundle domain, for example a HRA or HRB domain (eg endogenous N-HRA-endogenous HRB-first linker - HRA or HRB inserted-C). The linker sequence may be any length, preferably the linker is 3-30 amino acids long. In some embodiments, the linker is from about 5 to about 21 amino acids in length. In some embodiments, the linker is from about 10 to about 21 amino acids in length. In some embodiments, this binding sequence in the ectodomain polypeptide is a RSV sequence, preferably a sequence of the FVRS. Preferably, the linker is chosen to promote the interaction of the inserted HRA or HRB domain with the oligomerization peptide and to disadvantage the interaction of the inserted HRA or HRB domain with the endogenous HRA and HRB domains of the FVRS. In addition, the linker sequence does not include sequences that would promote the interaction of endogenous HRA and HRB domains with the inserted domains or oligomerization domains.
The ectodomain hybrids of the invention may comprise a second linker sequence through which the oligomerization domain is operably linked to the C-terminus of the ectodomain polypeptide, preferably in position adjacent, and the C-terminus of the inserted six-helix bundle fraction, for example an inserted HRA or HRB domain (e.g. endogenous-endogenous HRB-endogenous-HRA-linker-HRA or inserted HRB-2- linker oligomerization domain-C). The linker sequence may be any length, preferably the linker is about 3-30 amino acids in length. In some embodiments, the linker has a length of about 5 to about 21 amino acids and in some embodiments, a length of about 4-8 amino acids or a length of about 5-7 amino acids. In some embodiments, this second binding sequence in the ectodomain polypeptide is a RSV sequence, preferably a sequence of the FVRS. Preferably, the linker is chosen to promote the interaction of the oligomerization domain with the inserted six-helix bundle-forming fraction, for example an inserted HRA domain or the inserted HRB domain, and to disadvantage the interaction of the oligomerization domain. with the endogenous HRA and HRB domains of the FVRS. In addition, the linker sequence does not include sequences that would promote interaction of the inserted domain or oligomerization domain with the endogenous HRA and HRB domains of FVRS. For example, the second linker, when present, may be a structurally restricted linker, for example a proline-glycine linker that promotes interaction between the inserted six-helix bundle fraction, for example an inserted HRA or HRB sequence. with the adjacent oligomerization domain.
When using a T4 foldon trimerization sequence, a linker, preferably a peptide linker, is used to connect the foldon to the ectodomain polypeptide. The binding sequence may be any length, preferably the linker is about 3-30 amino acids in length. In some embodiments, the linker is from about 4 to about 21 amino acids in length. In some embodiments, the linker is from about 4 to about 21 amino acids in length. In some embodiments, the linker sequence is SAIG (SEQ ID NO: 116). In some embodiments, the linker is a sequence of the FVRS. In some embodiments, the linker is not a sequence of the FVRS.
Purification Labels
Purification tags may be used to facilitate the purification of the complexes of the invention and, in some embodiments, for the selection of complexes of the invention suitably assembled. In the ectodomain polypeptides, the purification tag is at the C-terminus on the inserted HRA or HRB domain when no oligomerization domain is bound to the ectodomain polypeptide, or at the end. C-terminal of the FVRS sequence when a T4 foldon domain is present. When the oligomerization peptide is not attached to the ectodomain polypeptide, the purification tag is at the N-terminus on the sequence of the oligomerization domain. In preferred embodiments with a separable oligomerization domain, if purification labels are present on both the ectodomain and the oligomerization domain, the purification labels are different. In a preferred embodiment with a separate oligomerization polypeptide, a purification tag is present only on the oligomerization polypeptide and not on the ectodomain polypeptide. Therefore, the affinity purification selects assembled complexes and unique oligomerization domains that are substantially of different size and can be easily removed using known purification methods, for example SEC, to provide a population of assembled trimers.
In some embodiments, the purification labels are relatively small, for example, less than 10 kDa, preferably less than 5 kDa. Preferred labels include, but are not limited to, strep labels, including strep tandem labels; 6 X His tags, myc tags, and HAI tags. Multiple copies of smaller labels may be inserted into the FVRS peptides of the invention. For example, the labels may be tandemly expressed adjacent to or almost adjacent to each other. In some embodiments, tags may be inserted at the N-terminus and C-terminus of a six-helix bundle domain, for example at the N-terminus and C-terminus of a domain. inserted, or at the N-terminus and C-terminus of an oligomerization domain, which is either connected or not connected to an ectodomain. The labels may then include larger labels, for example GST tags. However, larger labels are typically used as single copies.
In preferred embodiments, the purification tags may be removed by protease cleavage. Removal of the purification tags by protease cleavage preferably does not result in substantial cleavage of the other portions of the FVRS complex. The methods for selecting the protease cleavage sites and the appropriate conditions are well known in the state of the art.
Purification of the complex
The ectodomain polypeptides of the FVRS protein, the oligomerization peptides, and the complexes can be purified using any suitable method. For example, the methods for purifying ectodomain FVRS polypeptides by immunoaffinity chromatography are known in the art. Ruiz-Arguello et al., J. Gen. Viroy., 05: 3677-3687 (2004). Suitable methods of purifying the desired proteins including precipitation and various types of chromatography, such as hydrophobic interaction, ion exchange, affinity, chelation and steric exclusion are well known in the state of the art . Appropriate purification schemes can be created using two or more of these suitable methods, or other methods. If desired, the polypeptides of the FVRS ectodomain and the oligomerization peptides may comprise a "tag" that facilitates purification, such as an epitope tag or HIS tag. These labeled polypeptides can be purified adequately, for example from conditioned media, by chelation chromatography or by affinity chromatography. The use of purification labels can facilitate the purification of properly assembled trimers. For example, if two ectodomain polypeptides comprising endogenous HRA and HRB domains of the FVRS and an inserted HRA domain formed a complex in which the inserted HRA is complexed with the endogenous HRB, the affinity tags will likely be buried in the endogenous HRB. the complex so that the complex will not be captured by the affinity purification method. Similarly, the disordered multimerization of the peptides will likely mask the purification labels. In some embodiments, only the unbound oligomerization peptide comprises an affinity tag. Therefore, only complexes containing at least one oligomerization polypeptide with a naked purification tag are captured by the affinity purification methods. Because of the substantial difference in sizes between the assembled complexes and the oligomerization peptides, the complexes are easily separated from the oligomerization peptides giving a well formed population of trimers.
Affinity purification methods can be used in combination with other purification methods, for example, size exclusion chromatography is useful for the separation of well-formed trimers from monomers and other complexes. In some embodiments, the purification tags are cleaved from the assembled complexes prior to the subsequent purification steps.
In preferred embodiments, the FVRS complexes are assembled into cells and secreted into the growth media to facilitate purification. It is understood that the number and types of purification steps to be performed depend, at least in part, on the method of expression or production of the peptides for use in the complexes of the invention. Additional peptide sequences
The oligomerization polypeptides contain an oligomerization region and, if desired, may further contain a functional region as described herein. Suitable amino acid sequences for the oligomerization regions (e.g., the six-helix bundle fraction, e.g., the HRA domain amino acid sequence or the FVRS HRB domain) are well known to the state of the art, as are the appropriate functional regions. The oligomerization polypeptide can be prepared using any suitable method, such as by chemical synthesis, recombinant expression in a suitable host cell, chemical conjugation and the like.
Assembly and cleavage of FVRS complexes
Complexes with linked oligomerization domains
In certain aspects, the invention relates to a method for producing a FVRS complex that contains three FVRS ectodomain polypeptides each comprising a first C-terminal portion forming a 6-helix bundle and a second C-terminal fraction. 6-helix bundle terminal (i.e., a functionally-linked oligomerization domain), and therefore does not include a separate oligomerization polypeptide. The process for producing such complexes containing a bound oligomerization domain is substantially the same as the process for producing complexes that contain an oligomerization polypeptide except that the ratio of bound oligomerization domains to ectodomain polypeptides is fixed, and no separate oligomerization polypeptide is added to the ectodomain polypeptides during assembly of the trimers. In particular, the method comprises: a) providing FVRS ectodomain polypeptides comprising an endogenous HRA region and an endogenous HRB region further containing a first inserted (i.e., non-endogenous) C-terminal moiety forming a 6-helix bundle and a second non-endogenous C-terminal 6-helix bundle (i.e., the oligomerization domain), and b) combining the ectodomain polypeptides of FVRS under conditions suitable for the formation of a FVRS complex, whereby a FVRS complex is produced which comprises three FVRS ectodomain polypeptides and is characterized by a six-helix bundle formed by the first and second non-endogenous C-terminal fractions forming a 6-helix bundle (e.g., six-helix bundle inserted fractions and oligomerization domains). It is understood that these steps can take place inside a cell or outside a cell. This means that it is understood that the combination may comprise the coexpression of the polypeptides within a cell. Further, it is understood that the conditions appropriate for formation of a FVRS complex may include conditions within a cell or outside a cell. Suitable conditions outside the cell may include a series of conditions that promote partial deployment and refolding of the ectodomain monomers to produce the trimers of the invention.
The same methods will be used when a T4 foldon trimerization sequence is bound to the FVRS ectodomain polypeptide.
When it is desired to obtain FVRS complexes that contain cloned FRSO ectodomain polypeptides, the optional step is to c) cleave the ectodomain polypeptides of the FVRS protein into the protease-produced complex. appropriate. Suitable proteases include any protease that can cleave the FVRS ectodomain polypeptide (preferably an uncleaved FVRS ectodomain polypeptide) to form the Fl and F2 subunits. Usually, the protease will cleave a natural cleavage site or inserted between about position 101 and position about 161. Proteases that can be used include, but are not limited to, trypsin, chymotrypsin, TEV protease, rhinovirus 3c, and thrombin. If trypsin is used, digestion of the FVRS complex with trypsin is performed using 1: 1000 trypsin: FVRS complex by weight or 10-15 units BAEE trypsin per 1 mg FVRS complex. In a typical reaction, trypsin from bovine plasma (Sigma Aldrich, T8802: 10,000-15,000 BAEE units / mg trypsin) is diluted to 1 mg / ml concentration in 25 mM Tris pH 7.5, 300 mM of NaCl and the ectodomain polypeptide of the FVRS protein (in 25 mM Tris pH 7.5, 300 mM NaCl) was digested for 1 hour at 37 ° C. The cleavage reaction can be stopped using a trypsin inhibitor. In some embodiments, the cleavage site comprises a furine cleavage site, optionally an optimized furine cleavage site. When using a furine cleavage site, the complex is preferably assembled within the cells and furin cleavage takes place within the cells.
In some embodiments, the ectodomain polypeptides or oligomerization polypeptides may comprise purification tags that are removed by protease cleavage. Removal of the purification tag does not produce a cleaved ectodomain polypeptide since the purification tag is not present in the ectodomain polypeptide. The removal of purification labels by protease cleavage occurs outside the cell after purification of the protein complex. The proteases for removal of the purification tags are chosen so that no significant cleavage of the FVRS complex occurs within the sequences of the FVRS. Those skilled in the art are able to select the appropriate proteases.
Complexes with separate oligomerization domains
In some embodiments, the method includes
a) providing FVRS ectodomain polypeptides further comprising at least one inserted C-terminal moiety forming a 6-helix bundle and at least one oligomerization polypeptide (which may include more than one oligomerization domain) non-bound to the ectodomain polypeptide, and b) combining the ectodomain polypeptides of FVRS and at least one oligomerization polypeptide under conditions suitable for formation of a FVRS complex, whereby a complex of FVRS is produced, which comprises three of the FVRS ectodomain polypeptides, and the at least one oligomerization polypeptide, and is characterized by a six-helix bundle. The six-helix bundle comprises an inserted C-terminal portion forming a 6-helix bundle of each FVRS ectodomain polypeptide (e.g., FVRS-inserted FVRS or HRB inserted from FVRS) and three oligomerization domains. for example, each oligomerization domain of three oligomerization polypeptides (for example HRB of FVRS or HRA of FVRS, respectively). In some embodiments, three oligomerization oligomerization domains comprise the amino acid sequence of the HRB region of the FVRS, and the six helix bundle moiety comprises the inserted HRA region of each of the three polypeptides. of the ectodomain of FVRS. It is understood that these steps can take place inside a cell or outside a cell. This means that it is understood that the combination may comprise the coexpression of the polypeptides within a cell. Further, it is understood that the conditions appropriate for formation of a FVRS complex may include conditions within a cell or outside a cell. Suitable conditions outside the cell may include a series of conditions which promote the partial deployment and refolding of the ectodomain monomers to produce the trimers of the invention. Further, it is understood that the FVRS ectodomain polypeptides may include cleavage sites that can be cleaved outside of the cell or within the cell. Further, it is understood that the FVRS ectodomain polypeptides or oligomerization polypeptides may comprise purification tags which may be optionally removed by protease cleavage. The purification labels are removed outside the cell after purification.
In other embodiments, the method comprises a) providing recombinant ectodomain FVRS polypeptides each further comprising a C-terminal 6-helix bundle moiety and at least one oligomerization polypeptide ( wherein the oligomerization peptide may comprise more than one oligomerization domain), and b) combining the recombinant polypeptides of the FVRS ectodomain each further comprising a C-terminal moiety forming a 6-helix bundle and at least one an oligomerization polypeptide under conditions suitable for formation of a FVRS complex, whereby a FVRS complex is produced, which comprises three of the FVRS ectodomain polypeptides each further containing a C-fraction. 6-helix bundle, the at least one oligomerization polypeptide, preferably three of the oligomerization polypeptides, and is characterized by a six-helix bundle. The six-helix bundle comprises the inserted 6-helical bundle C-terminal fraction of each FVRS ectodomain recombinant polypeptide and three oligomerization domains, preferably one oligomerization domain in each of the three polypeptides. oligomerization. In some embodiments, the C-terminal 6-helix bundle is the HRB region of the HIV gp41 HRV or HR2, and the three oligomerization domains of the oligomerization peptide (s) comprise the FRVS HRA or HR1 amino acids of HIV gp41, respectively, or the other six helix bundle moieties include, but are not limited to, class I viral fusion proteins that contain beam forming fractions. with 6 propellers. In these embodiments, the six-helix bundle comprises the inserted 6-helix bundle C-terminal fraction (i.e., the inserted HRA region) of each FVRS ectodomain polypeptide and the HRB region of each oligomerization peptide. It is understood that these steps can take place inside a cell or outside a cell. This means that it is understood that the combination may comprise the coexpression of the polypeptides within a cell. Further, it is understood that the conditions appropriate for formation of a FVRS complex may include conditions within a cell or outside a cell. Suitable conditions outside the cell may include a series of conditions that promote the partial deployment and refolding of the monomodomains of the ectodomain to produce the trimers of the invention. Further, it is understood that the FVRS ectodomain polypeptides may include cleavage sites that can be cleaved outside of the cell or within the cell. Further, it is understood that the FVRS ectodomain polypeptides or oligomerization polypeptides may comprise purification tags which may be optionally removed by protease cleavage. The purification labels are removed outside the cell after purification. The invention thus includes complexes of FVRS produced using the methods described herein.
Immunogenic Compositions The invention provides immunogenic compositions that include the FVRS complexes disclosed herein. The compositions are preferably suitable for administration in a mammalian subject such as a human and comprise one or more pharmaceutically acceptable carriers and / or excipients, including adjuvants. A thorough presentation of these components is provided in Gennaro (2000) Remington: The Science and Practice of Pharmacy. 2nd edition, ISBN: 0683306472. The compositions will generally be in an aqueous form. When the composition is an immunogenic composition, it will elicit an immune response when administered to a mammal such as a human. In some embodiments, the immune response is a neutralizing immune response. The immunogenic composition can be used to prepare a vaccine formulation for immunization of a mammal.
The immunogenic compositions may include a single active immunogenic agent or a plurality of immunogenic agents. For example, the compositions may contain a complex of FVRS and one or more other RSV proteins (for example a G protein and / or a M protein) and / or one or more immunogens from other pathogens. The immunogenic composition may comprise a monovalent FVRS complex that contains the FVRS complexes provided herein, and if desired, one or more additional antigens from the FVRS or another pathogen, for example influenza. In one example, the immunogenic composition is divalent and comprises a FVRS complex that also contains another FVRS antigen, such as RSV G protein. As described herein, these multivalent complexes can be produced using an oligomerization polypeptide that contains an oligomerization region that is operably linked to an amino acid sequence from GVRS, such as an amino acid sequence derived from the amino acid sequence. central area G of the VRS.
The composition may include preservatives such as thiomersal or 2-phenoxyethanol. It is preferred, however, that the vaccine be substantially free (i.e., less than 5 μg / ml) of mercury, e.g., free of thiomersal. Immunogenic compositions containing no mercury are most preferred. Immunogenic compositions without preservatives are particularly preferred.
To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present in a concentration of between 1 and 20 mg / ml. Other salts that may be present include potassium chloride, potassium dihydrogenphosphate, dehydrated disodium phosphate, magnesium chloride, calcium chloride and the like.
The compositions will generally have an osmolality of between 200 mOsm / kg and 400 mOsm / kg, preferably between 240 and 360 mOsm / kg, and will preferably be in the range of 290 and 310 mOsm / kg.
The compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (especially with an aluminum hydroxide adjuvant); or a citrate buffer. The buffers will typically be in the range of 5 to 20 mM. The pH of a composition will generally be between 5.0 and 8.1, and more typically between 6.0 and 8.0, for example between 6.5 and 7.5, or between 7.0 and 7.8. . A method of the invention may therefore include a step of adjusting the pH of the bulk vaccine prior to conditioning.
The composition is preferably sterile. The composition is preferably non-pyrogenic, for example containing <1 EU (endotoxin unit, a standard measurement) per dose, and preferably <0.1 EU per dose. The composition is preferably free of gluten. Human vaccines are typically administered in a dosage volume of about 0.5 ml, although a half dose (i.e., about 0.25 ml) may be administered to children.
The immunogenic compositions of the invention may also comprise one or more immunoregulatory agents. Preferably, one or more immunoregulatory agents comprise one or more adjuvants, for example two, three, four or more adjuvants. Adjuvants may include TH1 adjuvant and / or TH2 adjuvant.
In certain embodiments, the immunogenic compositions provided by the invention may include one or more adjuvants selected from a metal salt (such as aluminum hydroxide), a lipid adjuvant, such as MF59 <D, AS03 ™, small molecule immunopotentiators, such as TLR agonists (toll receptor), such as TLR2, TLR7, TLR8, or TLR9 agonists, such as benzonapthyridines, aminobenzazepines, imidazoquinolines, and oxoadenines, as well as combinations of these.
Preferably, the immunogenic composition comprises a FVRS complex which has an epitope present in a pre-fusion conformation of the FVRS glycoprotein. An exemplary composition comprises a FRVS complex that contains cloned FVRS ectodomain polypeptides. Another exemplary composition includes a FRVS complex that contains uncleaved FVRS ectodomain polypeptides.
Processes of treatment and administration
The compositions of the invention are suitable for administration to mammals, and the invention provides a method for inducing an immune response in a mammal, comprising the step of administering a composition (e.g., immunogenic composition) of the invention to a mammal. In some embodiments, the immune response is a neutralizing immune response. The compositions (e.g., an immunogenic composition) can be used to produce a vaccine formulation to immunize a mammal. The mammal is typically a human and the FVRS complex typically contains human FVRS ectodomain polypeptides. However, the mammal may be any other mammal susceptible to RSV infection, such as a cow that may be infected with bovine RSV. The invention also provides a composition for use as a medicament, for example for use in immunizing a patient against RSV infection, e.g. for use in triggering a neutralizing immune response in a patient. The invention also provides the use of a FVRS complex as described above in the manufacture of a medicament for eliciting an immune response in a patient.
The immune response elicited by these methods and uses will generally include an antibody response, preferably a protective antibody response (i.e., a neutralizing response). Methods for evaluating antibody responses after RSV vaccination are well known in the art.
The compositions of the invention may be administered in a number of suitable ways, such as by intramuscular injection (eg, into the arm or leg), subcutaneous injection, intranasal administration, oral administration, intradermal administration, transcutaneous administration, by transdermal administration, and the like. The appropriate route of administration will depend on the age, health and other characteristics of the mammal. A physician will be able to determine an appropriate route of administration based on these and other factors.
Immunogenic compositions and vaccine formulations can be used to treat children and adults, including pregnant women. So, a subject can be less than 1 year old, 1 to 5 years old, 5 to 15 years old, 15 to 55 years old, or at least 55 years old. The preferred subjects likely to receive the vaccines are the elderly (for example> 50 years,> 60 years, and preferably> 65 years) and pregnant women. Vaccines are not appropriate only for these groups, and they can be used more generally in a population.
Treatment can be by single dose or multiple dose. The multiple doses may be used in a first-dose regimen and / or in a booster dose regimen. In a multiple dose regimen, the different doses may be administered by the same or different routes, for example parenteral primo-vaccination and mucosal booster, mucosal primo-vaccination and parenteral booster, etc. Administration of more than one dose (typically two doses) is particularly useful in immunologically naive patients. Multiple doses will typically be administered at least 1 week apart (eg, about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, and similar.).
Vaccine formulations produced using a composition of the invention may be administered to patients at substantially the same time as (for example during the same consultation or medical visit to a health professional or a vaccination center) other vaccines .
Other viruses
While being used with human RSV, the invention may be used with other members of Pneumoviridae and Paramyxoviridae, including, but not limited to, bovine respiratory syncytial virus, para-influenza virus 1, para virus influenza 2, para-influenza virus 3, and para-influenza virus 5.
Thus, the invention provides an immunogenic composition comprising a F glycoprotein derived from a Pneumoviridae or Paramyxoviridae, wherein the F glycoprotein is in pre-fusion conformation. The invention also provides an immunogenic composition comprising a polypeptide which has an epitope present in a pre-fusion conformation of the F glycoprotein of a Pneumoviridae or Paramyxoviridae, but absent from the post-fusion conformation of the glycoprotein. The invention also provides these polypeptides and compositions for use in immunization, etc.
Nucleic acids
In another aspect, the invention provides nucleic acids encoding the FVRS polypeptides provided by the invention, such as the Fodsectodomain polypeptides provided by the invention. In some embodiments, the nucleic acid is a vector, for example comprising one or more selectable markers and one or more origins of replication, and one or more promoters. In some embodiments, the nucleic acid encodes a self-replicating RNA encoding a FVRS polypeptide and a replicase (RNA-dependent RNA polymerase). Examples of replicases include viral replicases, for example corresponding to non-structural viral proteins. In certain particular embodiments, the self-replicating RNA is devoid of structural viral proteins capable of forming viral particles and can therefore, in the absence of complementary helper sequences, form mature viral particles (for example, as is evaluated by various techniques, such as crystallography or electron microscopy, for example may be devoid of sequences encoding the entire capsid protein). Nevertheless, a self-replicating RNA lacking structural viral proteins capable of forming virus particles may, in some embodiments, retain the elements required to replicate the RNA, for example cyclization sequences and signal sequences. In particular embodiments, the self-replicating RNA is derived from a (+) stranded virus, such as an alphavirus or flavivirus, including chimeric viruses. In related aspects, the invention provides self-replicating RNA as described above, optionally wherein the RNA is derived from a (+) stranded virus.
In some embodiments, a FVRS polypeptide and an oligomerization peptide are encoded on a single nucleic acid, either in the form of a fusion protein (optionally separated by a separation sequence, such as a 2A viral sequence) or in the form of a fusion protein. polycistronic hybrid, for example wherein the sequences encoding the FVRS polypeptide and the oligomerization peptide are separated by IRES.
In some particular embodiments, the nucleic acids provided by the invention encode a sequence comprising the amino acid sequence of any one of SEQ ID NOs: 47-87, 89-105, and 117-136, including their subsequences, for example, lacking a signal sequence, purification labels, and other elements that are not essential for the FVRS polypeptides to adopt the desired conformation.
A nucleic acid provided by the invention may be provided with a variety of carrier systems, comprising: a viral replicon particle (VRP), a lipid nanoparticle (LNP, for example wherein the nucleic acid is enveloped in the LNP ), a cationic nanoemulsion (where the nucleic acid is complexed with the outside of the particle), or a biodegradable polymer (where the nucleic acid is complexed with the outside of the particle). The useful delivery systems for the nucleic acids provided by the invention are described inter alia for CNEs: WO2012 / 006380, WO2013 / 006837, WO2013 / 006834; for LNP: WO2012 / 006378, WO2012 / 030901, WO2012 / 031046, WO2012 / 031043, WO2013 / 033563, WO2013 / 006825, WO2011 / 076807, USSN 61/774759, PCT / US14 / 70882, PCT / US14 / 70891, and USSN 62/046487; for other modalities, see: W02012 / 006359, W02012 / 006376; all previous applications being incorporated herein by reference. Overview
As used herein, the term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open ended and does not exclude elements or process steps. additional not mentioned. As used herein, the "consisting of" transition phrase excludes any element, step or ingredient that is not specified in the claim. Finally, as used herein, the transition phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps "and to those which do not materially affect the basic and novel features" of the invention. claimed, as understood under the United States Patent Law.
The word "substantially or substantially" does not exclude "completely", for example a composition that is "substantially or substantially free" of Y may be completely devoid of Y. Essentially or substantially, for example, may include at least 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%. When necessary, the word "substantially or substantially" may be omitted from the definition of the invention.
The term "about" in relation to a numerical value x designates, for example, + two standard deviations of the value. In some embodiments, "about" is understood to be an acceptable variation as well as tolerances in a specific state of the art. Of course, tolerances for SEC and western blot are higher, for example, than tolerances in BIACore® measurements. The methods and controls are known from the state of the art to give more quantitative or at least semi-quantitative results from certain methods. In addition, it is understood that certain methods are more useful for detecting relative amounts of components rather than absolute amounts of components (eg Western blot and SEC). For western blot and SEC when comparing relative levels of components, about is preferably understood to be less than or equal to 5%, preferably less than or equal to 3%. Unless it is apparent from the context, all numeric terms shown here are understood to be changed by approximately.
As used herein, "or" is understood to be inclusive and synonymous with "and / or" unless the context clearly indicates otherwise. For example, when referring to a population of FVRS complexes that have a certain percentage of complexes that are adequately folded or a certain percentage that are cleaved, "or" is understood to be synonymous with "and / or." For example, a population of polypeptides in which a first percentage are trimers and a second percentage are cleaved, or are included as and / or. Nevertheless, when referring to a polypeptide that includes any of the inserted HRAs or HRBs inserted, "or" is understood from the context to be exclusive, that is, an HRA inserted is present either an inserted HRB is present for this element, not both.
As used herein, "one" and "the" are understood to include both singular and plural forms unless the context clearly indicates otherwise.
Unless otherwise specifically stated, a process comprising a step of mixing two or more components does not require a specific mixing order. So the components can be mixed in any order. When there are three components, the two components can be combined with each other, and this combination can then be combined with the third component, etc.
When animal (and particularly bovine) material is used in cell culture, it should be obtained from sources that are free of transmissible spongiform encephalopathies (TSE), and in particular free from Bovine Spongiform Encephalopathy (BSE). ). Overall, it is preferred to culture the cells in the complete absence of animal derived materials.
When a compound is administered to the body as part of a composition, then this compound may alternatively be replaced by a suitable prodrug.
When a cell substrate is used for reverse reassortment procedures or genetirques, it will preferably be a substrate that has been licensed for use in the production of human vaccines, for example as in General Chapter 5.2.3 of the Ph. Eur. The identity between the polypeptide sequences is preferably determined by the homology search algorithm as it is installed in the Oxford Molecular (MPSRCH) program, using an affine gap search with penalty parameters of gap = 12 aperture and gap extension penalty = 1. The identity can be determined over the entire length of the sequence, over one or more domains of a sequence, or within overlapping portions of two sequences.
Embodiments of the Invention The invention comprises the following embodiments:
Embodiment 1. A respiratory syncytial virus F protein (FVRS) complex comprising a six-helix bundle comprising: three FVRS ectodomain polypeptides, each comprising an endogenous HRA region, an endogenous HRB region, further comprising one of a six-helix bundle inserted region, preferably one of an inserted HRA region of the FVRS or an inserted HRB region of the FVRS, and at least one oligomerization polypeptide, wherein the three ectodomain polypeptides and the at least one oligomerization polypeptide form a six-helix bundle, provided that the six-helix bundle does not include endogenous HRA regions and endogenous HRB regions of the FVRS polypeptides,
Embodiment 2. The FVRS complex of Embodiment 1, wherein each FVRS ectodomain polypeptide comprises an inserted HRA region.
Embodiment 3. The FVRS complex of Embodiment 1, wherein each FVRS ectodomain polypeptide comprises an inserted HRB region.
Embodiment 4. The FVRS complex of any one of embodiments 1 to 3, wherein the six helix bundle is detected by a method selected from the group consisting of size exclusion chromatography, western blot, and electron microscopy.
Embodiment 5. The FVRS complex of any one of embodiments 1 to 4, wherein the inserted HRA region of the FVRS or the inserted HRB region of the FVRS is bound to the ectodomain by a polypeptide linker .
Embodiment 6. The FVRS complex of Embodiment 5, wherein the polypeptide linker is 3-30, 3-21, 3-15, 3-10, 4-8, or 5-7 acids long. amines. In some embodiments, the linker sequence comprises a FVRS polypeptide sequence, for example ELSNIKENKSNGTDAK (SEQ ID NO: 115) and GVGSA (SEQ ID NO: 114). In some embodiments, the linker sequence does not include a FVRS binding sequence having at least four consecutive amino acids of the FVRS.
Embodiment 7. The FVRS complex of Embodiment 5 or 6, wherein the inserted HRA region of the FVRS or the inserted HRB region of the FVRS is at the C-terminus of the ectodomain in the polypeptide of the ectodomain of FVRS.
Embodiment 8. The FVRS complex of any one of embodiments 1 to 7, wherein the six-helix bundle comprises the inserted HRA region of each ectodomain polypeptide of FVRS and the polypeptide of oligomerization comprises an HRB region.
Embodiment 9. The FVRS complex of Embodiment 5, wherein the HRB region is operably linked to at least one FVRS ectodomain polypeptide.
Embodiment 10. The FVRS complex of Embodiment 6, wherein the HRB region is bound to at least one ectodomain polypeptide. FVRS by a covalent linker.
Embodiment 11. The FVRS complex of any one of embodiments 1 to 7, wherein the six-helix bundle comprises the inserted HRB region of each FVRS ectodomain polypeptide and the polypeptide of oligomerization comprises an HRA region.
Embodiment 12. The FVRS complex of Embodiment 11, wherein the HRA region is operably linked to at least one FVRS ectodomain polypeptide.
Embodiment 13. The FVRS complex of Embodiment 12, wherein the HRA region is linked to at least one FVRS ectodomain polypeptide by a covalent linker.
Embodiment 14. The FVRS complex of Embodiment 10 or 13, wherein the covalent linker comprises a polypeptide linker.
Embodiment 15. The FVRS complex of Embodiment 13 or 14, wherein the covalent linker comprises a structurally restricted linker.
Embodiment 16. The FVRS complex of Embodiment 14 or 15 wherein the polypeptide linker has a length of 3-30, 3-21, 3-15, 3-10, 4-8, or 5-7 amino acids. In some embodiments, the linker sequence comprises a FVRS polypeptide sequence, for example ELSNIKENKSNGTDAK (SEQ ID NO: 115) and GVGSA (SEQ ID NO: 114). In some embodiments, the linker sequence does not include a FVRS binding sequence having at least three consecutive amino acids of the FVRS.
Embodiment 17. The FVRS complex of any one of Embodiments 10 or 13 to 16, wherein the oligomerization domain is at the C-terminus of the inserted HRA region or HRB region. inserted.
Embodiment 18. The FVRS complex of any one of embodiments 1 to 8 and 11, wherein the oligomerization polypeptide is not bound to at least one FVRS ectodomain polypeptide.
Embodiment 19. The FVRS complex of any one of embodiments 1 to 18, wherein the oligomerization polypeptide comprises a heptad repeat region of a fusion protein of an enveloped virus. .
Embodiment 20. The FVRS complex of Embodiment 19, wherein the heptad repeat region of a fusion protein of an enveloped virus is selected from the group consisting of a HR1 region of gp41 of HIV, HR2 region of HIV gp41, HR1 / HR2 regions of Newcastle disease virus (NDV), HR1 / HR2 regions of human metapneumovirus or other class 1 viral fusion proteins that contain clusters of 6 propellers in the post-fusion state.
Embodiment 21. The FVRS complex of any one of embodiments 1 to 20, wherein the at least one oligomerization polypeptide comprises two polypeptides.
Embodiment 22. The FVRS complex of any one of embodiments 1 to 20, wherein the at least one oligomerization polypeptide comprises three polypeptides.
Embodiment 23. The FVRS complex of any one of embodiments 1 to 22, wherein the. oligomerization polypeptide comprises a purification tag.
Embodiment 24. The FVRS complex of Embodiment 23, wherein the purification tag comprises at least one tag selected from the group consisting of a 6X His tag (SEQ ID NO: 39), a strep tag, a myc tag.
Embodiment 25. The FVRS complex of Embodiment 23 or 24, wherein the purification tag comprises 2 tags in tandem.
Embodiment 26. The FVRS complex of Embodiment 23 or 24, wherein the purification tag comprises a cleavable purification tag.
Embodiment 27. The FVRS complex of any one of embodiments 1 to 26, wherein one or more of said oligomerization polypeptides further comprises a functional region that is operably linked to the oligomerization polypeptide. .
Embodiment 28. The FVRS complex of Embodiment 27, wherein the functional regions are selected from the group consisting of an immunogenic carrier protein, an antigen, a peptide-forming particle, a lipid, and a polypeptide that can associating the oligomerization polypeptide with a liposome or a particle; or any combination thereof.
Embodiment 29. The FVRS complex of Embodiment 28, wherein the functional region is a therapeutically relevant antigen.
Embodiment 30. The FVRS complex of embodiment 28 or 29, wherein the antigen is not present in the FVRS.
Embodiment 31. The FVRS complex of any one of embodiments 28 to 30, wherein the antigen is an artificial sequence.
Embodiment 32. The FVRS complex of Embodiment 28 to 30, wherein the antigen is GVRS.
Embodiment 33. The FVRS complex of any one of embodiments 1 to 32, wherein one or more of the FVRS ectodomain polypeptides comprise an uncleaved FVRS ectodomain polypeptide.
Embodiment 34. The FVRS complex of any one of embodiments 1 to 32, wherein one or more of the FVRS ectodomain polypeptides comprise a cloned FVRS ectodomain polypeptide. In some embodiments, at least 95%, 96%, 97%, 98%, or 99% of all of the FVRS ectodomain polypeptides are cleaved. In some embodiments, no uncleaved FVRS polypeptide can be detected, for example by staining with Coomassie blue, preferably by western blotting made by the following method, of a boiled and reduced sample resolved by SDS. -PAGE.
Embodiment 35. The FVRS complex of any one of embodiments 1-34, wherein each of the FVRS ectodomain polypeptides comprises a modified furine cleavage site.
Embodiment 36. The FVRS complex of any one of embodiments 1 to 35, wherein each of the FVRS ectodomain polypeptides comprises a protease cleavage site. For example, a FVRS complex in which each of the FVRS ectodomain polypeptides comprises a furine cleavage site, preferably an optimized furine cleavage site, preferably 2 optimized furine cleavage sites. . For example, a FVRS polypeptide comprising an F137S mutation at a position corresponding to the amino acid numbering of SEQ ID NO: 1.
Embodiment 37. The FVRS complex of Embodiment 36, wherein the protease cleavage site is selected from the group consisting of the furin cleavage site, the trypsin cleavage site, the cleavage with chymotrypsin, the TEV protease cleavage site, the thrombin cleavage site, and the rhinovirus 3c protease cleavage site.
Embodiment 38. The FVRS complex of any one of embodiments 1 to 37, wherein the amino acid sequence of the FVRS ectodomain polypeptides comprises a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 (Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO: 6 (Furx) R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 (Delp23 furdel), SEQ ID NO: 12 (N-term Furin), SEQ ID NO: 13 (Furin C-term), SEQ ID NO: 14 (Xa Factor), SEQ ID NO: 15, SEQ ID NO: 26 (Peptide Deletion). Fusion 1), an ectodomain sequence indicated in the sequence listing; and any one of the preceding wherein the signal peptide and / or the HIS tag and / or the fusion peptide is altered or absent.
Embodiment 39. The FVRS complex of any one of embodiments 1 to 38, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises S155C and S290C substitutions.
Embodiment 40. The FVRS complex of any one of embodiments 1 to 39, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises an F substitution on the acid. amine 190 and / or an L substitution on amino acid 207.
Embodiment 41. The FVRS complex of any one of embodiments 1 to 38, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises the S155C, S290C, SI90F substitutions. , and V207L.
Embodiment 42. The FVRS complex of Embodiment 1, wherein the oligomerization polypeptide comprises a 6-helix bundle moiety.
Embodiment 43. The complex of the. FVRS of Embodiment 42, wherein the six-helix bundle-forming fraction comprises a heptad repeat region of the fusion protein of an enveloped virus.
Embodiment 44. The FVRS complex of Embodiment 43, wherein the heptad repeat region is selected from the group consisting of a FVRS HRA domain, a FVRS HRB domain, an HR1 region. of HIV gp41, HR2 region of HIV gp41, HR1 / HR2 regions of Newcastle disease virus (NDV), HR1 / HR2 regions of human metapneumovirus, other class 1 viral fusion proteins which contain 6-helix beams in the post-fusion state.
Embodiment 45. The FVRS complex of any one of embodiments 42 to 44, wherein the six-helix bundle comprises the inserted H RA domain of the FVRS or the inserted HRV domain of the FVRS of three polypeptides. recombinants of the FVRS ectodomain and the oligomerization region of each oligomerization polypeptide.
Embodiment 46. The FVRS complex of any one of embodiments 1 to 45, wherein the FVRS ectodomain polypeptides are in pre-fusion conformation.
Embodiment 47. The FVRS complex of any one of Embodiments 1 to 46, wherein the complex is characterized by a rounded shape when viewed on negatively colored electron micrographs.
Embodiment 48. The FVRS complex of any one of embodiments 1 to 47, wherein the complex is characterized by binding to the antibody.
Embodiment 49. The FVRS complex of Embodiment 48, wherein the binding to the D25 antibody is indicative of a pre-fusion conformation.
Embodiment 50. The FVRS complex of any one of Embodiments 1 to 49, wherein the complex comprises pre-fusion epitopes that are not present on the post-fusion forms of FVRS.
Embodiment 51. The FVRS complex of any one of Embodiments 1 to 37 and 42 to 45, wherein the ectodomain polypeptides of the FVRS are in post-fusion conformation.
Embodiment 52. The FVRS complex of any one of embodiments 1 to 51, wherein the inserted HRA region or the inserted HRB region is at the C-terminus of the endogenous HRB region in the polypeptide of the ectodomain of FVRS.
Embodiment 53. The FVRS complex of embodiment 52, wherein the oligomerization polypeptide is bound to the FVRS ectodomain polypeptide at the C-terminus of the inserted HRA region or region. HRB inserted.
Embodiment 54. A respiratory syncytial virus F protein (FVRS) complex comprising a six-helix bundle, comprising three FVRS ectodomain polypeptides, each comprising (a) an endogenous HRA region, an HRB region further comprising (b) a region from an inserted HRA region of the FVRS or an inserted HRB region of the FVRS, further comprising (c) a C-terminal fraction forming a 6-helix bundle, the six-beam helices is formed by the C-terminal 6-helix bundle and the inserted HRA region or the inserted HRB region, provided that the six-helix bundle does not include the endogenous HRA regions and the endogenous HRB regions of the polypeptides of the FVRS.
Embodiment 55. The complex of Embodiment 54, wherein the ectodomain polypeptides each comprise an inserted HRA domain of the FVRS and the C-terminal 6-helix bundle fraction comprises an HRB domain of the FVRS.
Embodiment 56. The complex of embodiment 54, wherein the ectodomain polypeptides each comprise an HRB domain inserted from the FVRS and the C-terminal 6-helix bundle fraction comprises a HRA domain of the FVRS.
Embodiment 57. A method for producing a respiratory syncytial virus (FVRS) protein F complex, comprising a six-helix bundle, comprising: a) providing ectodomain polypeptides of the FVRS protein, comprising an endogenous HRA region and an endogenous HRB region, further comprising an inserted HRA region of the FVRS or an inserted HRB region of the FVRS; and at least one oligomerization polypeptide, and b) combining the FVRS ectodomain polypeptides and the at least one oligomerization polypeptide under conditions suitable for formation of a FVRS complex, whereby a complex FVRS is produced in which three of the FVRS ectodomain polypeptides and at least one of the oligomerization polypeptides form a six-helix bundle, provided that the endogenous HRA regions and the endogenous HRB regions of the polypeptides of the ectodomain of the FVRS are not part of the six-helix bundle.
Embodiment 58. The method of embodiment 57, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are provided in a cell.
Embodiment 59. The method of embodiment 57, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are provided in conditioned cell culture media.
Embodiment 60. The method of embodiment 58, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are provided by expression from an expression hybrid.
Embodiment 61. The method of Embodiment 60, wherein the expression hybrid comprises a DNA hybrid or an RNA hybrid.
Embodiment 62. The method of embodiment 60 or 61, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are expressed from a single hybrid.
Embodiment 63. The method of Embodiment 62, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are expressed under the control of a single promoter.
Embodiment 64. The method of embodiment 62, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are expressed under the control of separate promoters.
Embodiment 65. The method of Embodiment 64, wherein the promoters are the same.
Embodiment 66. The method of embodiment 64, wherein the promoters are different.
Embodiment 67. The method of embodiment 60 or 61, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are expressed from two separate hybrids.
Embodiment 68. The method of Embodiment 67, wherein the two separated hybrids have the same promoter sequences.
Embodiment 69. The method of Embodiment 67, wherein the two separated hybrids have different promoter sequences.
Embodiment 70. The method of any one of embodiments 67 to 69, wherein the number of coding sequences for ectodomain and the number of coding sequences for the oligomerization domain are present in a cell in one. ratio of 2: 1 to 1: 8.
Embodiment 71. The method of any one of embodiments 67 to 69, wherein the number of coding sequences for ectodomain and the number of coding sequences for the oligomerization domain are present in a cell in one. ratio of 1: 1 to 1: 8.
Embodiment 72. The method of any one of embodiments 67 to 69, wherein the number of coding sequences for ectodomain and the number of coding sequences for the oligomerization domain are present in a cell in one. ratio of 1: 1 to 1: 4.
Embodiment 73. The method of any one of embodiments 67 to 69, wherein the number of coding sequences for the ectodomain and the number of coding sequences for the oligomerization domain are present in a cell in one. ratio of 1: 1 to 1: 2.
Embodiment 74. The method of any of embodiments 59 to 73, wherein the ectodomain polypeptide and the oligomerization polypeptide are provided in a ratio of 2: 1 to 1: 8.
Embodiment 75. The method of any one of embodiments 59 to 73, wherein the ectodomain polypeptide and the oligomerization polypeptide are provided in a ratio of 1: 1 to 1: 8.
Embodiment 76. The method of any one of embodiments 59 to 73, wherein the ectodomain polypeptide and the oligomerization polypeptide are provided in a ratio of 1: 1 to 1: 4.
Embodiment 77. The method of any one of embodiments 59 to 73, wherein the ectodomain polypeptide and the oligomerization polypeptide are provided in a ratio of 1: 1 to 1: 2.
Embodiment 78. The method of embodiment 57, wherein the ectodomain polypeptides of the FVRS protein are provided as substantially purified polypeptides.
Embodiment 79. The method of embodiment 57 or 78, wherein the oligomerization polypeptide is provided as a substantially purified polypeptide.
Embodiment 80. The method of embodiment 57-63, wherein the ectodomain polypeptide is operably linked to the oligomerization polypeptide.
Embodiment 81. The method of embodiment 57 to 79, wherein the ectodomain polypeptide is not operably linked to the oligomerization polypeptide.
Embodiment 82. The method of any of embodiments 57 to 81, wherein the ectodomain polypeptide comprises a HRA region of the FVRS and the oligomerization polypeptide comprises a HRB region of the FVRS.
Embodiment 83. The method of any one of embodiments 57-81, wherein the ectodomain polypeptide comprises a HRB region of FVRS and the oligomerization polypeptide comprises a HRA region of FVRS.
Embodiment 84. The method of embodiment 57-83, wherein the FVRS ectodomain polypeptides provided in a) comprise uncleaved FVRS ectodomain polypeptides.
Embodiment 85. The method of embodiment 57-84, wherein the FVRS ectodomain polypeptides provided in a) each comprise one or more modified furine cleavage sites.
Embodiment 86. The method of embodiment 57 to 85, wherein the ectodomain polypeptides of FVRS comprise at least one protease cleavage site. For example, a FVRS complex in which each of the FVRS ectodomain polypeptides comprises a furine cleavage site, preferably an optimized furine cleavage site, preferably 2 optimized furine cleavage sites. . For example, a FVRS polypeptide comprising an F137S mutation at a position corresponding to the amino acid numbering of SEQ ID NO: 1.
Embodiment 87. The method of Embodiment 86, wherein the protease cleavage site is selected from the group consisting of the furin cleavage site, the trypsin cleavage site, the cleavage site, and the cleavage site. the TEV protease, the thrombin cleavage site, and the rhinovirus 3c protease cleavage site.
Embodiment 88. The method of any one of embodiments 57 to 87, wherein the FVRS ectodomain polypeptides provided in a) comprise purified monomers.
Embodiment 89. The method of any one of embodiments 57 to 88, further comprising the step of c) cleaving the ectodomain polypeptides of the FVRS protein into the protease-produced complex. In some embodiments, at least 95%, 96%, 97%, 98%, or 99% of all of the FVRS ectodomain polypeptides are cleaved. In some embodiments, no uncleaved FVRS polypeptide can be detected, for example by staining with Coomassie blue, preferably by western blotting made by the following method, of a boiled and reduced sample resolved by SDS. -PAGE.
Embodiment 90. The method of any one of embodiments 57 to 89, wherein each FVRS ectodomain polypeptide comprises an H RB region and each exogenous oligomerization polypeptide comprises an oligomerization region.
Embodiment 91. The method of any one of embodiments 57 to 90, wherein the inserted HRA region or the inserted HRB region is at the C-terminus of the endogenous HRA region and the endogenous HRB region. .
Embodiment 92. The method of Embodiment 80, wherein the oligomerization peptide is operably linked to the FVRS ectodomain polypeptide at the C-terminus of the inserted HRA region or inserted HRB region. .
Embodiment 93. The method of any one of embodiments 57 to 92, wherein the complex is composed of three FVRS ectodomain polypeptides and three oligomerization polypeptides.
Embodiment 94. The method of any one of embodiments 57 to 93, wherein one or more of said oligomerization polypeptides further comprises a functional region that is operably linked to the oligomerization region.
Embodiment 95. The method of any one of embodiments 57 to 94, wherein the amino acid sequence of the FVRS ectodomain polypeptides provided in step a) comprises a sequence selected from group consisting of: SEQ ID NO: 1, SEQ ID NO: 8 (Del21 Furx), SEQ ID NO: 3 (Furmt), SEQ ID NO: 4 (Furdel), SEQ ID NO: 5 (Furx), SEQ ID NO : (Furx R113Q, K123N, K124N), SEQ ID NO: 7 (Furx R113Q, K123Q, K124Q), SEQ ID NO: 9 (Delp23Furx), SEQ ID NO: 10 (Delp21 furdel), SEQ ID NO: 11 ( Delp23 furdel), SEQ ID NO: 12 (N-term Furin), SEQ ID NO: 13 (C-term Furin), SEQ ID NO: 14 (Xa Factor), SEQ ID NO: 15, SEQ ID NO: 26 ( Deletion of the Fusion Peptide 1), an ectodomain sequence indicated in the sequence listing; and any one of the preceding wherein the signal peptide and / or the HIS tag and / or the fusion peptide is altered or absent.
Embodiment 96. The method of embodiment 95, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises S155C and S290C substitutions.
Embodiment 97. The method of embodiment 95 or 96, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises an F substitution on amino acid 190 and / or an L substitution on the amino acid 207.
Embodiment 98. The method of Embodiment 95, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises S155C, S290C, S190F, and V207L substitutions.
Embodiment 99. The method of embodiment 57, wherein the oligomerization polypeptide comprises a 6-helix bundle moiety.
Embodiment 100. The method of embodiment 99, wherein the six-helix bundle C-terminal fraction comprises a heptad repeat region of the envelope virus fusion protein.
Embodiment 101. The method of embodiment 100, wherein the heptad repeat region is selected from the group consisting of a HRA domain of FVRS, a HRB domain of FVRS, an HRA domain of HIV gp41 and an HRB domain of HIV gp41,
Embodiment 102. The method of any one of embodiments 99 to 101, wherein the six helix bundle comprises the inserted HRA domain of the FVRS or the inserted HRV domain of the FVRS of three recombinant polypeptides of the ectodomain of the FVRS and the oligomerization region of each oligomerization polypeptide.
Embodiment 103. The method of any of embodiments 57 to 102, wherein the FVRS ectodomain polypeptides in the complex that is produced are in pre-fusion conformation.
Embodiment 104. The method of any of embodiments 57 to 103, wherein the FVRS ectodomain polypeptides in the complex that is produced are characterized by a rounded shape when viewed on micrographs. negatively colored electronics.
Embodiment 105. The method of embodiment 57-104, wherein the FVRS ectodomain polypeptides in the complex that is produced are characterized by binding to the D25 antibody.
Embodiment 106. The method of any one of embodiments 57 to 105, wherein the ectodomain FVRS polypeptides in the complex that is produced comprise pre-fusion epitopes that are not present on the the post-fusion forms of the FVRS.
Embodiment 107. A method for producing a respiratory syncytial virus F protein (FVRS) complex, comprising a six-helix bundle, comprising: a) providing ectodomain polypeptides of the FVRS protein, comprising an endogenous HRA domain of FVRS and an endogenous HRB domain of FVRS which contain a C-terminal 6-helix bundle comprising an inserted HRA domain of FVRS and an inserted HRB domain of FVRS, and b) combining the ectodomain polypeptides of FVRS under conditions suitable for formation of a FVRS complex, whereby a FVRS complex is produced, which comprises three FVRS ectodomain polypeptides and is characterized by a beam six-helix formed by the C-terminal 6-helix bundle comprising the inserted HRA domain of the FVRS and an inserted HRB domain of the FVRS.
Embodiment 108. A respiratory syncytial virus (FVRS) protein F complex produced by the method of any one of embodiments 57 to 107.
Embodiment 109. A respiratory syncytial virus (FVRS) protein F complex of any one of Embodiments 1 to 56 produced by the method of any one of Embodiments 57 to 107.
Embodiment 110. A population of respiratory syncytial virus F (FVRS) complexes of any of Embodiments 1 to 56 and 108.
Embodiment 111. The population of FVRS complexes of Embodiment 110, wherein at least 60% of the complexes in the population are trimers.
Embodiment 112. The FVRS complex population of Embodiment 110, wherein at least 70% of the complexes in the population are trimers.
Embodiment 113. The FVRS complex population of Embodiment 110, wherein at least 80% of the complexes in the population are trimers.
Embodiment 114. The FVRS complex population of Embodiment 110, wherein at least 90% of the complexes in the population are trimers.
Embodiment 115. The population of FVRS complexes of any one of embodiments 110 to 114, wherein at least 60% of the complexes in the population bind to the D25 antibody.
Embodiment 116. The population of FVRS complexes of any one of embodiments 110 to 114, wherein at least 70% of the complexes in the population bind to the D25 antibody.
Embodiment 117. The population of FVRS complexes of any one of embodiments 110 to 114, wherein at least 80% of the complexes in the population bind to the D25 antibody.
Embodiment 118. The population of FVRS complexes of any of embodiments 110 to 114, wherein at least 90% of the complexes in the population bind to the D25 antibody.
Embodiment 119. The population of FVRS complexes of any one of embodiments 110 to 118, wherein at least 60% of the complexes in the population comprise a cleaved ectodomain polypeptide.
Embodiment 120. The population of FVRS complexes of any of embodiments 110 to 118, wherein at least 70% of the complexes in the population comprise a cleaved ectodomain polypeptide.
Embodiment 121. The population of FVRS complexes of any of embodiments 110 to 118, wherein at least 80% of the complexes in the population comprise a cleaved ectodomain polypeptide.
Embodiment 122. The population of FVRS complexes of any one of embodiments 110 to 118, wherein at least 90% of the complexes in the population comprise a cleaved ectodomain polypeptide. Preferably, wherein at least 95%, 96%, 97%, 98%, or 99% of all ectodomain FVRS polypeptides are cleaved. In some embodiments, no uncleaved FVRS polypeptide can be detected, for example by staining with Coomassie blue, preferably by western blotting made by the following method, of a boiled and reduced sample resolved by SDS. -PAGE.
Embodiment 123. The population of FVRS complexes of any of embodiments 110 to 122, wherein the complex population is substantially free of contaminating lipids.
Embodiment 124. An immunogenic composition comprising a respiratory syncytial virus (FVRS) protein F complex according to any one of embodiments 1 to 57 and 108 to 109, or a population of FVRS complexes according to the present invention. any of embodiments 110 to 123.
Embodiment 125. A method of inducing an immune response to FVRS in a subject comprising administering an immunogenic composition of embodiment 124 to the subject.
Embodiment 126. A FVRS ectodomain polypeptide comprising an endogenous HRA region, an endogenous HRB region, an inserted HRA region of FVRS, an inserted HRB region of FVRS.
Embodiment 127. The FVRS ectodomain polypeptide of Embodiment 126, wherein the inserted HRA region of the FVRS is at the C-terminus of the endogenous HRA region and the endogenous HRB region.
Embodiment 128. The FVRS ectodomain polypeptide of Embodiment 126 or 127, wherein the inserted HRB region of the FVRS is at the C-terminus of the endogenous HRA region and the endogenous HRB region. .
Embodiment 129. The FVRS ectodomain polypeptide of any one of embodiments 126 to 128, wherein the inserted HRB region of the FVRS is at the C-terminus of the HRA region inserted from the FVRS.
Embodiment 128. The FVRS ectodomain polypeptide of any one of Embodiments 12 to 128, further comprising a linker between the endogenous HRB region and the inserted HRA region of the FVRS or the HRB region inserted from the FVRS.
Embodiment 130. The ectodomain polypeptide of FVRS of Embodiment 129, wherein the linker limits the pairing of the endogenous HRB region and the inserted HRA region of the FVRS.
Embodiment 131. The FVRS ectodomain polypeptide of any one of Embodiments 12 to 128, further comprising a linker between the inserted HRA region of the FVRS and the inserted HRB region of the FVRS.
Embodiment 132. The FVRS ectodomain polypeptide of Embodiment 131, wherein the linker promotes pairing of the inserted HRA region inserted pairing of the FVRS with the inserted HRB region of the FVRS.
Embodiment 133. The FVRS ectodomain polypeptide of Embodiment 132, wherein the linker is a structurally restricted linker.
Embodiment 134. A polypeptide comprising a FVRS peptide having a 90% sequence identity with a sequence listing FVRS peptide sequence, the peptide comprising a sequence that may be part of a six-helix bundle .
Embodiment 135. The polypeptide of Embodiment 134, comprising a peptide sequence of the Sequence Listing.
Embodiment 136. A nucleic acid encoding a polypeptide of Embodiment 134 or 135.
Embodiment 137. An expression vector comprising the nucleic acid of any one of Embodiments 60 to 69 or 136.
Embodiment 138. An expression hybrid for use in the method of any one of Embodiments 60 to 69.
Embodiment 139. A composition comprising a pair of expression hybrids for use in the method of any one of Embodiments 60 to 61 and 63 to 69.
Embodiment 140. A cell containing the nucleic acid of Embodiment 136 or the expression vectors of Embodiment 137 or 138.
Embodiment 141. A polypeptide comprising a FVRS ectodomain polypeptide having a F137S mutation corresponding to the numbering of SEQ ID NO: 1.
Embodiment 142. A polypeptide comprising an FVRS ectodomain polypeptide having an optimized furine cleavage site.
Embodiment 143. A polypeptide comprising a FVRS ectodomain polypeptide having two optimized furine cleavage sites.
Embodiment 144. The polypeptide of any one of embodiments 141 to 143, wherein the ectodomain polypeptide further comprises an inserted H RA domain or an inserted HRB domain.
Embodiment 145. The polypeptide of any one of embodiments 141 to 143, wherein the ectodomain polypeptide further comprises a T4 bacteriophage foldon domain.
Embodiment 146. The polypeptide of any one of embodiments 141 to 145, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises S155C and S290C substitutions.
Embodiment 147. The polypeptide of any one of embodiments 141 to 146, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises an F substitution on amino acid 190 and or an L substitution on the amino acid 207.
Embodiment 148. The polypeptide of any one of embodiments 141 to 147, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises the S155C, S290C, S190F, and V207L substitutions. .
Embodiment 149. The polypeptide of any one of embodiments 141 to 146, wherein the FVRS ectodomain comprises an ectodomain of cleaved FVRS.
Embodiment 150. A FVRS complex comprising the FVRS ectodomain polypeptides of any one of embodiments 141 to 149, wherein the complex comprises a trimer.
Embodiment 151. A population of the FVRS complexes of embodiment 150, wherein at least 95%, at least 96%, at least 97%, at least 98%, or at least 9% of the polypeptides of the ectodomain of the FVRS in the complexes include cleaved ectodomain polypeptides.
Embodiment 152. The FVRS complex population of embodiment 151, in which uncleaved ectodomain polypeptides can not be detected in the trimers, for example by staining with Coomassie blue, preferably by western blot. performed by the following method, of a boiled and reduced sample solved by SDS-PAGE.
Embodiment 153. A polypeptide comprising the amino acid sequence 137-154 of SEQ ID NO: 1, wherein the polypeptide comprises a substitution at a position corresponding to F137S.
Embodiment 154. A polypeptide comprising the amino acid sequence 107-154 of SEQ ID NO: 1, wherein the polypeptide comprises substitutions at a position corresponding to A107K, E110S, and F137S.
Embodiment 155. A polypeptide comprising at least 90% sequence identity with amino acids 23-520 of the sequence of SEQ ID NO: 1 wherein the polypeptide comprises A107K, E110S, and F137S substitution.
Embodiment 156. The polypeptide of Embodiment 155, wherein the polypeptide comprises substitutions S155C and S290C.
Embodiment 157. The polypeptide of Embodiment 155, wherein the polypeptide further comprises S190F and V207L substitutions.
Embodiment 158. The polypeptide of any one of embodiments 155 to 157, wherein the polypeptide comprises a sequence identity of at least 95% with amino acids 107-154 of SEQ ID NO: 1.
Embodiment 158. The polypeptide of any one of embodiments 155 to 157, wherein the polypeptide comprises a sequence identity of at least 95% with amino acids 25-520 of SEQ ID NO: 1.
Embodiment 159. A FVRS complex comprising the FVRS ectodomain polypeptides of any one of embodiments 141 to 149, wherein the complex comprises a trimer.
Embodiment 160. A population of FVRS complexes of embodiment 159, wherein at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the polypeptides of the ectodomain of the FVRS in the complexes include cleaved ectodomain polypeptides.
Embodiment 161. The FVRS complex population of Embodiment 160, in which uncleaved ectodomain polypeptides can not be detected in the trimers, for example by staining with Coomassie blue, preferably by Western blot. performed by the following method, of a boiled and reduced sample solved by SDS-PAGE.
Embodiment 162. The population of any one of embodiments 151 to 152 or 160 to 161 wherein at least 60%, 70%, 80%, 90% of the complexes in the population are trimers.
Embodiment 163. The population of any one of embodiments 151 to 152 or 160 to 162 in which at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% of the complexes in the population bind the D25 antibody.
Embodiment 164. The population of FVRS complexes of any of embodiments 151 to 152 and 160 to 163, wherein the complex population is substantially free of contaminating lipids.
Embodiment 165. The population of FVRS complexes of any of embodiments 110 to 123, 151 to 152, and 160 to 164 wherein less than 95% of the ectodomain polypeptides are trimers.
Embodiment 166. The population of FVRS complexes of any of embodiments 110 to 123, 151 to 152, and 160 to 164 wherein less than 90% of the ectodomain polypeptides are trimers.
Embodiment 167. The population of FVRS complexes of any of embodiments 110 to 123, 151 to 152, and 160 to 164 wherein less than 95% of the complexes in the population bind the D25 antibody.
Embodiment 168. The population of FVRS complexes of any of embodiments 110 to 123, 151 to 152, and 160 to 164 wherein less than 90% of the complexes in the population bind the D25 antibody.
Embodiment 169. A nucleic acid encoding a polypeptide of any one of embodiments 141 to 149 or 153 to 158.
Embodiment 170. An expression hybrid comprising the nucleic acid of Embodiment 169.
Embodiment 171. A cell comprising the expression hybrid of Embodiment 170.
Embodiment 172. A polypeptide comprising the sequences of an HRA domain of FVRS-SEQ ID NO: 115-H RB domain of FVRS in this order from the N-terminus to the C-terminus. Preferably, the sequences are contiguous. Preferably, no additional binding sequence is present between the HRA domain and the HRB domain other than the sequence of SEQ ID NO: 115. In some embodiments, the polypeptide comprises a sequence for trimerization, e.g. ectodomain polypeptide of FVRS at the N-terminus of the H RA domain of the FVRS-SEQ ID NO: 115-HRB domain of the FVRS. Alternatively or additionally, the polypeptide further comprises a purification tag at the C-terminus of the HRA domain of FVRS-SEQ ID NO: 115-HRB domain of FVRS.
Embodiment 173. A polypeptide comprising an identity of at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, 100% any of the sequences including the FVRS ectodomain provided herein, such as any of SEQ ID NOS: 47-87, 89105, or 117-136, including truncations thereof, e.g., absences signal sequences, purification labels, or signal sequences and purification labels.
Embodiment 174. A polypeptide comprising at least 50, 100, 150, 200, 250, or 300 consecutive amino acids of any of the sequences including the FVRS ectodomain provided herein.
Embodiment 175. A nucleic acid encoding a polypeptide of embodiment 173 or 174.
Embodiment 176. The nucleic acid of embodiment 175 which encodes or is a self-replicating RNA, optionally wherein the nucleic acid is provided in a delivery system selected from a viral replicon particle (VRP), a lipid nanoparticle (LNP), a cationic nanoemulsion or a biodegradable polymer.
Embodiment 177. An antibody that specifically binds a polypeptide of Embodiment 173 or 174.
PART EXAMPLES
The following examples are merely illustrative of the scope of the present invention and therefore are not intended to limit its scope in any way.
Example 1 - Purification Protocol for FVRS Proteins from Insect Cells
Methods for expressing a protein in a number of cellular systems are known in the art. Growth and purification of the proteins and complexes provided herein can be easily adapted to various cell types. Baculoviruses expressing FVRS hybrids can be propagated and FVRS proteins labeled with 6XHis (SEQ ID NO: 39) can be purified as follows:
One hundred microliters of virus from the PI stock is added to 50 ml of SF9 cells (Invitrogen®) diluted to 0.8 x 10 6 / ml (cultured in Sf500 media) and subjected to infection / growth for approximately 5-6 days. Infection is monitored using the Cedex® instrument. Baculovirus growth is considered complete when cell viability is <50%, while cell diameter increases preponderantly from ~ 13 nm to ~ 16nm.
One ml of stock P2 is added to 1 liter of Sf9 cells diluted to 0.8x10 6 / ml and grown for 5-6 days. Infection is monitored using the Cedex® instrument. Baculovirus growth is considered complete when cell viability is <50%, while cell diameter increases preponderantly from ~ 13 nm to ~ 16nm. The expression is carried out in cultures of either Sf9 cellsor HiFive® cells (Invitrogen®) in which, unless an expression test is performed to determine the m.o.i. 10 ml of the baculovirus stock P3 (passage 3) are added to each liter of cells at 2 x 10 6 / ml. The expression continued for ~ 72 hours.
The cells are harvested, after taking an aliquot of cell suspension / media for SDS-PAGE analysis, by granulating the cells out of the media by centrifuging the cells at 3000 rpm for ~ 30 minutes.
Copper (II) sulfate is added to the media in a final concentration of 500 micromoles and 1 liter of medium with copper is added to ~ 15 ml of chelating IMAC resin (BioRad® Profinity).
The resin bound to the protein is then separated from the eluent using a gravity column. The resin was washed with at least 10 equilibrium buffer resin volumes (25 mM Tris pH 7.5, 300 mM NaCl), and the protein was eluted with at least 10 elution buffer resin volumes (25 μM). mM Tris pH 7.5, 300 mM NaCl, 250 mM imidazole).
The elution solution is pitted with a complete protease inhibitor free of EDTA (Pierce®) and EDTA to a final concentration of 1 mM. The elution solution is then dialysed at least twice at 4 ° C. against 16 volumes of equilibration buffer. The elution solution is loaded onto one or two HiTrap® chelating columns pre-treated with Ni ++. (A single 5 ml column is typically sufficient for 10 liters of expression.) The protein is eluted from the column using an FPLC capable of delivering an elution buffer gradient with the following gradient profile (2 ml flow rate). / min) a. 0 to 5% elution buffer over 60 ml b. 5 to 40% elution buffer on 120 ml c. 40 to 100% of elution buffer over 60 ml
Fractions containing the FVRS protein are evaluated by SDS-PAGE analysis using blue stain.
Coomassie and / or western blot (typically, the FVRS elutes ~ 170 ml in the gradient): the material is concentrated to about 0.5-1 mg / ml; and EDTA is added to a final concentration of 1 mM
Using FPLC, 1 ml fractions are recovered. The FVRS material (retention volume about 75 ml) is resolved against insect protein contaminants (retention volume of about 60 ml) by steric exclusion chromatography (SEC) with a column. 16/60 Superdex (GE® Healthcare) using a balancing buffer as a mobile phase.
The fractions are analyzed using SDS-PAGE with Coomassie blue staining and a sufficiently pure FVRS material is pooled and concentrated to about 1 mg / ml.
Example 2 - Chemical Synthesis of Oligomerization Peptides
The chemical synthesis can be used for the generation of oligomerization peptides that are not expressed in cells, for example as part of the ectodomain peptide. The HRA peptide or HRB peptide (the oligomerization polypeptide) is synthesized by Anaspec® (HRA peptide from FVRS, residues from RSV 160-2 07, HRB from FVRS, residues from RSV 474-525) is resuspended in buffer SEC (25 mM Tris pH 7.5, 300 mM NaCl) and the UV absorbance at 280 nm (1 AU per 1 mg / ml: estimated) is used to estimate the protein concentration.
Example 3 - Formation of FVRS complexes
An exemplary method of forming trimeric complexes of FVRS with a separate oligomerization domain is shown below. The Fods ectodomain peptides further comprising an inserted HRA domain are recombinantly expressed and purified using methods such as those proposed above. The oligomerization domains containing HRB domains are chemically synthesized by a commercial supplier.
To assemble the complexes, 0.5 ml of -0.75 mg / ml of FVRS-containing ectodomain polypeptide monomer containing an inserted HRA domain is added to 0.5 ml of an oligomerization peptide solution containing HRB, and 1 ml of the complex solution is separated on a SEC column according to the FVRS purification protocol. The main peak migrates similarly to the trimeric region of the FVRS. In general, the trimeric FVRS protein (deletion of the FVRS fusion peptide) elutes in the trimer peak, the uncleaved RSV monomer elutes in the peak of the monomer. The main peak for the FVRS + HRA monomer is more consistent with trimer elution than monomer. This shift in the elution volume suggests the peptide-protein F interaction and trimer formation of complexes between the HRA oligomerization peptides and the FVRS ectodomains (i.e., a hetero-hexamer with three HRB peptides and three uncleaved ectodomain F polypeptides comprising an inserted HRA domain).
This non-cleavable ectodomain HRA: F peptide complex is evaluated by electron microscopy (ME) to determine whether a three-lobed species or a prefusion globular head is formed. Alternatively, the complex is analyzed by antibody binding and SEC as described below, using D25 Fab antibody to detect FVRS proteins with pre-fusion structures and Motavisumab Fab to detect total FVRS protein. (that is, pre-fusion and post-fusion). In addition, the formation of the peptide complex is repeated with the ectodomain of the cleavable FVRS which can be digested by proteases giving F1 / F2 species. If the prefusion globular head is formed, and this prefusion FVRS behaves similarly to para-influenza F protein, we hope that the stabilization of the prefusion form will prevent rosetting.
Example 4 - Addition of a C-terminal 6-helix bundle sequence or other trimerization sequence
A sequence, such as an additional HIV RSV HRB or HRB of gp41, is added to the complex described in Example 2 to form a C-terminal 6-helix bundle, thus allowing trimerization with insertion of RSV H HRA. HIV gp41 RA, respectively. This may have the additional advantage of restricting the native repetition of VRS HR heptads from the monomer in its native prefusion trimer HRB, in place of the post-fusion helix bundle.
Alternatively, a T4 foldon domain to promote trimerization is linked to an FVRS ectodomain polypeptide which comprises only endogenous HRA and HRB domains to promote trimerization of the expressed polypeptides.
Example 5 - Addition of HRB disulfides
Disulfides are added to the synthesized oligomerization domain described in Example 2. Thus, when the trimerization of the monomer occurs, the cysteine additions are in suitable positions to form the desired disulfides between the oligomerization domains and the subunits. -units, providing an additional level of prefusion stability.
Example 6 - Addition of Conjugated Fusion Proteins to Peptides In place of adding HRA, HRB, or gp41 peptides alone (Example 3) conjugated proteins fused with functional peptides are added such as RSV G protein, albumin , or the conjugated KLF protein. For example, a hybrid of HRA peptide - central VRS domain G is added to the ectodomain F protein containing an inserted HRB. During HRA peptide-induced trimerization, the RSV core domain protein G is bound to F to form an F / G complex, which can provide additional immunogenicity upon vaccination.
Example 7 Trimerization of FVRS Monomers with HRA Peptides
In this example, the FVRS monomers (a Delp23 Furdel truncated HIS hybrid) containing a HRV domain inserted from the RSV are mixed with 5 times the mass of synthetically produced RSV HRA peptides (SEQ ID NO: 40), using the same method as described in Example 2.
MALS analysis is performed using a Wyatt® SEC column and Waters® HPLC with PBS as the mobile phase of the FVRS monomers before and after mixing with RSV HRA peptides. The retention time of the major peak of the FVRS monomers is shifted to an earlier time when the HRA peptides are added. This shift is broadly consistent with a monomer converted to a trimer upon peptide addition, indicating that the HRA peptides trimerized the FVRS monomers.
Example 8 - Binding of the FVRS Monomer to the Fab-specific D25 Fab Antibody was Demonstrated by the BIAcore ™ Assay
McLellan, J.S. et al. (Science, 340: 1113-7 (2013)) have exposed the crystal structure of FVRS in its Fab-binding prefusion of a D25 antibody, which binds unique epitopes to the pre-fusion conformation, but is not present in the post-fusion structure.
It can be verified that the FRVS monomer is a precursor of prefusion (i.e. a folded protein capable of binding to antibodies or Fabs specific to prefusion) by binding the protein to D25 Fab, for example by ELISA, surface plasmon resonance imaging such as BIAcore ™, ITC, size exclusion chromatography (SEC), native gel electrophoresis offset, AUC, Western or dot blot, etc.
The D25 Fab used for this study had the sequence set forth in McLellan, JS et al., 2013 (and referring to US20100239593, hereby incorporated by reference for its description of these antibody sequences) harboring an HIS tag and a Strep tag. used for purification in E. coli cells using conventional laboratory methods.
In this example, a BIAcore ™ assay is performed, which demonstrated the specific binding of the FVRS monomer (F uncleaved) by D25 Fab. D25 Fab is immobilized on a CM5 chip using standard amide chemistry, as indicated by the directions for use (BIAcore ™ / GE Healthscience). D25 Fab is loaded at ~ 75 UR on the surface of the chip. The FVRS monomer (Delp23 Furdel uncleaved FVRS) is diluted in the BIAcore ™ mobile phase (PBS with 0.05% N20 detergent) at concentrations of 30 nM, 20 nM, 15 nM, 10 nM, 7.5 nM, 5nM, 3.75nM, 0.5nM and 0nM. Sensorgrams of the link are recorded in front of a double vacuum (the initial sensorgrams represent a channel F2-F1 where F2 is a channel immobilized on D25 and Fl is no protein channel treated with the amine coupling.) The initial sensorgram at 0 nM is immediately subtracted from each of the other sensorgrams to generate the final concentration sensorgrams used for adjustment). The constant and the link error are determined by fitting to a 1: 1 binding model using the BIAcore ™ evaluation software. BIAcore ™ analysis demonstrates that the FVRS monomer is able to bind to the specific D25 antibody of the pre-fusion. In addition, the tight binding data suggests that the prefusion epitope is preformed on the surface of the protein. D25 is known to bind closely to prefusion FVRS (McLellan, J.S. et al., 2013). If the FVRS monomer is in a prefusion conformation, the binding affinity will be expected to be very tight, in the μ du range or even closer.
It is first shown that the antigen of the uncleaved subunit of FVRS (the F monomer) is preformed in this work. The antigen should elicit a superior immune response to post-fusion antigens previously disclosed.
Example 9 - FVRS monomer binding to Fab D25 was demonstrated by SEC
Size exclusion chromatography is useful for demonstrating the binding of antigens and antibodies. This is typically done either by preparative chromatography (ie, Superdex P200 or Superdex 200 PC 3.2 / 30) or analytical HPLC such as a Wyatt SEC MALS column.
Analytical HPLC-SEC is performed on the FVRS monomer with or without the addition of a 1: 1 molar amount of D25 Fab. The SEC can be performed on a Waters® MALS system as described in Example 6 with PBS as the mobile phase to detect an offset in the FVRS monomer to a new retention time that is consistent with a mass of the monomer of FVRS bound to a D25 Fab, as demonstrated by Stokes and MALS radius analysis. In particular, the analysis of the FVRS monomer (Delp23 Furdel) without Fab using analytic steric HPLC shows a specific retention time which decreases upon the addition of D25 Fab in a molar ratio of 1: 1. A (near) complete shift of the FVRS monomer to a new retention time indicates that almost all of the FVRS monomer is competent to bind the prefusion-specific Fab D25, suggesting that the FVRS monomer is quite homogeneous in its prefusion conformation.
EXAMPLE 10 Binding of the FVRS Monomer and Trimer Complex to D25 Fab Demonstrated by Size Exclusion Chromatography (SEC)
In this example, a preparatory SEC is performed to demonstrate that the FVRS monomer and trimer are pre-fusion antigens. The experiment is performed with a microFPLC (GE Healthcare) using 25 mM Tris pH 7.5 and 50 mM NaCl as the mobile phase. The FVRS monomer (Delp23 Furdel uncleaved FVRS) is tested on the SEC preparatory column (GE® Healthcare micro Superdex® 200) and the elution peak retention time is noted. Adding D25 Fab to the RSV monomer at a molar ratio of 1: 1 and testing on a SEC column gives a shift of the main peak to a lower retention volume, consistent with the monomer ratio of FVRS: Fab D25 to 1: 1, with a double peak additional to a higher retention volume which is consistent with the retention volume of the unbound substance. These results would show that the FVRS monomer is able to bind to the prefusion-specific Fab and is probably the pre-fusion antigen.
Example 11 - Formation of FVRS complexes with linked oligomerization domains
Examples of FVRS hybrids comprising ectodomains containing an endogenous H domain and an endogenous HRB domain, further comprising an inserted HRA domain and an inserted HRB domain are illustrated in Figure 4. The arm groups 1, 2, and 3 Proteins contain a sequence of FVRS 1'ododomaine with substitutions S155C, S290C, S190F, and V207L within 1'ododomaine, and the inserted domains and oligomerization domains indicated.
In addition, the FVRS hybrids comprising ectodomains containing an endogenous HRA domain and an endogenous HRB domain further comprising a bacteriophage T4 foldon sequence. The ectodomain further contains the S155C, S290C, S190F, and V207L substitutions within the ectodomain and optionally a modified or optimized furine cleavage site (Figure 5).
Peptides were expressed in 293 cells and purified from conditioned media. Trimerization was analyzed by western blot and size exclusion chromatography (SEC) antibody-related complexes. The domain structure of FVRS in trimers was analyzed using the D25 antibody, which recognizes FVRS in pre-fusion conformation, and the motavizumab antibody, which recognizes FVRS in both pre- and post-fusion conformations. in ELISA and SEC methods.
Examples of hybrids for trimerization have been shown. In addition, the trimers were recognized by both D25 and motavizumab antibodies.
These results show that the FVRS trimers are formed by FVRS ectodomain polypeptides further containing an inserted HRA domain and an HBB oligomerization domain. In addition, the results show that the ectodomain of FVRS has a prefusic structure in the trimerized form.
These results show that the FVRS trimers are formed by FVRS ectodomain polypeptides further containing a T4 foldon domain. In addition, the results show that polypeptides comprising one or two optimized furin cleavage sites result in substantially complete cleavage of the ectodomain polypeptide so that no uncleaved peptide can be detected by Coomassie blue staining. of a boiled reduced sample resolved by SDS-PAGE or western blot. This is higher than the cleavage rate observed in hybrids in which the p27 sequence is deleted and the non-optimized furine cleavage site (s) are encoded between the F1 and F2 domains or in which the p27 sequence is present. and the furin cleavage sites are not optimized, at least about 5% of the ectodomain polypeptides in the assembled complexes being uncleaved.
Western blots for determining the amount of uncleaved 1'ododomain polypeptide are made using routine methods. For example, 0.1 to 0.5 μg, preferably about 0.1 μg, of the RSV F protein, for example in conditioned media in which the protein has been secreted during expression, is loaded onto 4-12% SDS-PAGE gel of NuPAGE ™ Bis-Tris (Invitrogen ™), and tested at approximately 200V for 45 minutes using the NuPAGE ™ SDS MES Test Buffer (Invitrogen ™). Commercially available molecular weight references are used with SDS-PAGE, for example the full range Rainbow Molecular Weight Marker (GE® Healthcare) to estimate the molecular weights of the bands. Proteins resolved by SDS-PAGE are transferred to a nitrocellulose membrane for 1.5 h at 10V. The membrane is blocked with a blocking buffer (Odyssey® Locking Buffer (Li-Cor cat # 927-40000)) for 0.5 h at room temperature. The membrane is incubated with a primary antibody solution (polyclonal goat anti-RSV antibody (Maine Biotech cat # PAB7133P) diluted 1: 2000 in a 1: 1 mixture of Odyssey blocking buffer: PBS) for 0.5 h. at room temperature. The membrane is washed 3x 1.5 min with a wash buffer and subsequently incubated with Donkey's secondary anti-goat solution (Donkey anti-goat 800CW) (Li-Cor cat # 926-68074) diluted 1: 3000 in a mixture. Odyssey blocking buffer: 1) for 0.5 hr at room temperature. The membrane is washed 2x 1.5 min and 1x 2.5 min with a wash buffer. Final wash with PBS for 2 min. Image using the Li-Cor infrared imaging system (channel 800). The amount of F protein cleaved relative to uncleaved F protein is determined using routine methods.
EXAMPLE 12 Co-Expression and Assembly of the Eododomain of FVRS and Oligomerization Domains in Cells
The ectodomains of FVRS provided herein were expressed in 293 cells from various expression hybrids containing substitutions S155C, S290C, S190F, and V207L in the endogenous ectodomain sequence. Plasmids encoding FVRS hybrids containing ectodomains with endogenous HRA and endogenous HRB and inserted HRA were cotransfected with a separate plasmid expressing the peptide sequence of the HRB oligomerization domain of FVRS. Transfections were performed with format ratios between FVRS-encoded ectodomain DNA with inserted HRA and DNA encoding the HRB peptide of 1: 1, 1: 2, 1: 3 or 1: 4 all keeping the total amount of transfected DNA constant. IRES hybrids were also generated for the expression of ectodomain peptides and peptides of the oligomerization domain from a single hybrid. The total amount of transfected DNA was the same as in the co-transfected wells. For hybrids containing endogenous HRA, endogenous HRB, inserted HRA, and bound HRB oligomerization domain, the total amount of transfected DNA was the same as in the co-transfected wells.
Purification tags such as single or double strep or 6-His labels (SEQ ID NO: 39) were present on the ectodomain hybrids of the FVRS at the C-terminus of the inserted HRA (or HRB). inserted when both an inserted HRA domain and an HRB oligomerization domain were present in the hybrid), or on the hybridization of the oligomerization peptide HRB at the N-terminus of the HRB sequence. Proteolytic cleavage sites such as those recognized by thrombin or TEV protease have been present between the purification tag (if present) and the HRB peptide in the oligomerization domain to allow removal of the tag after purification. using routine methods. The purification labels were preferably removed before evaluating the trimerization state of the complexes.
Hybrids for the FVRS ectodomain polypeptides included the "leader" sequence of native FVRS. IgK "leader" sequences have been included in hybrids of the oligomerization domain of the HRB peptide of the oligomerization domain. These sequences ensure proper targeting of the peptide in the endoplasmic reticulum where it can be assembled into trimers with the FVRS ectodomain hybrid and promote secretion of the assembled complex into the growth medium to facilitate production and purification. The "leader" sequences were encoded at the N-terminus of the purification tag if present. . Expression of the protein from various hybrids was evaluated using western blotting with an anti-RSV antibody. When the six helix bundle containing the HRA inserted into the FVRS ectodomain and the peptide of the oligomerization domain HRB assemble, the trimerized molecule appears as a discrete band on the SDS-PAGE at size. a trimer (~ 200 kDa) with a minimal protein appearing at the size of the monomer. Under boiled and reduced conditions, the band in the western blot is detected at the size of a monomod of the FRVS lectodomain (-60-70 kDa). The oligomerization state of the expressed protein was also evaluated in the expression media using a fluorescence HPLC technique. D25 Fab was labeled with fluorescent dye as Alexa® Fluor 488 and 1 μg labeled Fab was incubated with 100 μl of expression media. The complex was resolved on an HPLC column (Waters® 2695, separation module, column type: Agilent® Bio SEC-3, 300A, 7.8x300mm, cat: 5190-2511, serial #: USDLV01746) in DPBS buffer (IX) (Cat No: 14190-144, Invitrogen®), detected using a suitable detector (Waters® 996, photodiode array detector), and the retention time was recorded. The retention times were compared to the elution time of the control monomer and trimeric complexes. The retention time for a well folded trimer was determined based on McClellan et al., DS-CAV1 hybrid, 2013 which contains a foldon trimerization domain (in this example, about 6.3 minutes) and for well-folded prefusion monomer (delta p23 furdel, about 7.1 minutes). The presence of higher molecular weights, when present, is indicated by one or more peaks eluting before 6.3 minutes. The shape of the elution curve was appreciated in the sense that a well-formed smooth peak was indicative of a homogeneous population of well-formed trimers.
The assay simultaneously confirmed the presence of trimers in the prefusion conformation. The assay was repeated with similarly labeled Fab motavizumab, which recognizes both pre-fusion and post-fusion F.
Cells expressing the antigen stably can be prepared for this strategy by selecting either clones that express the FVRS ectodomain with inserted HRA and HRB peptide hybrids from two separate plasmids with different mammalian selection markers. as DHFR, either stable clones transfected with a single vector encoding the FVRS ectodomain and the HRB peptide from two separate promoters on the same plasmid.
The presence of a purification tag such as a single or double Strep or 6-His tag (SEQ ID NO: 39) on the separately expressed HRB peptide allows easy purification of the fully formed prefusion trimer F, the beam trimerization domain. with six helices being composed of the inserted HRA and the peptide of the oligomerization domain HRB. Any peptide of the excess HRB oligomerization domain alone which co-purifies is readily removed in the SEC due to the large size difference between the two species. This purification scheme also ensures that any trimer that forms due to the interaction of the inserted HRA with the upstream endogenous HRB is not captured (due to the lack of a purification label on this hybrid) . This in turn guarantees. that the purified protein is a homogeneous population.
Hybrids are designed with a proteolytic cleavage site as a thrombin site between the purification tag and the HRB protein or peptide. Once the label is cleaved, the protein contains substantially no additional heterologous sequence and thus the immune response can be concentrated only on the sites present on the FVRS.
Example 13 Expression of FVRS complexes with various linker lengths and various related oligomerization domains
The ectodomain hybrids of the FVRS described in Example 11 and Figure 4 contain two inserted binding sequences, the first between the endogenous HRB and the inserted HRA (linker 1), and the second between the inserted HRA and the oligomerization domain HRB (linker 2), if present. The length and composition of the linkers may affect the proper assembly of the trimeric complex. For example, the linker 2 may have an effect by promoting the folding of the oligomerization domain HRB on the HRA inserted upstream of the same monomer, which makes it possible to avoid the formation of aggregates. Similarly, linker 1 may also have an effect in preventing the inserted HRA from interacting with endogenous HRB upstream. Various lengths of linkers were tested in both positions, with lengths ranging from 7 to 21 residues. The hybrids included the substitutions S155C, S290C, S190F, and V207L in the endogenous sequence of the ectodomain.
On the basis of secreted trimeric levels in growth media, a longer sequence was favored for linker 1, as assessed by HPLC fluorescence detailed in Example 12. Without wishing to be bound by theory, this suggests that, by putting a sufficient distance between the endogenous HRB and the inserted HRA, the longer linker promotes interaction between the inserted HRA domain and the HRB oligomerization domain. However, a shorter sequence was favored for linker 2. Longer linkers in this position had a higher proportion of earlier elution peak in the fluorescence HPLC, indicating the potential formation of higher order oligomers .
When the long binding sequence was replaced and a sequence based on FVRS ELSNIKENKSNGTDAK (SEQ ID NO: 115) that includes two predicted glycosylation sites and a C to S mutation to prevent disulfide bond formation, expression of The polypeptide was higher, and almost all of the polypeptide appeared to be present in the trimers, as assessed by the SEC. Without wishing to be bound by theory, this suggests that the binding sequence becomes glycosylated and that glycosylation improves the folding and / or solubility of the peptide.
The binding sequence 2 can be manipulated to further promote the interaction between the inserted HRA domain and the HRB oligomerization domain. For example, the binding sequence may be shortened and / or modified to introduce flexion into the protein chain through the use of Pro-Gly sequences and / or disulfide bonds to promote the interaction of the oligomerization domain. containing HRB with the HRA domain inserted upstream.
EXAMPLE 14 Expression of the FVRS complexes with various lengths of linkers with detached oligomerization domains
As demonstrated above, linker 2 may play a role in determining the proportion of the expressed protein that forms a well-folded trimer relative to higher order oligomers because of the possibility of the inserted HRA domain and of the oligomerization domain HRB to form complexes other than suitably folded trimers. In order to eliminate this possibility, a second strategy was employed in which the HRB oligomerization domain was expressed as a separate polypeptide, either from a separate plasmid, or from the same mRNA with an IRES between the FVRS and the peptide. HRB. Hybrids included S155C, S290C, S190F, and V207L substitutions in the endogenous ectodomain sequence.
A longer sequence for linker 1 again favored higher expression for the trimer having a separate HRB oligomerization domain, however, the effects of linker length 1 on the expression of hybrids with oligomerization domains detached were less striking than the expression of hybrids with the bound oligomerization domain.
Example 15 Expression of the FVRS complexes with various reports of detached oligomerization domains
Assays were performed to evaluate the effect of ratio changes between ectodomain polypeptides and oligomerization polypeptides on expression levels (ratios of 1: 1 to 1: 4 of the ectodomain: oligomerization). Various reports of expression hybrids of the plasmid containing either a coding sequence for the ectodomain polypeptides containing the substitutions S155C, S290C, S190F, and V207L in the context of an endogenous HRA domain of the FVRS, an HRB domain endogenous FVRS, and a HRA domain of the inserted FVRS; either a coding sequence for the HRB-containing oligomerization polypeptide of FVRS were cotransfected into 293 cells as described above, keeping the total DNA constant. IRES hybrids were also used to coexpress ectodomain polypeptides and oligomerization peptides in a cell where the coding sequences were present in a ratio of 1: 1.
The level of expression of the trimers assembled in the growth media was analyzed by western blot. A ratio of 1: 2 of the ectodomain to the oligomerization domain was found to provide somewhat higher expression levels of the FVRS complex. However, expression of the complexes was detectable in all ratios (1: 1-1: 4).
EXAMPLE 16 Expression of the FVRS Complexes with Internal Sites of Erodin Dectodomain Cleavage
The wild-type FVRS protein sequence contains two internal furin cleavage sites separated by a 27 residue stretch, termed p27. This p27 peptide is excised during the folding of the protein in the ER by cellular furin protease, yielding a mature protein consisting of two distinct polypeptide chains, F1 and F2, linked together by disulfide bonds. Cleavage at both sites to remove the p27 peptide is required for secretion of the mature protein into cell culture media since the uncleaved F ectodomains containing the p27 sequence remain trapped within the cell. A set of hybrids where F1 is bound to F2 by a furin cleavage site in between, with the deleted p27 sequence, was generated to optimize the furin cleavage site. The hybrids were designed so that the mature transformed protein was virtually identical to the wild-type protein of the final transformed FVRS. The hybrids include substitutions S155C, S290C, S190F, and V207L in the sequence of endogenous ectodomain.
The two furin cleavage sites in wild type FVRS have different sequences. The furin cleavage site 1, which has the RARR sequence (SEQ ID NO: 109), results in cleavage at amino acid 109 on SEQ ID NO: 1 and the furin cleavage site 2, which has the sequence RKRR (SEQ ID NO: 110), results in cleavage at amino acid 136 of SEQ ID NO: 1. Hybrids were generated in which the p27 sequence was deleted and replaced by the sequence of either the furin cleavage site 1 or the furin cleavage site 2. Upon expression in the cells, the cleavage site Furin 2 was cleaved much more efficiently than the furin cleavage site 1. Although not cleaved, the p27-containing FVRS polypeptides are not secreted from the cell, an uncleaved population of p27-deleted hybrids with unique furine sites were secreted into cell culture media. Without wishing to be bound by theory, this suggests that secretion of the peptides was possible because of the ability of the protein to always fold correctly in the absence of the p27 sequence.
After determining that the RKRR protease cleavage site (SEQ ID NO: 110) was cleaved much more efficiently than the RARR cleavage site (SEQ ID NO: 109), hybrids were generated to further optimize the cleavage site. In the present case, mutations have been made in which a serine and optionally a glycine have been placed at the immediately C-terminus of the RKRR cleavage site (SEQ ID NO: 110), either by mutation of the position or insertion amino acids near the cleavage site. This Ser either replaced Phel37 (starting from the fusion peptide) or was an N-terminal insertion thereon. Additional amino acids were inserted either before or after the fur site to ensure that the protein chain would not be restricted in length for proper folding if cleavage did not occur. Mutants with a combination of furin 2 site cleavage where Phel37 was replaced by Ser or where Ser was inserted between the cloning site and Phel37 displayed higher levels of expression relative to the DS-fold fold hybrid. CAV1 parent provided with two endogenous furine cleavage sites flanking the p27 sequence. An advantage provided by the inclusion of a single furin cleavage site is that the final transformed FVRS polypeptide is almost identical to the parent protein except for the A107K in the improved fur site, and a Ser replacing the Phe inside the embedded fusion peptide.
Expression levels were lower for 6HB hybrids (compared to foldon), which was not unexpected given the complexity of 6HB hybrids. However, in both trimerization modalities, switching to optimized furin cleavage sites enhanced expression. For example, SEQ ID NO: 103 (unique optimized cleavage site, foldon, 20.5 mg / L) and SEQ ID NO: 121 (optimized double cleavage, foldon, 14.5 mg / L) had an expression greater than SEQ ID NO: 106 (wild-type cleavage sites, foldon, 10.1 mg / L). And SEQ ID NO: 136 (optimized double cleavage, 6HB, RSV linker hybrid, 2.5 mg / L) had expression greater than SEQ ID NO: 75 (wild-type cleavage sites, 6HB; 81 mg / L). It should be noted that the hybrid SEQ ID NO: 135 (optimized double furin sites, generic linker, 6HB) had a slightly lower expression than the RSV linker hybrid, but still remained superior to wild-type cleavage - 1.3 mg / ml. L.
A summary of the experimental results of Examples 9 to 16 is given in the table below.
Example 17 In vivo Data
BALB / c mice were immunized intramuscularly with 5 μg of the indicated FVRS proteins (SEQ ID NO: 26 (partial sequence, replacing the amino acids corresponding to amino acids 100-150 of the ectodomain of FVRS), 103, 121 or 136) adjuvanted with MF59® on days 0 and 21. Blood was collected on day 38 and the RSV neutralization titers were measured in individual serum samples by RSV plaque reduction assay using HEp-2 cells and a VRS virus length A. The test results were expressed as 60% neutralization titers, defined as the reciprocal of the serum dilution giving a 60% reduction in wells. syncytia relative to serum-free virus control wells. SEQ ID NOs: 106, 103, 121, and 136 triggered each of the neutralization titers greater than SEQ ID NO: 26, SEQ ID NOs: 106 and 136, obtaining statistical significance (p <0.05 by Kruskal-Wallis test ANOVA and Dunn post). The results are shown in FIG. 6.
To determine whether different FVRS proteins induced neutralizing antibodies specific to FVRS pre-fusion and / or post-fusion conformations, a competition of in vitro RSV neutralization experiments was performed using the soluble FVRS protein, SEQ ID NO : 26 (post-fusion) or FVRS SEQ ID NO: 106 (pre-fusion) to adsorb antibodies from immunized mouse sera. In these experiments, competition with excess post-fusion F protein revealed a neutralizing antibody titer that is specific to F-prefusion, whereas competition with excess F-prefusion protein revealed a titer that is specific for post-fusion F. The antibodies that bind the two F conformations are competed by the two proteins. In detail, BALB / c mice were immunized intramuscularly with 5 μg of FVRS protein of SEQ ID NOs: 106, 103, 121, or 136, each adjuvanted with MF59 on days 0 and 21. Blood was collected on day 38 and a batch of serum was generated for each group. The three different RSV neutralization titers were determined for each of the 4 batches of serum: (1) titre after preincubation of the serum with 20 μg / ml of the FVRS protein of SEQ ID NO: 106, (2) title after preincubation of the serum with 40 μg / ml of the FVRS protein of SEQ ID NO: 26, and (3) titre after preincubation of the serum with buffer (no FVRS protein added). The percentage of neutralization titer remaining after competition was calculated by taking a ratio of the titers measured with the competing protein and without the competing protein. FVRS protein SEQ ID NO: 106 was able to block substantially all the serum neutralizing capacity, whereas SEQ ID NO: 26 of the FVRS protein blocked less than 40% of the neutralizing response. This suggests that the majority of the neutralizing antibody response triggered by the FVRS proteins of SEQ ID NOs: 26, 103, 121, and 136 is specific to the FVRS protein of SEQ ID NO: 106 (prefusion). The results are summarized in FIG. 7.
A brief description of the sequences provided in the sequence listing with their corresponding SEQ ID NOS is given in the table below.
TABLE OF SEQUENCES
It should be understood that for all numeric links describing certain parameters of this request, such as "about," "at least," "less than," and "greater than," the description necessarily also encompasses any range bound by the indicated values . Accordingly, for example, the description "at least 1, 2, 3, 4, or 5" therefore describes, inter alia, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2- 4, 2-5, 3-4, 3-5, and 4-5, etc.
For all patents, all applications or other references cited here, such as non-patent literature and reference sequence information, it should be understood that they are incorporated herein by reference in their entirety for all purposes as well as for the proposal. which is indicated. If there is any conflict between a document incorporated herein by reference and this application, the present application applies. All information associated with reference gene sequences set forth in this application, such as GenelDs or depot numbers (typically referencing NCBI deposit numbers), including, for example, genomic loci, genomic sequences, functional annotations , allelic variants and reference mRNA (including eg exon boundaries or response elements) and protein sequences (such as conserved domain structures), as well as chemical references (eg PubChem compound , PubChem substance, or PubChem Bioassay entries, including annotations therein, such as structures and assays, etc.) are hereby incorporated by reference in their entirety.
The titles used in this application are for convenience only and do not affect the interpretation of this application.
Preferred features of each of the aspects provided by the invention are applicable to all other aspects of the invention mutatis mutandis and, without limitation, are exemplified by the dependent claims and also include feature combinations and permutations. individual (eg elements including digital ranges and exemplary embodiments) embodiments and particular aspects of the invention, including working examples. For example, the particular experimental parameters exemplified in the working examples may be adapted for use in the claimed invention in a fragmented manner without departing from the invention. For example, for the materials that are exposed, while the specific reference of each of the various collective and individual combinations and permutations of these compounds may not be explicitly stated, each is specifically considered and described here. So if a class of elements A, B, and C is exposed as well as a class of elements D, E, and F, and an example of a combination of elements AD is exposed, then, even if each is not individually stated, each is considered individually and collectively. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F is specifically contemplated and should be considered as set forth from the disclosure of A, B, and C; D, E, and F; and the example of combinations A-D. Similarly, any subset or combination of these is also specifically considered and exposed. Thus, for example, the subgroups of A-E, B-F, and C-E are specifically contemplated and should be considered as exposed from the disclosure of A, B, and C; D, E, and F; and the combination example A-D. This concept applies to all aspects of the present application, including elements of a composition of materials and process steps for preparing or using the compositions.
The foregoing aspects of the invention, as will be recognized by one of ordinary skill in the art by following the teachings of the specification, may be claimed in any combination or permutation insofar as they are novel and non-obvious in relation to the prior art - therefore, insofar as an element is described in one or more references known to those skilled in the ordinary art, it can be excluded from the claimed invention, inter alia by a negative condition or a disclaimer of the characteristic or combination of characteristics.

权利要求:
Claims (15)
[1]
A respiratory syncytial virus F protein (FVRS) complex, comprising a six-helix bundle, comprising: three FVRS ectodomain polypeptides, each comprising an endogenous HRA region, an endogenous HRB region, further comprising a one of an inserted HRS region of the inserted FVRS or an HRB region of the inserted FVRS, and at least one oligomerization polypeptide, wherein the three ectodomain polypeptides and the at least one oligomerization polypeptide form a six-membered propellers, provided that the six-helix bundle does not include the endogenous HRA regions and endogenous HRB regions of the FVRS polypeptides, wherein the inserted HRA region or the inserted HRB region is optionally operably linked to the C-terminus -terminal to the endogenous HRB region of the ectodomain of FVRS in the ectodomain polypeptide of FVRS.
[2]
A FVRS complex according to claim 1, wherein the six helix bundle comprises the inserted HRA region of each FVRS ectodomain polypeptide and the oligomerization polypeptide comprises a HRB region; or the six-helix bundle comprises the inserted HRB region of each ectodomain polypeptide of the FVRS and the oligomerization polypeptide comprises an HRA region.
[3]
3. A FVRS complex according to claim 1 or 2, wherein the oligomerization polypeptide is not operably linked to an FVRS ectodomain polypeptide.
[4]
4. A FVRS complex according to claim 1 or 2, wherein the oligomerization polypeptide is operably linked to at least one FVRS ectodomain polypeptide.
[5]
5. A FVRS complex according to any one of claims 1 to 4, wherein at least one functional linkage comprises a polypeptide linker and / or a structurally restricted linker.
[6]
A FVRS complex according to any one of claims 1 to 6, wherein the six helix bundle inserted fraction and the oligomerization polypeptide comprise heptad repeat regions complementary to a fusion protein. an enveloped virus, optionally selected from the group consisting of a HRA region of the FVRS and a HRB region of the FVRS; HR1 region of HIV gp41 and HR2 region of HIV gp41; a Newcastle disease virus (NDV) HR1 region and an HR2 region of VMN, an HR1 region of human metapneumovirus and HR of human metapneumovirus; and other class I viral fusion proteins that contain 6-helix bundles in the post-fusion state.
[7]
A FVRS complex according to any one of claims 1 to 6, wherein the at least one oligomerization polypeptide comprises three oligomerization polypeptides.
[8]
8. A FVRS complex according to any one of claims 1 to 7, wherein the oligomerization polypeptide comprises a purification tag.
[9]
A FVRS complex according to any one of claims 1 to 8, wherein one or more of the FVRS ectodomain polypeptides comprises an uncleaved FVRS ectodomain polypeptide or an ectodomain polypeptide cleaved FVRS.
[10]
10. A FVRS complex according to any one of claims 1 to 9, wherein each of the FVRS ectodomain polypeptides comprises a protease cleavage site.
[11]
11. The FVRS complex of claim 10, wherein the protease cleavage site comprises a furin cleavage site.
[12]
The FVRS complex according to any one of claims 1 to 11, wherein the amino acid sequence of the FVRS ectodomain polypeptides further comprises the substitutions selected from the group consisting of S155C and S290C substitutions. ; substitutions S190F, and V207L; and substitutions S155C, S290C, S190F, and V207L.
[13]
A method for producing a respiratory syncytial virus F protein (FVRS) complex comprising a six-helix bundle comprising: a) providing FodRS proteinectodomain polypeptides comprising an endogenous HRA region and an endogenous HRB region, further comprising a six-helix bundle-forming moiety; and at least one oligomerization polypeptide, and b) combining the FVRS ectodomain polypeptides and the at least one oligomerization polypeptide under conditions suitable for formation of a FVRS complex, whereby a complex FVRS is produced in which three of the FVRS ectodomain polypeptides and at least one of the oligomerization polypeptides form a six-helix bundle, provided that the endogenous HRA regions and the endogenous HRB regions of the polypeptides of the ectodomain of the FVRS are not part of the six-helix bundle.
[14]
The method of claim 13, wherein the six helix bundle inserted fraction and the oligomerization polypeptide comprise heptad repeat regions complementary to an envelope virus fusion protein, selected from group consisting of a HRA region of the FVRS and a HRB region of the FVRS; HR1 region of HIV gp41 and HR2 region of HIV gp41; a Newcastle disease virus (NDV) HR1 region and an HR2 region of VMN, an HR1 region of human metapneumovirus and HR of human metapneumovirus; and other class I viral fusion proteins that contain 6-helix bundles in the post-fusion state.
[15]
The method of claim 13 or 14, wherein the ectodomain polypeptides of the FVRS protein and the oligomerization polypeptide are provided in a manner selected from the group consisting of: in a cell, in culture media conditioned cells, in the form of expression hybrids and in the form of purified components.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US20210101940A1|2021-04-08|Stabilized Soluble Pre-Fusion RSV F Polypeptides

---

US20140141037A1|2014-05-22|Rsv f prefusion trimers

---

US20150329597A1|2015-11-19|Rsv f prefusion trimers

---

BE1022778B1|2016-09-02|AREAS OF TRIMERIZATION OF FVRS

---

EP2029748B1|2016-11-16|N protein fusion proteins of a virus in the paramyxoviridae-protein of interest family and their uses for vaccination and intra-cellular vectorisation

---

EP1409692B1|2008-09-17|Novel peptides of the respiratory syncytial virus | g protein and their use in a vaccine

---

BE1023213B1|2016-12-21|COMPLEXES FROM CYTOMEGALOVIRUS AND USES THEREOF

---

US11267848B2|2022-03-08|Conformationally stabilized RSV pre-fusion F proteins

---

WO2019092002A1|2019-05-16|Pharmaceutical compositions for treatment or prevention of viral infections

---

Zhang et al.2019|A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection

---

FR2819810A1|2002-07-26|NON-GLYCOSYL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE

---

CA2574340A1|2006-02-23|Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions

---

BE1024598B1|2018-04-25|NEW INFLUENZA ANTIGENS

---

JP2020162607A|2020-10-08|Influenza virus vaccines and uses thereof

---

NZ752808A|2021-02-26|Stabilized soluble prefusion rsv f polypeptides

---

NZ713371B2|2021-05-27|Stabilized soluble prefusion rsv f polypeptides

---

OA17539A|2017-02-10|Stabilized soluble prefusion RSV F polypeptides.

---

NZ752808B2|2021-05-27|Stabilized soluble prefusion rsv f polypeptides

同族专利:

---

公开号 | 公开日

---

BE1022778A1|2016-09-02|

---

WO2015177312A1|2015-11-26|

---

EP2974739A1|2016-01-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2012158613A1|2011-05-13|2012-11-22|Novartis Ag|Pre-fusion rsv f antigens|

---

WO2014079842A1|2012-11-20|2014-05-30|Novartis Ag|Rsv f prefusion trimers|

---

US5340740A|1992-05-15|1994-08-23|North Carolina State University|Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process|

---

FR2726003B1|1994-10-21|2002-10-18|Agronomique Inst Nat Rech|CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS|

---

FR2832423B1|2001-11-22|2004-10-08|Vivalis|EXOGENOUS PROTEIN EXPRESSION SYSTEM IN AN AVIAN SYSTEM|

---

FR2836924B1|2002-03-08|2005-01-14|Vivalis|AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES|

---

EP1528101A1|2003-11-03|2005-05-04|ProBioGen AG|Immortalized avian cell lines for virus production|

---

EP1997830A1|2007-06-01|2008-12-03|AIMM Therapeutics B.V.|RSV specific binding molecules and means for producing them|

---

JP6088123B2|2008-02-01|2017-03-01|アルファ−オー・ペプチドズ・アーゲーＡｌｐｈａ−Ｏ Ｐｅｐｔｉｄｅｓ Ａｇ|Self-assembling peptide nanoparticles useful as vaccines|

---

WO2010009277A2|2008-07-15|2010-01-21|Novartis Ag|Immunogenic amphipathic peptide compositions|

---

WO2010009065A2|2008-07-15|2010-01-21|Novartis Ag|Amphipathic peptide compositions|

---

JP5813513B2|2008-12-09|2015-11-17|ノババックス，インコーポレイテッド|Modified RSVF protein and method of using the same|

---

BR112012001666A2|2009-07-15|2019-09-24|Novartis Ag|rsv f protein compositions and methods for making the same|

---

WO2011076807A2|2009-12-23|2011-06-30|Novartis Ag|Lipids, lipid compositions, and methods of using them|

---

US9192661B2|2010-07-06|2015-11-24|Novartis Ag|Delivery of self-replicating RNA using biodegradable polymer particles|

---

US20130195968A1|2010-07-06|2013-08-01|Novartis Ag|Virion-like delivery particles for self-replicating rna molecules|

---

CA2804396C|2010-07-06|2021-06-29|Novartis Ag|Liposomes with lipids having an advantageous pka-value for rna delivery|

---

NZ606591A|2010-07-06|2015-02-27|Novartis Ag|Cationic oil-in-water emulsions|

---

JP5911870B2|2010-08-31|2016-04-27|ノバルティス アーゲー|PEGylated liposomes for delivery of RNA encoding immunogens|

---

EP2611420B1|2010-08-31|2019-03-27|GlaxoSmithKline Biologicals SA|Lipids suitable for liposomal delivery of protein-coding rna|

---

MX341989B|2010-08-31|2016-09-09|Novartis Ag |Small liposomes for delivery of immunogen-encoding rna.|

---

WO2013006834A1|2011-07-06|2013-01-10|Novartis Ag|Oil-in-water emulsions that contain nucleic acids|

---

RU2649133C2|2011-07-06|2018-03-29|Новартис Аг|Cationic oil-in-water emulsions|

---

MX350764B|2011-07-06|2017-09-18|Novartis Ag|Liposomes having useful n:p ratio for delivery of rna molecules.|

---

RU2628705C2|2011-08-31|2017-08-21|Новартис Аг|Pegylated liposomes for immunougen-coding rna delivery|SG11201804148TA|2015-12-23|2018-07-30|Pfizer|Rsv f protein mutants|

---

TWI683826B|2016-11-22|2020-02-01|國立臺灣大學|Recombinant rsv antigens|

---

WO2018176103A1|2017-03-30|2018-10-04|The University Of Queensland|"chimeric molecules and uses thereof"|

---

WO2018187325A1|2017-04-04|2018-10-11|University Of Washington|Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use|

法律状态:
2018-04-25| FG| Patent granted|Effective date: 20160902 |

---

2018-04-25| MM| Lapsed because of non-payment of the annual fee|Effective date: 20170531 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201462002023P| true| 2014-05-22|2014-05-22|

---

US62/002,023|2014-05-22|

---

EP62/002,023|2014-05-22|

---

EP14177182.4A|EP2974739A1|2014-07-15|2014-07-15|RSVF trimerization domains|

---

US201462051527P| true| 2014-09-17|2014-09-17|

---